In the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	106-153	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	281-324	

Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	21-64	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	150-197	
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	21-64	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	321-364	
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	21-64	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	366-413	
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	21-64	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	422-465	
3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	150-197	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	321-364	
3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	150-197	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	366-413	
3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	150-197	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	422-465	
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	321-364	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	366-413	
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	321-364	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	422-465	
3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	366-413	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	422-465	

After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	18-61	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	78-121	
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	18-61	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	200-243	
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	18-61	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	245-292	
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	78-121	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	200-243	
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	78-121	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	245-292	
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	200-243	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	245-292	

These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	349-392	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	394-441	
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	349-392	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	467-510	
3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	394-441	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	467-510	

The 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine treatment also had a significant effect on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups.
3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	4-51	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	100-143	

In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-46	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	283-326	
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-46	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	328-375	
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	283-326	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	328-375	

Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, significantly reduces 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity towards dopaminergic and noradrenergic cell groups in non-human primates.
3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	99-146	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	171-214	

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
ketoconazole	10-21	panobinostat	82-93	
ketoconazole	10-21	LBH589	96-101	
ketoconazole	10-21	histone deacetylase inhibitor	122-150	
panobinostat	82-93	LBH589	96-101	
panobinostat	82-93	histone deacetylase inhibitor	122-150	
LBH589	96-101	histone deacetylase inhibitor	122-150	

This study evaluated the effect of a potent CYP3A inhibitor, ketoconazole, on the pharmacokinetics and safety of panobinostat.
ketoconazole	61-72	panobinostat	113-124	

On day 8, a single panobinostat dose was co-administered with ketoconazole.
panobinostat	19-30	ketoconazole	62-73	

In the presence of ketoconazole, there was 1.6- and 1.8-fold increase in C (max) and AUC of panobinostat, respectively.
ketoconazole	19-30	panobinostat	92-103	

Co-administration of panobinostat with CYP3A inhibitors is feasible as the observed increase in panobinostat PK parameters was not considered clinically relevant.
panobinostat	21-32	panobinostat	96-107	

Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of panobinostat was not studied with CYP3A inhibitors, close monitoring of panobinostat-related adverse events is necessary.
panobinostat	104-115	panobinostat	176-187	

Interaction study of moxifloxacin and lomefloxacin with co-administered drugs.
moxifloxacin	21-32	lomefloxacin	38-49	

Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections.
Moxifloxacin	0-11	lomefloxacin	17-28	
Moxifloxacin	0-11	fluoroquinolone antibiotics	34-60	
lomefloxacin	17-28	fluoroquinolone antibiotics	34-60	

Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.
moxifloxacin	6-17	fluoroquinolones	36-51	
moxifloxacin	6-17	sucralfate	99-108	
moxifloxacin	6-17	gelusil	111-117	
moxifloxacin	6-17	erythromycin	120-131	
moxifloxacin	6-17	multi minerals	137-150	
fluoroquinolones	36-51	sucralfate	99-108	
fluoroquinolones	36-51	gelusil	111-117	
fluoroquinolones	36-51	erythromycin	120-131	
fluoroquinolones	36-51	multi minerals	137-150	
sucralfate	99-108	gelusil	111-117	
sucralfate	99-108	erythromycin	120-131	
sucralfate	99-108	multi minerals	137-150	
gelusil	111-117	erythromycin	120-131	
gelusil	111-117	multi minerals	137-150	
erythromycin	120-131	multi minerals	137-150	

The response of moxifloxacin and lomefloxacin after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector.
moxifloxacin	16-27	lomefloxacin	33-44	

Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
Moxifloxacin	0-11	Lomefloxacin	17-28	
Moxifloxacin	0-11	sucralfate	49-58	
Moxifloxacin	0-11	gelusil	64-70	
Moxifloxacin	0-11	erythromycin	101-112	
Moxifloxacin	0-11	multi-minerals	133-146	
Lomefloxacin	17-28	sucralfate	49-58	
Lomefloxacin	17-28	gelusil	64-70	
Lomefloxacin	17-28	erythromycin	101-112	
Lomefloxacin	17-28	multi-minerals	133-146	
sucralfate	49-58	gelusil	64-70	
sucralfate	49-58	erythromycin	101-112	
sucralfate	49-58	multi-minerals	133-146	
gelusil	64-70	erythromycin	101-112	
gelusil	64-70	multi-minerals	133-146	
erythromycin	101-112	multi-minerals	133-146	

Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
S-ketamine	17-26	itraconazole	45-56	
S-ketamine	17-26	ticlopidine	83-93	
itraconazole	45-56	ticlopidine	83-93	

This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole.
S-ketamine	51-60	ticlopidine	107-117	
S-ketamine	51-60	itraconazole	143-154	
ticlopidine	107-117	itraconazole	143-154	

In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks.
S-ketamine	87-96	ticlopidine	128-138	
S-ketamine	87-96	itraconazole	162-173	
ticlopidine	128-138	itraconazole	162-173	

Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine.
Ticlopidine	0-10	ketamine	134-141	
Ticlopidine	0-10	itraconazole	164-175	
Ticlopidine	0-10	S-ketamine	220-229	
ketamine	134-141	itraconazole	164-175	
ketamine	134-141	S-ketamine	220-229	
itraconazole	164-175	S-ketamine	220-229	

The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo.
norketamine	13-23	ketamine	39-46	
norketamine	13-23	ticlopidine	94-104	
norketamine	13-23	itraconazole	125-136	
ketamine	39-46	ticlopidine	94-104	
ketamine	39-46	itraconazole	125-136	
ticlopidine	94-104	itraconazole	125-136	

In the ticlopidine and itraconazole phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05).
ticlopidine	7-17	itraconazole	23-34	

The findings suggest that the dosage of S-ketamine should be reduced in patients receiving ticlopidine.
S-ketamine	40-49	ticlopidine	91-101	

The 3-Deazaneplanocin A (DZNep), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia.
3-Deazaneplanocin A	4-22	DZNep	25-29	

We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells.
DZNep	46-50	DZNep	92-96	
DZNep	46-50	ABT-737	102-108	
DZNep	46-50	DZNep	195-199	
DZNep	92-96	ABT-737	102-108	
DZNep	92-96	DZNep	195-199	
ABT-737	102-108	DZNep	195-199	

In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis.
DZNep	13-17	ABT-737	106-112	
DZNep	13-17	DZNep	118-122	
ABT-737	106-112	DZNep	118-122	

Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.
Implanon	0-7	antiretroviral	47-60	

We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.
antiretroviral	59-72	Implanon	138-145	

Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study.
Antidepressant	0-13	warfarin	15-22	

We sought to evaluate whether initiation of an antidepressant increases the risk of hospitalization for gastrointestinal bleeding in warfarin users.
antidepressant	47-60	warfarin	133-140	

In total, 430,455 warfarin users contributed 407,370 person-years of warfarin use.
warfarin	18-25	warfarin	69-76	

Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]).
Warfarin	0-7	citalopram	91-100	
Warfarin	0-7	fluoxetine	139-148	
Warfarin	0-7	paroxetine	187-196	
Warfarin	0-7	amitriptyline	235-247	
citalopram	91-100	fluoxetine	139-148	
citalopram	91-100	paroxetine	187-196	
citalopram	91-100	amitriptyline	235-247	
fluoxetine	139-148	paroxetine	187-196	
fluoxetine	139-148	amitriptyline	235-247	
paroxetine	187-196	amitriptyline	235-247	

Also mirtazapine, which is not believed to interact with warfarin, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]).
mirtazapine	5-15	warfarin	57-64	

Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
Warfarin	0-7	citalopram	29-38	
Warfarin	0-7	fluoxetine	41-50	
Warfarin	0-7	paroxetine	53-62	
Warfarin	0-7	amitriptyline	65-77	
Warfarin	0-7	mirtazapine	83-93	
citalopram	29-38	fluoxetine	41-50	
citalopram	29-38	paroxetine	53-62	
citalopram	29-38	amitriptyline	65-77	
citalopram	29-38	mirtazapine	83-93	
fluoxetine	41-50	paroxetine	53-62	
fluoxetine	41-50	amitriptyline	65-77	
fluoxetine	41-50	mirtazapine	83-93	
paroxetine	53-62	amitriptyline	65-77	
paroxetine	53-62	mirtazapine	83-93	
amitriptyline	65-77	mirtazapine	83-93	

The incubations were performed in the absence and presence of the non-specific CYP inhibitor, 1-aminobenzotriazole (ABT) and isoform-specific inhibitors.
1-aminobenzotriazole	94-113	ABT	116-118	

ABT decreased the toxicity of precocene I, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner.
ABT	0-2	precocene I	30-40	

Of the isoform-specific CYP inhibitors tested for an effect on the precocene I metabolite profile, only tranylcypromine was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1.
precocene I	67-77	tranylcypromine	104-118	

With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole.
ABT	71-73	diethyldithiocarbamate	75-96	
ABT	71-73	tranylcypromine	98-112	
ABT	71-73	ketoconazole	114-125	
diethyldithiocarbamate	75-96	tranylcypromine	98-112	
diethyldithiocarbamate	75-96	ketoconazole	114-125	
tranylcypromine	98-112	ketoconazole	114-125	

Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity.
Furafylline	0-10	sulfaphenazole	16-29	
Furafylline	0-10	quinidine	52-60	
Furafylline	0-10	precocene I	82-92	
sulfaphenazole	16-29	quinidine	52-60	
sulfaphenazole	16-29	precocene I	82-92	
quinidine	52-60	precocene I	82-92	

These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of precocene I and therefore may not be an appropriate model for precocene I metabolism.
precocene I	103-113	precocene I	165-175	

To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of adeno-associated virus-2 (AAV2).
adeno-associated virus-2	145-168	AAV2	171-174	

AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase.
AAV2	0-3	collagenase	214-224	
AAV2	0-3	hyaluronan lyase	227-242	
AAV2	0-3	heparinase III	245-258	
AAV2	0-3	chondroitin ABC lyase	264-284	
collagenase	214-224	hyaluronan lyase	227-242	
collagenase	214-224	heparinase III	245-258	
collagenase	214-224	chondroitin ABC lyase	264-284	
hyaluronan lyase	227-242	heparinase III	245-258	
hyaluronan lyase	227-242	chondroitin ABC lyase	264-284	
heparinase III	245-258	chondroitin ABC lyase	264-284	

The addition of heparinase III or chondroitin ABC lyase greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina.
heparinase III	16-29	chondroitin ABC lyase	34-54	

Hyaluronan lyase had a limited effect and collagenase was ineffective.
Hyaluronan lyase	0-15	collagenase	42-52	

Electroretinograms survived with higher concentrations of heparinase III and chondroitin ABC lyase than were required for optimal retinal transduction.
heparinase III	58-71	chondroitin ABC lyase	77-97	

AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase.
AAV2	0-3	heparinase III	66-79	
AAV2	0-3	chondroitin ABC lyase	84-104	
heparinase III	66-79	chondroitin ABC lyase	84-104	

Prevention of emergence agitation in seven children receiving low-dose ketamine and propofol total intravenous anesthesia.
ketamine	71-78	propofol	84-91	

We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose ketamine in conjunction with propofol for total intravenous anesthesia (TIVA) repeatedly for radiation therapy.
ketamine	95-102	propofol	124-131	

EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol.
propofol	61-68	ketamine	161-168	
propofol	61-68	propofol	183-190	
ketamine	161-168	propofol	183-190	

Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.
ketamine	51-58	propofol	69-76	
ketamine	51-58	propofol	156-163	
propofol	69-76	propofol	156-163	

Tamoxifen, an estrogen antagonist, is the standard hormone treatment for breast cancer.
Tamoxifen	0-8	estrogen antagonist	14-32	

Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%.
Paroxetine	0-9	fluoxetine	15-24	
Paroxetine	0-9	endoxifen	61-69	
fluoxetine	15-24	endoxifen	61-69	

It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine.
tamoxifen	85-93	SSRI antidepressants	125-144	
tamoxifen	85-93	paroxetine	154-163	
tamoxifen	85-93	fluoxetine	169-178	
SSRI antidepressants	125-144	paroxetine	154-163	
SSRI antidepressants	125-144	fluoxetine	169-178	
paroxetine	154-163	fluoxetine	169-178	

Depression does not always require antidepressant drug therapy, and antidepressants have no proven preventive impact on hot flushes linked to the menopause.
antidepressant drug	35-53	antidepressants	68-82	

If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.
antidepressant	24-37	tamoxifen	95-103	
antidepressant	24-37	anastrozole	110-120	
tamoxifen	95-103	anastrozole	110-120	

Amphetamine locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with quinpirole.
Amphetamine	0-10	quinpirole	128-137	

The objective was to analyze the effects of neonatal quinpirole treatment on effects of amphetamine in adolescent rats using locomotor sensitization and conditioned place preference procedures.
quinpirole	53-62	amphetamine	88-98	

In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine.
quinpirole	25-34	amphetamine	55-65	
quinpirole	25-34	quinpirole	105-114	
quinpirole	25-34	amphetamine	144-154	
amphetamine	55-65	quinpirole	105-114	
amphetamine	55-65	amphetamine	144-154	
quinpirole	105-114	amphetamine	144-154	

Male rats demonstrated sensitization to amphetamine, although this was muted compared with female rats, and were unaffected by neonatal quinpirole.
amphetamine	40-50	quinpirole	136-145	

Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.
quinpirole	27-36	amphetamine	65-75	
quinpirole	27-36	quinpirole	106-115	
quinpirole	27-36	amphetamine	148-158	
quinpirole	27-36	amphetamine	203-213	
amphetamine	65-75	quinpirole	106-115	
amphetamine	65-75	amphetamine	148-158	
amphetamine	65-75	amphetamine	203-213	
quinpirole	106-115	amphetamine	148-158	
quinpirole	106-115	amphetamine	203-213	
amphetamine	148-158	amphetamine	203-213	

In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.
cyclosporine	49-60	tacrolimus	87-96	

In vitro studies have identified cyclosporine and tacrolimus as CYP3A inhibitors.
cyclosporine	33-44	tacrolimus	50-59	

Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).
midazolam	27-35	cyclosporine	181-192	
midazolam	27-35	tacrolimus	236-245	
cyclosporine	181-192	tacrolimus	236-245	

The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6).
midazolam	21-29	tacrolimus	95-104	
midazolam	21-29	calcineurin inhibitor	168-188	
tacrolimus	95-104	calcineurin inhibitor	168-188	

This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition.
cyclosporine	112-123	tacrolimus	149-158	
cyclosporine	112-123	cyclosporine	228-239	
tacrolimus	149-158	cyclosporine	228-239	

Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease.
cinacalcet	40-49	darbepoetin	83-93	

Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to erythropoietin (EPO) resistance.
erythropoietin	75-88	EPO	91-93	

Medical treatment with cinacalcet is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on darbepoetin dosing is unknown.
cinacalcet	23-32	darbepoetin	118-128	

The primary objective of the study was to ascertain the difference in darbepoetin responsiveness before and after 12 months of cinacalcet therapy.
darbepoetin	70-80	cinacalcet	127-136	

Reduction of PTH by cinacalcet is associated with a decrease in darbepoetin requirement.
cinacalcet	20-29	darbepoetin	64-74	

Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.
celecoxib	15-23	anti-cancer drugs	40-56	

This study investigates the ability of cyclooxygenase-2 inhibitors to sensitize cells from different origins to several chemotherapeutic agents.
cyclooxygenase-2 inhibitors	39-65	chemotherapeutic agents	120-142	

The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.
5-FU	130-133	cisplatin	136-144	
5-FU	130-133	doxorubicin	147-157	
5-FU	130-133	etoposide	163-171	
5-FU	130-133	celecoxib	175-183	
cisplatin	136-144	doxorubicin	147-157	
cisplatin	136-144	etoposide	163-171	
cisplatin	136-144	celecoxib	175-183	
doxorubicin	147-157	etoposide	163-171	
doxorubicin	147-157	celecoxib	175-183	
etoposide	163-171	celecoxib	175-183	

We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells.
celecoxib	28-36	celecoxib	136-144	
celecoxib	28-36	doxorubicin	150-160	
celecoxib	136-144	doxorubicin	150-160	

These results, if confirmed in-vivo, indicate that celecoxib is not a suitable chemosensitizer for breast cancer or with doxorubicin for other cancers.
celecoxib	51-59	doxorubicin	121-131	

[Interaction between clopidogrel and proton pump inhibitors].
clopidogrel	21-31	proton pump inhibitors	37-58	

The drug interaction between proton pump inhibitors and clopidogrel has been the subject of much study in recent years.
proton pump inhibitors	29-50	clopidogrel	56-66	

Contradictory results regarding the effect of proton pump inhibitors on platelet reactivity and on clinical outcome in clopidogrel-treated patients have been reported in literature.
proton pump inhibitors	46-67	clopidogrel	119-129	

Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme.
omeprazole	19-28	clopidogrel	34-44	
omeprazole	19-28	omeprazole	203-212	
clopidogrel	34-44	omeprazole	203-212	

Pantoprazole has a much weaker effect on clopidogrel's pharmacokinetics and on platelet reactivity during concomitant use.
Pantoprazole	0-11	clopidogrel	41-51	

The influence of the other proton pump inhibitors when used simultaneously with clopidogrel has not yet been investigated in adequately randomized studies.
proton pump inhibitors	27-48	clopidogrel	80-90	

Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided.
clopidogrel	50-60	omeprazole	89-98	
clopidogrel	50-60	esomeprazole	104-115	
omeprazole	89-98	esomeprazole	104-115	

To date, there is no conclusive evidence of a clinically-relevant interaction between any of the proton pump inhibitors and clopidogrel.
proton pump inhibitors	97-118	clopidogrel	124-134	

In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
minocycline	21-31	fosfomycin	47-56	
minocycline	21-31	methicillin	87-97	
fosfomycin	47-56	methicillin	87-97	

This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA).
minocycline	54-64	fosfomycin	80-89	
minocycline	54-64	methicillin	111-121	
fosfomycin	80-89	methicillin	111-121	

The susceptibility results for minocycline and fosfomycin were interpreted according to the most relevant criteria.
minocycline	31-41	fosfomycin	47-56	

The combination of minocycline and fosfomycin can be synergistic against MRSA.
minocycline	19-29	fosfomycin	35-44	

The authors report the case of an infant with confirmed congenital hypothyroidism on levothyroxine who experienced a possible drug interaction with simeticone.
levothyroxine	85-97	simeticone	148-157	

Questioning revealed the child was taking Infacol drops before feeds while on levothyroxine.
Infacol	42-48	levothyroxine	78-90	

Drug interaction of thyroxine with simeticone has not been reported previously and is not listed in the British National Formulary for Children.
thyroxine	20-28	simeticone	35-44	

Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.
Calcium	0-6	nonheme iron	59-65;75-78	
Calcium	0-6	heme iron	70-78	
nonheme iron	59-65;75-78	heme iron	70-78	

Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron.
Calcium	0-6	nonheme iron	83-89;100-103	
Calcium	0-6	heme iron	95-103	
nonheme iron	83-89;100-103	heme iron	95-103	

However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies.
calcium	28-34	iron	46-49	
calcium	28-34	calcium	123-129	
iron	46-49	calcium	123-129	

Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal.
calcium	52-58	nonheme iron	77-83;94-97	
calcium	52-58	heme iron	89-97	
nonheme iron	77-83;94-97	heme iron	89-97	

We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate).
calcium	28-34	nonheme iron	88-99	
calcium	28-34	ferrous sulfate	105-119	
nonheme iron	88-99	ferrous sulfate	105-119	

We also evaluated the effects of calcium doses between 200 and 800 mg on absorption of 5 mg heme iron [as concentrated RBC (CRBC)].
calcium	33-39	heme iron	92-100	

Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach.
Calcium	0-6	calcium chloride	28-43	
Calcium	0-6	minerals	64-71	
calcium chloride	28-43	minerals	64-71	

Calcium doses   1000 mg diminished nonheme iron absorption by an average of 49.6%.
Calcium	0-6	nonheme iron	35-46	

A calcium dose of 800 mg diminished absorption of 5 mg heme iron by 37.7%.
calcium	2-8	heme iron	55-63	

In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron.
calcium	53-59	nonheme iron	117-123;157-160	
calcium	53-59	heme iron	142-145;157-160	
nonheme iron	117-123;157-160	heme iron	142-145;157-160	

Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.
sunitinib	32-40	docetaxel	46-54	

This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.
sunitinib	66-74	sunitinib	131-139	
sunitinib	66-74	docetaxel	145-153	
sunitinib	131-139	docetaxel	145-153	

NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either sunitinib or docetaxel or both based on various sequential administrations.
sunitinib	84-92	docetaxel	97-105	

Sunitinib exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas docetaxel arrested at S phase.
Sunitinib	0-8	docetaxel	118-126	

Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity.
sunitinib	37-45	docetaxel	51-59	

When cells were exposed to docetaxel followed by sunitinib, synergism was observed.
docetaxel	27-35	sunitinib	49-57	

The molecular basis of this synergism is that the signaling pathways that were initially activated by docetaxel exposure were efficiently suppressed by the subsequent exposure to sunitinib.
docetaxel	102-110	sunitinib	179-187	

Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.
Sunitinib	0-8	docetaxel	166-174	
Sunitinib	0-8	sunitinib	188-196	
Sunitinib	0-8	sunitinib	213-221	
Sunitinib	0-8	docetaxel	235-243	
docetaxel	166-174	sunitinib	188-196	
docetaxel	166-174	sunitinib	213-221	
docetaxel	166-174	docetaxel	235-243	
sunitinib	188-196	sunitinib	213-221	
sunitinib	188-196	docetaxel	235-243	
sunitinib	213-221	docetaxel	235-243	

Distinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa.
piperacillin	31-42	methylglyoxal	48-60	

Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels.
piperacillin	84-95	carbenicillin	98-110	
piperacillin	84-95	amikacin	113-120	
piperacillin	84-95	ciprofloxacin	126-138	
carbenicillin	98-110	amikacin	113-120	
carbenicillin	98-110	ciprofloxacin	126-138	
amikacin	113-120	ciprofloxacin	126-138	

Distinct and statistically significant synergism was observed between methylglyoxal and piperacillin by disc diffusion tests when compared with their individual effects.
methylglyoxal	70-82	piperacillin	88-99	

Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.
methylglyoxal	30-42	carbenicillin	62-74	
methylglyoxal	30-42	amikacin	80-87	
carbenicillin	62-74	amikacin	80-87	

Protective effect of acetyl-l-carnitine and  alpha lipoic acid against the acute toxicity of diepoxybutane to human lymphocytes.
acetyl-l-carnitine	21-38	alpha lipoic acid	45-61	

(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.
acetyl-l-carnitine	5-22	alpha-lipoic acid	115-131	

[Influence of hemantane and doxycycline on MPTP-evoked behavior violations in C57BL/6 mice].
hemantane	14-22	doxycycline	28-38	

The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.)
anti-parkinsonian drug	15-36	hemantane	38-46	
anti-parkinsonian drug	15-36	(2-adamantyl)hexamethylenimine	49-78	
hemantane	38-46	(2-adamantyl)hexamethylenimine	49-78	

and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.)
antibiotic drug	7-21	doxycycline	23-33	
antibiotic drug	7-21	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	85-128	
antibiotic drug	7-21	MPTP	131-134	
doxycycline	23-33	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	85-128	
doxycycline	23-33	MPTP	131-134	
1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	85-128	MPTP	131-134	

Acute administration of hemantane or doxycycline failed to influence locomotion in mice, while their combination normalized motor activity.
hemantane	24-32	doxycycline	37-47	

The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
dasatinib	25-33	paclitaxel	44-53	

The effect of dasatinib, an inhibitor of Src and Abl kinases, on paclitaxel sensitivity was measured in ovarian cancer cells and HEY xenografts.
dasatinib	14-22	paclitaxel	65-74	

The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by dasatinib and paclitaxel were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry.
dasatinib	64-72	paclitaxel	78-87	

HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone.
dasatinib	23-31	paclitaxel	38-47	

Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);
dasatinib	45-53	paclitaxel	60-69	
dasatinib	45-53	dasatinib	171-179	
dasatinib	45-53	paclitaxel	183-192	
dasatinib	45-53	paclitaxel	197-206	
paclitaxel	60-69	dasatinib	171-179	
paclitaxel	60-69	paclitaxel	183-192	
paclitaxel	60-69	paclitaxel	197-206	
dasatinib	171-179	paclitaxel	183-192	
dasatinib	171-179	paclitaxel	197-206	
paclitaxel	183-192	paclitaxel	197-206	

dasatinib + paclitaxel vs.
dasatinib	0-8	paclitaxel	12-21	

The siRNA knockdown of p27(Kip1) decreased dasatinib- and paclitaxel-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017).
dasatinib	43-51	paclitaxel	58-67	

Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression.
dasatinib	82-90	paclitaxel	133-142	

Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.
dasatinib	63-71	paclitaxel	82-91	

Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
lenalidomide	17-28	CCI-779	34-40	
lenalidomide	17-28	lenalidomide	99-110	
lenalidomide	17-28	CCI-779	112-118	
CCI-779	34-40	lenalidomide	99-110	
CCI-779	34-40	CCI-779	112-118	
lenalidomide	99-110	CCI-779	112-118	

The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM.
lenalidomide	31-42	CCI-779	68-74	

Enhancement of humoral immune responses to inactivated Newcastle disease and avian influenza vaccines by oral administration of ginseng stem-and-leaf saponins in chickens.
avian influenza vaccines	77-100	ginseng stem-and-leaf saponins	128-157	

The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines.
ginseng stem-and-leaf saponins	81-110	GSLS	113-116	
ginseng stem-and-leaf saponins	81-110	inactivated ND vaccines	166-179;188-195	
ginseng stem-and-leaf saponins	81-110	inactivated AI vaccines	166-176;185-186;188-195	
GSLS	113-116	inactivated ND vaccines	166-179;188-195	
GSLS	113-116	inactivated AI vaccines	166-176;185-186;188-195	
inactivated ND vaccines	166-179;188-195	inactivated AI vaccines	166-176;185-186;188-195	

In experiment 1, oral administration of GSLS at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with inactivated ND vaccine was evaluated.
GSLS	40-43	inactivated ND vaccine	145-166	

In experiment 2, the same regimen of GSLS was administered to chickens inoculated with inactivated AI vaccines, and an enhanced serum antibody response to AI vaccination was also observed.
GSLS	37-40	inactivated AI vaccines	87-109	

Considering the safety of GSLS, because no adverse effect was found throughout the experiments, GSLS may be a promising oral adjuvant to improve immunization in poultry.
GSLS	26-29	GSLS	96-99	

Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells.
dacarbazine	15-25	imexon	31-36	

We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.
dacarbazine	67-77	DTIC	80-83	
dacarbazine	67-77	imexon	107-112	
DTIC	80-83	imexon	107-112	

The effect of DTIC and imexon, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay).
DTIC	14-17	imexon	23-28	

There was a >75% reduction in cellular glutathione and cysteine with imexon but not DTIC.
imexon	69-74	DTIC	84-87	

Imexon and dacarbazine show additive effects in vitro but not in vivo in human A375 melanoma cells.
Imexon	0-5	dacarbazine	11-21	

Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.
Lapatinib	0-8	herceptin	19-27	

Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
lapatinib	41-49	Herceptin	65-73	
lapatinib	41-49	lapatinib	133-141	
lapatinib	41-49	Herceptin	167-175	
Herceptin	65-73	lapatinib	133-141	
Herceptin	65-73	Herceptin	167-175	
lapatinib	133-141	Herceptin	167-175	

We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC).
lapatinib	17-25	Herceptin	42-50	
lapatinib	17-25	Herceptin	111-119	
Herceptin	42-50	Herceptin	111-119	

In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC.
lapatinib	22-30	Herceptin	149-157	

Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer.
Herceptin	56-64	lapatinib	86-94	

Lapatinib may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.
Lapatinib	0-8	Herceptin	44-52	
Lapatinib	0-8	Herceptin	68-76	
Herceptin	44-52	Herceptin	68-76	

The aim of the present study was to investigate whether HB-EGF is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-EGF, cross-reacting material 197 (CRM197).
cross-reacting material 197	180-206	CRM197	209-214	

We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of CRM197 on these cells alone or in combination with anticancer agent.
CRM197	88-93	anticancer agent	139-154	

CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line.
CRM197	0-5	CRM197	62-67	
CRM197	0-5	doxorubicin	74-84	
CRM197	62-67	doxorubicin	74-84	

Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.
Ephedrine	0-8	dexmedetomidine	49-63	

The purpose of this study was to evaluate whether the psychostimulant drug ephedrine has any effect on dexmedetomidine-induced antinociception and locomotor inhibitor activity in mice in acute application.
ephedrine	75-83	dexmedetomidine	103-117	

saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.
ephedrine	17-25	dexmedetomidine	59-73	
ephedrine	17-25	ephedrine	93-101	
ephedrine	17-25	dexmedetomidine	118-132	
dexmedetomidine	59-73	ephedrine	93-101	
dexmedetomidine	59-73	dexmedetomidine	118-132	
ephedrine	93-101	dexmedetomidine	118-132	

In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine.
dexmedetomidine	64-78	ephedrine	96-104	
dexmedetomidine	64-78	dexmedetomidine	205-219	
ephedrine	96-104	dexmedetomidine	205-219	

At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine.
dexmedetomidine	53-67	ephedrine	89-97	

We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.
dexmedetomidine	49-63	ephedrine	70-78	
dexmedetomidine	49-63	dexmedetomidine	183-197	
dexmedetomidine	49-63	analgesic	205-213	
ephedrine	70-78	dexmedetomidine	183-197	
ephedrine	70-78	analgesic	205-213	
dexmedetomidine	183-197	analgesic	205-213	

[Efficacy of fixed combination amlodipine/valsartan in hospitalized patients with hypertensive disease]
amlodipine	31-40	valsartan	42-50	

Efficacy and tolerability of fixed amlodipine/valsartan combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology.
amlodipine	35-44	valsartan	46-54	

All patients had indications for antihypertensive therapy and were randomized either to fixed combination amlodipine/valsartan (n=43) or to therapy which corresponded to the hospital formulary (n=43).
amlodipine	106-115	valsartan	117-125	

Rate of achievement of target BP with fixed combination amlodipine/valsartan (93%) was comparable with that on traditional therapy (90%).
amlodipine	56-65	valsartan	67-75	

But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05).
amlodipine	33-42	valsartan	44-52	
amlodipine	33-42	antihypertensive drugs	247-268	
valsartan	44-52	antihypertensive drugs	247-268	

We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.
amlodipine	75-84	valsartan	86-94	
amlodipine	75-84	antihypertensive drugs	192-213	
valsartan	86-94	antihypertensive drugs	192-213	

Ticagrelor (Brilinta)--better than clopidogrel (Plavix)
Ticagrelor	0-9	Brilinta	12-19	
Ticagrelor	0-9	clopidogrel	35-45	
Ticagrelor	0-9	Plavix	48-53	
Brilinta	12-19	clopidogrel	35-45	
Brilinta	12-19	Plavix	48-53	
clopidogrel	35-45	Plavix	48-53	

The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
ticagrelor	21-30	Brilinta	33-40	
ticagrelor	21-30	antiplatelet drug	64-80	
ticagrelor	21-30	aspirin	105-111	
Brilinta	33-40	antiplatelet drug	64-80	
Brilinta	33-40	aspirin	105-111	
antiplatelet drug	64-80	aspirin	105-111	

It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use.
clopidogrel	21-31	Plavix	34-39	
clopidogrel	21-31	prasugrel	46-54	
clopidogrel	21-31	Effient	57-63	
Plavix	34-39	prasugrel	46-54	
Plavix	34-39	Effient	57-63	
prasugrel	46-54	Effient	57-63	

Influence of piperine on ibuprofen induced antinociception and its pharmacokinetics.
piperine	13-20	ibuprofen	25-33	

In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen.
piperine	21-28	ibuprofen	112-120	
piperine	21-28	acetic acid	140-150	
piperine	21-28	ibuprofen	210-218	
ibuprofen	112-120	acetic acid	140-150	
ibuprofen	112-120	ibuprofen	210-218	
acetic acid	140-150	ibuprofen	210-218	

Ibuprofen plasma concentration was also increased when it was administered with piperine.
Ibuprofen	0-8	piperine	80-87	

The synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen.
ibuprofen	44-52	piperine	77-84	
ibuprofen	44-52	ibuprofen	141-149	
piperine	77-84	ibuprofen	141-149	

From this study it can be concluded that piperine can be used as a bioenhancer along with ibuprofen.
piperine	41-48	ibuprofen	90-98	

Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine.
abacavir	30-37	lamivudine	82-91	
abacavir	30-37	zidovudine	96-105	
abacavir	30-37	lamivudine	129-138	
abacavir	30-37	zidovudine	144-153	
lamivudine	82-91	zidovudine	96-105	
lamivudine	82-91	lamivudine	129-138	
lamivudine	82-91	zidovudine	144-153	
zidovudine	96-105	lamivudine	129-138	
zidovudine	96-105	zidovudine	144-153	
lamivudine	129-138	zidovudine	144-153	

No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir.
lamivudine	37-46	zidovudine	51-60	
lamivudine	37-46	abacavir	133-140	
zidovudine	51-60	abacavir	133-140	

Abacavir has no effect on the pharmacokinetic properties of ethanol.
Abacavir	0-7	ethanol	60-66	

Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir.
Ethanol	0-6	abacavir	37-44	
Ethanol	0-6	methadone	104-112	
Ethanol	0-6	abacavir	188-195	
abacavir	37-44	methadone	104-112	
abacavir	37-44	abacavir	188-195	
methadone	104-112	abacavir	188-195	

In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%).
methadone	49-57	ZIAGEN	118-123	
methadone	49-57	methadone	182-190	
ZIAGEN	118-123	methadone	182-190	

Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%.
Cholestyramine	0-13	cholestyramine	28-41	
Cholestyramine	0-13	ezetimibe	90-98	
cholestyramine	28-41	ezetimibe	90-98	

The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction.
ezetimibe	46-54	cholestyramine	59-72	

Fibrates: The safety and effectiveness of ezetimibe administered with fibrates have not been established.
Fibrates	0-7	ezetimibe	42-50	
Fibrates	0-7	fibrates	70-77	
ezetimibe	42-50	fibrates	70-77	

Co-administration of ZETIA with fibrates is not recommended until use in patients is studied.
ZETIA	21-25	fibrates	32-39	

Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold.
Fenofibrate	0-10	fenofibrate	53-63	
Fenofibrate	0-10	ezetimibe	96-104	
fenofibrate	53-63	ezetimibe	96-104	

Gemfibrozil: In a pharmacokinetic study, concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold.
Gemfibrozil	0-10	gemfibrozil	53-63	
Gemfibrozil	0-10	ezetimibe	96-104	
gemfibrozil	53-63	ezetimibe	96-104	

HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.
HMG-CoA reductase inhibitors	0-27	ezetimibe	100-108	
HMG-CoA reductase inhibitors	0-27	atorvastatin	135-146	
HMG-CoA reductase inhibitors	0-27	simvastatin	149-159	
HMG-CoA reductase inhibitors	0-27	pravastatin	162-172	
HMG-CoA reductase inhibitors	0-27	lovastatin	175-184	
HMG-CoA reductase inhibitors	0-27	fluvastatin	190-200	
ezetimibe	100-108	atorvastatin	135-146	
ezetimibe	100-108	simvastatin	149-159	
ezetimibe	100-108	pravastatin	162-172	
ezetimibe	100-108	lovastatin	175-184	
ezetimibe	100-108	fluvastatin	190-200	
atorvastatin	135-146	simvastatin	149-159	
atorvastatin	135-146	pravastatin	162-172	
atorvastatin	135-146	lovastatin	175-184	
atorvastatin	135-146	fluvastatin	190-200	
simvastatin	149-159	pravastatin	162-172	
simvastatin	149-159	lovastatin	175-184	
simvastatin	149-159	fluvastatin	190-200	
pravastatin	162-172	lovastatin	175-184	
pravastatin	162-172	fluvastatin	190-200	
lovastatin	175-184	fluvastatin	190-200	

Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine.
Cyclosporine	0-11	ezetimibe	24-32	
Cyclosporine	0-11	cyclosporine	132-143	
ezetimibe	24-32	cyclosporine	132-143	

Patients who take both ezetimibe and cyclosporine should be carefully monitored.
ezetimibe	23-31	cyclosporine	37-48	

Carcinogenesis, Mutagenesis, Impairment of Fertility A 104-week dietary carcinogenicity study with ezetimibe was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe).
ezetimibe	99-107	ezetimibe	271-279	

A 104-week dietary carcinogenicity study with ezetimibe was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe).
ezetimibe	46-54	ezetimibe	187-195	

In oral (gavage) fertility studies of ezetimibe conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe).
ezetimibe	38-46	ezetimibe	240-248	

In rabbits treated with ezetimibe, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe).
ezetimibe	24-32	ezetimibe	186-194	

Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.
ezetimibe	25-33	HMG-CoA reductase inhibitors	61-88	
ezetimibe	25-33	statins	91-97	
ezetimibe	25-33	ezetimibe	158-166	
HMG-CoA reductase inhibitors	61-88	statins	91-97	
HMG-CoA reductase inhibitors	61-88	ezetimibe	158-166	
statins	91-97	ezetimibe	158-166	

When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor.
ZETIA	5-9	HMG-CoA reductase inhibitor	35-61	
ZETIA	5-9	HMG-CoA reductase inhibitor	162-188	
HMG-CoA reductase inhibitor	35-61	HMG-CoA reductase inhibitor	162-188	

These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
hypoglycemics	51-63	Coumarin-type anticoagulants	66-93	
hypoglycemics	51-63	Phenytoin	96-104	
hypoglycemics	51-63	Cyclosporine	107-118	
hypoglycemics	51-63	Rifampin	121-128	
hypoglycemics	51-63	Theophylline	131-142	
hypoglycemics	51-63	Terfenadine	145-155	
hypoglycemics	51-63	Cisapride	158-166	
hypoglycemics	51-63	Astemizole	169-178	
hypoglycemics	51-63	Rifabutin	181-189	
hypoglycemics	51-63	Tacrolimus	192-201	
hypoglycemics	51-63	Short-acting benzodiazepines	204-231	
hypoglycemics	51-63	hypoglycemics	240-252	
hypoglycemics	51-63	DIFLUCAN	325-332	
hypoglycemics	51-63	hypoglycemic agents	344-362	
Coumarin-type anticoagulants	66-93	Phenytoin	96-104	
Coumarin-type anticoagulants	66-93	Cyclosporine	107-118	
Coumarin-type anticoagulants	66-93	Rifampin	121-128	
Coumarin-type anticoagulants	66-93	Theophylline	131-142	
Coumarin-type anticoagulants	66-93	Terfenadine	145-155	
Coumarin-type anticoagulants	66-93	Cisapride	158-166	
Coumarin-type anticoagulants	66-93	Astemizole	169-178	
Coumarin-type anticoagulants	66-93	Rifabutin	181-189	
Coumarin-type anticoagulants	66-93	Tacrolimus	192-201	
Coumarin-type anticoagulants	66-93	Short-acting benzodiazepines	204-231	
Coumarin-type anticoagulants	66-93	hypoglycemics	240-252	
Coumarin-type anticoagulants	66-93	DIFLUCAN	325-332	
Coumarin-type anticoagulants	66-93	hypoglycemic agents	344-362	
Phenytoin	96-104	Cyclosporine	107-118	
Phenytoin	96-104	Rifampin	121-128	
Phenytoin	96-104	Theophylline	131-142	
Phenytoin	96-104	Terfenadine	145-155	
Phenytoin	96-104	Cisapride	158-166	
Phenytoin	96-104	Astemizole	169-178	
Phenytoin	96-104	Rifabutin	181-189	
Phenytoin	96-104	Tacrolimus	192-201	
Phenytoin	96-104	Short-acting benzodiazepines	204-231	
Phenytoin	96-104	hypoglycemics	240-252	
Phenytoin	96-104	DIFLUCAN	325-332	
Phenytoin	96-104	hypoglycemic agents	344-362	
Cyclosporine	107-118	Rifampin	121-128	
Cyclosporine	107-118	Theophylline	131-142	
Cyclosporine	107-118	Terfenadine	145-155	
Cyclosporine	107-118	Cisapride	158-166	
Cyclosporine	107-118	Astemizole	169-178	
Cyclosporine	107-118	Rifabutin	181-189	
Cyclosporine	107-118	Tacrolimus	192-201	
Cyclosporine	107-118	Short-acting benzodiazepines	204-231	
Cyclosporine	107-118	hypoglycemics	240-252	
Cyclosporine	107-118	DIFLUCAN	325-332	
Cyclosporine	107-118	hypoglycemic agents	344-362	
Rifampin	121-128	Theophylline	131-142	
Rifampin	121-128	Terfenadine	145-155	
Rifampin	121-128	Cisapride	158-166	
Rifampin	121-128	Astemizole	169-178	
Rifampin	121-128	Rifabutin	181-189	
Rifampin	121-128	Tacrolimus	192-201	
Rifampin	121-128	Short-acting benzodiazepines	204-231	
Rifampin	121-128	hypoglycemics	240-252	
Rifampin	121-128	DIFLUCAN	325-332	
Rifampin	121-128	hypoglycemic agents	344-362	
Theophylline	131-142	Terfenadine	145-155	
Theophylline	131-142	Cisapride	158-166	
Theophylline	131-142	Astemizole	169-178	
Theophylline	131-142	Rifabutin	181-189	
Theophylline	131-142	Tacrolimus	192-201	
Theophylline	131-142	Short-acting benzodiazepines	204-231	
Theophylline	131-142	hypoglycemics	240-252	
Theophylline	131-142	DIFLUCAN	325-332	
Theophylline	131-142	hypoglycemic agents	344-362	
Terfenadine	145-155	Cisapride	158-166	
Terfenadine	145-155	Astemizole	169-178	
Terfenadine	145-155	Rifabutin	181-189	
Terfenadine	145-155	Tacrolimus	192-201	
Terfenadine	145-155	Short-acting benzodiazepines	204-231	
Terfenadine	145-155	hypoglycemics	240-252	
Terfenadine	145-155	DIFLUCAN	325-332	
Terfenadine	145-155	hypoglycemic agents	344-362	
Cisapride	158-166	Astemizole	169-178	
Cisapride	158-166	Rifabutin	181-189	
Cisapride	158-166	Tacrolimus	192-201	
Cisapride	158-166	Short-acting benzodiazepines	204-231	
Cisapride	158-166	hypoglycemics	240-252	
Cisapride	158-166	DIFLUCAN	325-332	
Cisapride	158-166	hypoglycemic agents	344-362	
Astemizole	169-178	Rifabutin	181-189	
Astemizole	169-178	Tacrolimus	192-201	
Astemizole	169-178	Short-acting benzodiazepines	204-231	
Astemizole	169-178	hypoglycemics	240-252	
Astemizole	169-178	DIFLUCAN	325-332	
Astemizole	169-178	hypoglycemic agents	344-362	
Rifabutin	181-189	Tacrolimus	192-201	
Rifabutin	181-189	Short-acting benzodiazepines	204-231	
Rifabutin	181-189	hypoglycemics	240-252	
Rifabutin	181-189	DIFLUCAN	325-332	
Rifabutin	181-189	hypoglycemic agents	344-362	
Tacrolimus	192-201	Short-acting benzodiazepines	204-231	
Tacrolimus	192-201	hypoglycemics	240-252	
Tacrolimus	192-201	DIFLUCAN	325-332	
Tacrolimus	192-201	hypoglycemic agents	344-362	
Short-acting benzodiazepines	204-231	hypoglycemics	240-252	
Short-acting benzodiazepines	204-231	DIFLUCAN	325-332	
Short-acting benzodiazepines	204-231	hypoglycemic agents	344-362	
hypoglycemics	240-252	DIFLUCAN	325-332	
hypoglycemics	240-252	hypoglycemic agents	344-362	
DIFLUCAN	325-332	hypoglycemic agents	344-362	

one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use.
DIFLUCAN	78-85	glyburide	91-99	

DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents.
DIFLUCAN	0-7	tolbutamide	35-45	
DIFLUCAN	0-7	glyburide	48-56	
DIFLUCAN	0-7	glipizide	63-71	
tolbutamide	35-45	glyburide	48-56	
tolbutamide	35-45	glipizide	63-71	
glyburide	48-56	glipizide	63-71	

When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary.
DIFLUCAN	5-12	sulfonylurea oral hypoglycemic agents	56-92	
DIFLUCAN	5-12	sulfonylurea	174-185	
sulfonylurea oral hypoglycemic agents	56-92	sulfonylurea	174-185	

Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants.
Coumarin-type anticoagulants	0-27	DIFLUCAN	98-105	
Coumarin-type anticoagulants	0-27	coumarin-type anticoagulants	111-138	
DIFLUCAN	98-105	coumarin-type anticoagulants	111-138	

In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin.
azole antifungals	44-60	fluconazole	242-252	
azole antifungals	44-60	warfarin	272-279	
fluconazole	242-252	warfarin	272-279	

Careful monitoring of prothrombin time in patients receiving DIFLUCAN and coumarin-type anticoagulants is recommended.
DIFLUCAN	61-68	coumarin-type anticoagulants	74-101	

Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin.
Phenytoin	0-8	DIFLUCAN	11-18	
Phenytoin	0-8	phenytoin	59-67	
DIFLUCAN	11-18	phenytoin	59-67	

Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended.
phenytoin	22-30	DIFLUCAN	69-76	
phenytoin	22-30	phenytoin	82-90	
DIFLUCAN	69-76	phenytoin	82-90	

Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment.
Cyclosporine	0-11	DIFLUCAN	14-21	
Cyclosporine	0-11	cyclosporine	50-61	
DIFLUCAN	14-21	cyclosporine	50-61	

Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine.
cyclosporine	22-33	DIFLUCAN	108-115	
cyclosporine	22-33	cyclosporine	121-132	
DIFLUCAN	108-115	cyclosporine	121-132	

Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN.
Rifampin	0-7	Rifampin	10-17	
Rifampin	0-7	DIFLUCAN	72-79	
Rifampin	10-17	DIFLUCAN	72-79	

Depending on clinical circumstances, consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin.
DIFLUCAN	93-100	rifampin	131-138	

Theophylline: DIFLUCAN increases the serum concentrations of theophylline.
Theophylline	0-11	DIFLUCAN	14-21	
Theophylline	0-11	theophylline	61-72	
DIFLUCAN	14-21	theophylline	61-72	

Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended.
theophylline	28-39	DIFLUCAN	78-85	
theophylline	28-39	theophylline	91-102	
DIFLUCAN	78-85	theophylline	91-102	

Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed.
Terfenadine	0-10	azole antifungals	139-155	
Terfenadine	0-10	terfenadine	177-187	
azole antifungals	139-155	terfenadine	177-187	

Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly.
fluconazole	51-61	DIFLUCAN	81-88	
fluconazole	51-61	terfenadine	175-185	
DIFLUCAN	81-88	terfenadine	175-185	

The combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated.
fluconazole	20-30	terfenadine	67-77	

The coadministration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored.
fluconazole	24-34	terfenadine	72-82	

Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered.
Cisapride	0-8	fluconazole	103-113	
Cisapride	0-8	cisapride	119-127	
fluconazole	103-113	cisapride	119-127	

A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.
fluconazole	42-52	cisapride	76-84	
fluconazole	42-52	cisapride	143-151	
cisapride	76-84	cisapride	143-151	

The combined use of fluconazole with cisapride is contraindicated.
fluconazole	20-30	cisapride	37-45	

Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.
Astemizole	0-9	fluconazole	23-33	
Astemizole	0-9	astemizole	67-76	
fluconazole	23-33	astemizole	67-76	

Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered.
Rifabutin	0-8	fluconazole	66-76	
Rifabutin	0-8	rifabutin	82-90	
fluconazole	66-76	rifabutin	82-90	

Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored.
rifabutin	19-27	fluconazole	33-43	

Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered.
Tacrolimus	0-9	fluconazole	74-84	
Tacrolimus	0-9	tacrolimus	90-99	
fluconazole	74-84	tacrolimus	90-99	

Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored.
tacrolimus	19-28	fluconazole	34-44	

Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects.
Short-acting Benzodiazepines	0-27	midazolam	63-71	
Short-acting Benzodiazepines	0-27	fluconazole	74-84	
Short-acting Benzodiazepines	0-27	midazolam	123-131	
midazolam	63-71	fluconazole	74-84	
midazolam	63-71	midazolam	123-131	
fluconazole	74-84	midazolam	123-131	

This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously.
midazolam	15-23	fluconazole	88-98	
midazolam	15-23	fluconazole	110-120	
fluconazole	88-98	fluconazole	110-120	

If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored.
short-acting benzodiazepines	3-30	fluconazole	122-132	
short-acting benzodiazepines	3-30	benzodiazepine	183-196	
fluconazole	122-132	benzodiazepine	183-196	

Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;
Fluconazole	0-10	ethinyl estradiol	40-56	
Fluconazole	0-10	levonorgestrel	63-76	
Fluconazole	0-10	contraceptives	94-107	
Fluconazole	0-10	ethinyl estradiol	146-162	
Fluconazole	0-10	levonorgestrel	168-181	
ethinyl estradiol	40-56	levonorgestrel	63-76	
ethinyl estradiol	40-56	contraceptives	94-107	
ethinyl estradiol	40-56	ethinyl estradiol	146-162	
ethinyl estradiol	40-56	levonorgestrel	168-181	
levonorgestrel	63-76	contraceptives	94-107	
levonorgestrel	63-76	ethinyl estradiol	146-162	
levonorgestrel	63-76	levonorgestrel	168-181	
contraceptives	94-107	ethinyl estradiol	146-162	
contraceptives	94-107	levonorgestrel	168-181	
ethinyl estradiol	146-162	levonorgestrel	168-181	

however, in some patients there were decreases up to 47% and 33% of ethinyl estradiol and levonorgestrel levels.
ethinyl estradiol	68-84	levonorgestrel	90-103	

The data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel AUC values with fluconazole treatment are likely the result of random variation.
ethinyl estradiol	76-92	levonorgestrel	98-111	
ethinyl estradiol	76-92	fluconazole	129-139	
levonorgestrel	98-111	fluconazole	129-139	

While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.
fluconazole	29-39	ethinyl estradiol	71-87	
fluconazole	29-39	levonorgestrel	93-106	
fluconazole	29-39	fluconazole	135-145	
fluconazole	29-39	ethinyl estradiol	167-183	
fluconazole	29-39	levonorgestrel	188-201	
ethinyl estradiol	71-87	levonorgestrel	93-106	
ethinyl estradiol	71-87	fluconazole	135-145	
ethinyl estradiol	71-87	ethinyl estradiol	167-183	
ethinyl estradiol	71-87	levonorgestrel	188-201	
levonorgestrel	93-106	fluconazole	135-145	
levonorgestrel	93-106	ethinyl estradiol	167-183	
levonorgestrel	93-106	levonorgestrel	188-201	
fluconazole	135-145	ethinyl estradiol	167-183	
fluconazole	135-145	levonorgestrel	188-201	
ethinyl estradiol	167-183	levonorgestrel	188-201	

You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
mazindol	16-23	monoamine oxidase inhibitor	45-71	
mazindol	16-23	MAOI	74-77	
mazindol	16-23	isocarboxazid	88-100	
mazindol	16-23	Marplan	103-109	
mazindol	16-23	tranylcypromine	113-127	
mazindol	16-23	Parnate	130-136	
mazindol	16-23	phenelzine	143-152	
mazindol	16-23	Nardil	155-160	
monoamine oxidase inhibitor	45-71	MAOI	74-77	
monoamine oxidase inhibitor	45-71	isocarboxazid	88-100	
monoamine oxidase inhibitor	45-71	Marplan	103-109	
monoamine oxidase inhibitor	45-71	tranylcypromine	113-127	
monoamine oxidase inhibitor	45-71	Parnate	130-136	
monoamine oxidase inhibitor	45-71	phenelzine	143-152	
monoamine oxidase inhibitor	45-71	Nardil	155-160	
MAOI	74-77	isocarboxazid	88-100	
MAOI	74-77	Marplan	103-109	
MAOI	74-77	tranylcypromine	113-127	
MAOI	74-77	Parnate	130-136	
MAOI	74-77	phenelzine	143-152	
MAOI	74-77	Nardil	155-160	
isocarboxazid	88-100	Marplan	103-109	
isocarboxazid	88-100	tranylcypromine	113-127	
isocarboxazid	88-100	Parnate	130-136	
isocarboxazid	88-100	phenelzine	143-152	
isocarboxazid	88-100	Nardil	155-160	
Marplan	103-109	tranylcypromine	113-127	
Marplan	103-109	Parnate	130-136	
Marplan	103-109	phenelzine	143-152	
Marplan	103-109	Nardil	155-160	
tranylcypromine	113-127	Parnate	130-136	
tranylcypromine	113-127	phenelzine	143-152	
tranylcypromine	113-127	Nardil	155-160	
Parnate	130-136	phenelzine	143-152	
Parnate	130-136	Nardil	155-160	
phenelzine	143-152	Nardil	155-160	

Changes in insulin and other diabetes drug therapies may be necessary during treatment with mazindol.
insulin	11-17	mazindol	92-99	

Mazindol may reduce the effects of guanethidine (Ismelin).
Mazindol	0-7	guanethidine	35-46	
Mazindol	0-7	Ismelin	49-55	
guanethidine	35-46	Ismelin	49-55	

Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
tricyclic antidepressant	68-91	amitriptyline	101-113	
tricyclic antidepressant	68-91	Elavil	116-121	
tricyclic antidepressant	68-91	amoxapine	125-133	
tricyclic antidepressant	68-91	Asendin	136-142	
tricyclic antidepressant	68-91	doxepin	146-152	
tricyclic antidepressant	68-91	Sinequan	155-162	
tricyclic antidepressant	68-91	nortriptyline	166-178	
tricyclic antidepressant	68-91	Pamelor	181-187	
tricyclic antidepressant	68-91	imipramine	191-200	
tricyclic antidepressant	68-91	Tofranil	203-210	
tricyclic antidepressant	68-91	clomipramine	214-225	
tricyclic antidepressant	68-91	Anafranil	228-236	
tricyclic antidepressant	68-91	protriptyline	240-252	
tricyclic antidepressant	68-91	Vivactil	255-262	
tricyclic antidepressant	68-91	desipramine	269-279	
tricyclic antidepressant	68-91	Norpramin	282-290	
amitriptyline	101-113	Elavil	116-121	
amitriptyline	101-113	amoxapine	125-133	
amitriptyline	101-113	Asendin	136-142	
amitriptyline	101-113	doxepin	146-152	
amitriptyline	101-113	Sinequan	155-162	
amitriptyline	101-113	nortriptyline	166-178	
amitriptyline	101-113	Pamelor	181-187	
amitriptyline	101-113	imipramine	191-200	
amitriptyline	101-113	Tofranil	203-210	
amitriptyline	101-113	clomipramine	214-225	
amitriptyline	101-113	Anafranil	228-236	
amitriptyline	101-113	protriptyline	240-252	
amitriptyline	101-113	Vivactil	255-262	
amitriptyline	101-113	desipramine	269-279	
amitriptyline	101-113	Norpramin	282-290	
Elavil	116-121	amoxapine	125-133	
Elavil	116-121	Asendin	136-142	
Elavil	116-121	doxepin	146-152	
Elavil	116-121	Sinequan	155-162	
Elavil	116-121	nortriptyline	166-178	
Elavil	116-121	Pamelor	181-187	
Elavil	116-121	imipramine	191-200	
Elavil	116-121	Tofranil	203-210	
Elavil	116-121	clomipramine	214-225	
Elavil	116-121	Anafranil	228-236	
Elavil	116-121	protriptyline	240-252	
Elavil	116-121	Vivactil	255-262	
Elavil	116-121	desipramine	269-279	
Elavil	116-121	Norpramin	282-290	
amoxapine	125-133	Asendin	136-142	
amoxapine	125-133	doxepin	146-152	
amoxapine	125-133	Sinequan	155-162	
amoxapine	125-133	nortriptyline	166-178	
amoxapine	125-133	Pamelor	181-187	
amoxapine	125-133	imipramine	191-200	
amoxapine	125-133	Tofranil	203-210	
amoxapine	125-133	clomipramine	214-225	
amoxapine	125-133	Anafranil	228-236	
amoxapine	125-133	protriptyline	240-252	
amoxapine	125-133	Vivactil	255-262	
amoxapine	125-133	desipramine	269-279	
amoxapine	125-133	Norpramin	282-290	
Asendin	136-142	doxepin	146-152	
Asendin	136-142	Sinequan	155-162	
Asendin	136-142	nortriptyline	166-178	
Asendin	136-142	Pamelor	181-187	
Asendin	136-142	imipramine	191-200	
Asendin	136-142	Tofranil	203-210	
Asendin	136-142	clomipramine	214-225	
Asendin	136-142	Anafranil	228-236	
Asendin	136-142	protriptyline	240-252	
Asendin	136-142	Vivactil	255-262	
Asendin	136-142	desipramine	269-279	
Asendin	136-142	Norpramin	282-290	
doxepin	146-152	Sinequan	155-162	
doxepin	146-152	nortriptyline	166-178	
doxepin	146-152	Pamelor	181-187	
doxepin	146-152	imipramine	191-200	
doxepin	146-152	Tofranil	203-210	
doxepin	146-152	clomipramine	214-225	
doxepin	146-152	Anafranil	228-236	
doxepin	146-152	protriptyline	240-252	
doxepin	146-152	Vivactil	255-262	
doxepin	146-152	desipramine	269-279	
doxepin	146-152	Norpramin	282-290	
Sinequan	155-162	nortriptyline	166-178	
Sinequan	155-162	Pamelor	181-187	
Sinequan	155-162	imipramine	191-200	
Sinequan	155-162	Tofranil	203-210	
Sinequan	155-162	clomipramine	214-225	
Sinequan	155-162	Anafranil	228-236	
Sinequan	155-162	protriptyline	240-252	
Sinequan	155-162	Vivactil	255-262	
Sinequan	155-162	desipramine	269-279	
Sinequan	155-162	Norpramin	282-290	
nortriptyline	166-178	Pamelor	181-187	
nortriptyline	166-178	imipramine	191-200	
nortriptyline	166-178	Tofranil	203-210	
nortriptyline	166-178	clomipramine	214-225	
nortriptyline	166-178	Anafranil	228-236	
nortriptyline	166-178	protriptyline	240-252	
nortriptyline	166-178	Vivactil	255-262	
nortriptyline	166-178	desipramine	269-279	
nortriptyline	166-178	Norpramin	282-290	
Pamelor	181-187	imipramine	191-200	
Pamelor	181-187	Tofranil	203-210	
Pamelor	181-187	clomipramine	214-225	
Pamelor	181-187	Anafranil	228-236	
Pamelor	181-187	protriptyline	240-252	
Pamelor	181-187	Vivactil	255-262	
Pamelor	181-187	desipramine	269-279	
Pamelor	181-187	Norpramin	282-290	
imipramine	191-200	Tofranil	203-210	
imipramine	191-200	clomipramine	214-225	
imipramine	191-200	Anafranil	228-236	
imipramine	191-200	protriptyline	240-252	
imipramine	191-200	Vivactil	255-262	
imipramine	191-200	desipramine	269-279	
imipramine	191-200	Norpramin	282-290	
Tofranil	203-210	clomipramine	214-225	
Tofranil	203-210	Anafranil	228-236	
Tofranil	203-210	protriptyline	240-252	
Tofranil	203-210	Vivactil	255-262	
Tofranil	203-210	desipramine	269-279	
Tofranil	203-210	Norpramin	282-290	
clomipramine	214-225	Anafranil	228-236	
clomipramine	214-225	protriptyline	240-252	
clomipramine	214-225	Vivactil	255-262	
clomipramine	214-225	desipramine	269-279	
clomipramine	214-225	Norpramin	282-290	
Anafranil	228-236	protriptyline	240-252	
Anafranil	228-236	Vivactil	255-262	
Anafranil	228-236	desipramine	269-279	
Anafranil	228-236	Norpramin	282-290	
protriptyline	240-252	Vivactil	255-262	
protriptyline	240-252	desipramine	269-279	
protriptyline	240-252	Norpramin	282-290	
Vivactil	255-262	desipramine	269-279	
Vivactil	255-262	Norpramin	282-290	
desipramine	269-279	Norpramin	282-290	

Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.
cimetidine	35-44	mebendazole	55-65	
cimetidine	35-44	mebendazole	136-146	
mebendazole	55-65	mebendazole	136-146	

Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.
antibiotics	19-29	sulfonamides	35-46	
antibiotics	19-29	ganglion blockers	85-101	
sulfonamides	35-46	ganglion blockers	85-101	

The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.
Mecamylamine	14-25	antihypertensive drugs	67-88	
Mecamylamine	14-25	alcohol	94-100	
antihypertensive drugs	67-88	alcohol	94-100	

Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA.
Aminoglutethimide	0-16	depo-subQ provera 104	50-70	
Aminoglutethimide	0-16	MPA	127-129	
depo-subQ provera 104	50-70	MPA	127-129	

Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs.
zidovudine	104-113	rifabutin	118-126	
zidovudine	104-113	megestrol acetate	162-178	
rifabutin	118-126	megestrol acetate	162-178	

A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir.
megestrol acetate	62-78	indinavir	84-92	
megestrol acetate	62-78	indinavir	198-206	
indinavir	84-92	indinavir	198-206	

Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate.
indinavir	35-43	megestrol acetate	92-108	

The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.
indinavir	15-23	zidovudine	26-35	
indinavir	15-23	rifabutin	40-48	
indinavir	15-23	megestrol acetate	77-93	
zidovudine	26-35	rifabutin	40-48	
zidovudine	26-35	megestrol acetate	77-93	
rifabutin	40-48	megestrol acetate	77-93	

Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
Melatonin	0-8	aspirin	49-55	
Melatonin	0-8	NSAIDs	67-72	
Melatonin	0-8	melatonin	85-93	
Melatonin	0-8	fluvoxamine	104-114	
Melatonin	0-8	melatonin	141-149	
Melatonin	0-8	beta blockers	188-200	
Melatonin	0-8	melatonin	216-224	
Melatonin	0-8	fluoxetine	235-244	
Melatonin	0-8	progestin	299-307	
Melatonin	0-8	melatonin	330-338	
Melatonin	0-8	progestin	345-353	
Melatonin	0-8	benzodiazepenes	395-409	
Melatonin	0-8	corticosteroids	521-535	
Melatonin	0-8	melatonin	558-566	
Melatonin	0-8	corticosteroids	572-586	
Melatonin	0-8	corticosteroids	627-641	
aspirin	49-55	NSAIDs	67-72	
aspirin	49-55	melatonin	85-93	
aspirin	49-55	fluvoxamine	104-114	
aspirin	49-55	melatonin	141-149	
aspirin	49-55	beta blockers	188-200	
aspirin	49-55	melatonin	216-224	
aspirin	49-55	fluoxetine	235-244	
aspirin	49-55	progestin	299-307	
aspirin	49-55	melatonin	330-338	
aspirin	49-55	progestin	345-353	
aspirin	49-55	benzodiazepenes	395-409	
aspirin	49-55	corticosteroids	521-535	
aspirin	49-55	melatonin	558-566	
aspirin	49-55	corticosteroids	572-586	
aspirin	49-55	corticosteroids	627-641	
NSAIDs	67-72	melatonin	85-93	
NSAIDs	67-72	fluvoxamine	104-114	
NSAIDs	67-72	melatonin	141-149	
NSAIDs	67-72	beta blockers	188-200	
NSAIDs	67-72	melatonin	216-224	
NSAIDs	67-72	fluoxetine	235-244	
NSAIDs	67-72	progestin	299-307	
NSAIDs	67-72	melatonin	330-338	
NSAIDs	67-72	progestin	345-353	
NSAIDs	67-72	benzodiazepenes	395-409	
NSAIDs	67-72	corticosteroids	521-535	
NSAIDs	67-72	melatonin	558-566	
NSAIDs	67-72	corticosteroids	572-586	
NSAIDs	67-72	corticosteroids	627-641	
melatonin	85-93	fluvoxamine	104-114	
melatonin	85-93	melatonin	141-149	
melatonin	85-93	beta blockers	188-200	
melatonin	85-93	melatonin	216-224	
melatonin	85-93	fluoxetine	235-244	
melatonin	85-93	progestin	299-307	
melatonin	85-93	melatonin	330-338	
melatonin	85-93	progestin	345-353	
melatonin	85-93	benzodiazepenes	395-409	
melatonin	85-93	corticosteroids	521-535	
melatonin	85-93	melatonin	558-566	
melatonin	85-93	corticosteroids	572-586	
melatonin	85-93	corticosteroids	627-641	
fluvoxamine	104-114	melatonin	141-149	
fluvoxamine	104-114	beta blockers	188-200	
fluvoxamine	104-114	melatonin	216-224	
fluvoxamine	104-114	fluoxetine	235-244	
fluvoxamine	104-114	progestin	299-307	
fluvoxamine	104-114	melatonin	330-338	
fluvoxamine	104-114	progestin	345-353	
fluvoxamine	104-114	benzodiazepenes	395-409	
fluvoxamine	104-114	corticosteroids	521-535	
fluvoxamine	104-114	melatonin	558-566	
fluvoxamine	104-114	corticosteroids	572-586	
fluvoxamine	104-114	corticosteroids	627-641	
melatonin	141-149	beta blockers	188-200	
melatonin	141-149	melatonin	216-224	
melatonin	141-149	fluoxetine	235-244	
melatonin	141-149	progestin	299-307	
melatonin	141-149	melatonin	330-338	
melatonin	141-149	progestin	345-353	
melatonin	141-149	benzodiazepenes	395-409	
melatonin	141-149	corticosteroids	521-535	
melatonin	141-149	melatonin	558-566	
melatonin	141-149	corticosteroids	572-586	
melatonin	141-149	corticosteroids	627-641	
beta blockers	188-200	melatonin	216-224	
beta blockers	188-200	fluoxetine	235-244	
beta blockers	188-200	progestin	299-307	
beta blockers	188-200	melatonin	330-338	
beta blockers	188-200	progestin	345-353	
beta blockers	188-200	benzodiazepenes	395-409	
beta blockers	188-200	corticosteroids	521-535	
beta blockers	188-200	melatonin	558-566	
beta blockers	188-200	corticosteroids	572-586	
beta blockers	188-200	corticosteroids	627-641	
melatonin	216-224	fluoxetine	235-244	
melatonin	216-224	progestin	299-307	
melatonin	216-224	melatonin	330-338	
melatonin	216-224	progestin	345-353	
melatonin	216-224	benzodiazepenes	395-409	
melatonin	216-224	corticosteroids	521-535	
melatonin	216-224	melatonin	558-566	
melatonin	216-224	corticosteroids	572-586	
melatonin	216-224	corticosteroids	627-641	
fluoxetine	235-244	progestin	299-307	
fluoxetine	235-244	melatonin	330-338	
fluoxetine	235-244	progestin	345-353	
fluoxetine	235-244	benzodiazepenes	395-409	
fluoxetine	235-244	corticosteroids	521-535	
fluoxetine	235-244	melatonin	558-566	
fluoxetine	235-244	corticosteroids	572-586	
fluoxetine	235-244	corticosteroids	627-641	
progestin	299-307	melatonin	330-338	
progestin	299-307	progestin	345-353	
progestin	299-307	benzodiazepenes	395-409	
progestin	299-307	corticosteroids	521-535	
progestin	299-307	melatonin	558-566	
progestin	299-307	corticosteroids	572-586	
progestin	299-307	corticosteroids	627-641	
melatonin	330-338	progestin	345-353	
melatonin	330-338	benzodiazepenes	395-409	
melatonin	330-338	corticosteroids	521-535	
melatonin	330-338	melatonin	558-566	
melatonin	330-338	corticosteroids	572-586	
melatonin	330-338	corticosteroids	627-641	
progestin	345-353	benzodiazepenes	395-409	
progestin	345-353	corticosteroids	521-535	
progestin	345-353	melatonin	558-566	
progestin	345-353	corticosteroids	572-586	
progestin	345-353	corticosteroids	627-641	
benzodiazepenes	395-409	corticosteroids	521-535	
benzodiazepenes	395-409	melatonin	558-566	
benzodiazepenes	395-409	corticosteroids	572-586	
benzodiazepenes	395-409	corticosteroids	627-641	
corticosteroids	521-535	melatonin	558-566	
corticosteroids	521-535	corticosteroids	572-586	
corticosteroids	521-535	corticosteroids	627-641	
melatonin	558-566	corticosteroids	572-586	
melatonin	558-566	corticosteroids	627-641	
corticosteroids	572-586	corticosteroids	627-641	

ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors.
ACE inhibitors	0-13	NSAIDs	36-41	
ACE inhibitors	0-13	angiotensin-converting enzyme (ACE) inhibitors	87-132	
NSAIDs	36-41	angiotensin-converting enzyme (ACE) inhibitors	87-132	

This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
NSAIDs	66-71	ACE inhibitors	92-105	

Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam.
Aspirin	0-6	aspirin	39-45	
Aspirin	0-6	meloxicam	134-142	
aspirin	39-45	meloxicam	134-142	

however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.
NSAIDs	23-28	meloxicam	61-69	
NSAIDs	23-28	aspirin	75-81	
meloxicam	61-69	aspirin	75-81	

Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone.
aspirin	39-45	MOBIC	52-56	
aspirin	39-45	MOBIC	150-154	
MOBIC	52-56	MOBIC	150-154	

MOBIC is not a substitute for aspirin for cardiovascular prophylaxis.
MOBIC	0-4	aspirin	30-36	

Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%.
Cholestyramine	0-13	cholestyramine	48-61	
Cholestyramine	0-13	meloxicam	104-112	
cholestyramine	48-61	meloxicam	104-112	

Cimetidine: Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam.
Cimetidine	0-9	cimetidine	49-58	
Cimetidine	0-9	meloxicam	120-128	
cimetidine	49-58	meloxicam	120-128	

Digoxin: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses.
Digoxin	0-6	Meloxicam	9-17	
Digoxin	0-6	digoxin	97-103	
Meloxicam	9-17	digoxin	97-103	

In vitro testing found no protein binding drug interaction between digoxin and meloxicam.
digoxin	67-73	meloxicam	79-87	

Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients.
Furosemide	0-9	NSAIDs	86-91	
Furosemide	0-9	furosemide	130-139	
Furosemide	0-9	thiazide diuretics	145-162	
NSAIDs	86-91	furosemide	130-139	
NSAIDs	86-91	thiazide diuretics	145-162	
furosemide	130-139	thiazide diuretics	145-162	

Studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect.
furosemide	13-22	meloxicam	35-43	

Furosemide: single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of meloxicam.
Furosemide	0-9	meloxicam	113-121	

Nevertheless, during concomitant therapy with furosemide and MOBIC, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy.
furosemide	46-55	MOBIC	61-65	

Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
Lithium	0-6	NSAIDs	29-34	
Lithium	0-6	lithium	73-79	
Lithium	0-6	lithium	113-119	
NSAIDs	29-34	lithium	73-79	
NSAIDs	29-34	lithium	113-119	
lithium	73-79	lithium	113-119	

In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone.
lithium	56-62	lithium	130-136	
lithium	56-62	meloxicam	181-189	
lithium	56-62	lithium	234-240	
lithium	130-136	meloxicam	181-189	
lithium	130-136	lithium	234-240	
meloxicam	181-189	lithium	234-240	

Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn.
lithium	12-18	MOBIC	63-67	

Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly.
Methotrexate	0-11	meloxicam	106-114	
Methotrexate	0-11	methotrexate	143-154	
meloxicam	106-114	methotrexate	143-154	

Meloxicam did not have a significant effect on the pharmacokinetics of single doses of methotrexate.
Meloxicam	0-8	methotrexate	87-98	

In vitro, methotrexate did not displace meloxicam from its human serum binding sites.
methotrexate	10-21	meloxicam	40-48	

Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding.
Warfarin	0-7	MOBIC	118-122	
Warfarin	0-7	warfarin	154-161	
MOBIC	118-122	warfarin	154-161	

The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8.
meloxicam	14-22	warfarin	55-62	
meloxicam	14-22	warfarin	132-139	
warfarin	55-62	warfarin	132-139	

In these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time.
meloxicam	19-27	warfarin	43-50	
meloxicam	19-27	warfarin	109-116	
warfarin	43-50	warfarin	109-116	

Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.
MOBIC	42-46	warfarin	53-60	
MOBIC	42-46	warfarin	80-87	
warfarin	53-60	warfarin	80-87	

DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.
ALKERAN	71-77	live organism vaccines	98-119	
ALKERAN	71-77	Nalidixic acid	175-188	
ALKERAN	71-77	melphalan	226-234	
live organism vaccines	98-119	Nalidixic acid	175-188	
live organism vaccines	98-119	melphalan	226-234	
Nalidixic acid	175-188	melphalan	226-234	

Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease
melphalan	126-134	cyclosporin	166-176	

The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
anticholinergic drugs	69-89	amantadine	92-101	
anticholinergic drugs	69-89	antiarrhythmic agents of class I	104-135	
anticholinergic drugs	69-89	quinidine	144-152	
anticholinergic drugs	69-89	antihistamines	156-169	
anticholinergic drugs	69-89	antipsychotic agents	172-191	
anticholinergic drugs	69-89	phenothiazines	200-213	
anticholinergic drugs	69-89	benzodiazepines	217-231	
anticholinergic drugs	69-89	MAO inhibitors	234-247	
anticholinergic drugs	69-89	narcotic analgesics	250-268	
anticholinergic drugs	69-89	meperidine	277-286	
anticholinergic drugs	69-89	nitrates	290-297	
anticholinergic drugs	69-89	nitrites	303-310	
anticholinergic drugs	69-89	sympathomimetic agents	313-334	
anticholinergic drugs	69-89	tricyclic antidepressants	337-361	
amantadine	92-101	antiarrhythmic agents of class I	104-135	
amantadine	92-101	quinidine	144-152	
amantadine	92-101	antihistamines	156-169	
amantadine	92-101	antipsychotic agents	172-191	
amantadine	92-101	phenothiazines	200-213	
amantadine	92-101	benzodiazepines	217-231	
amantadine	92-101	MAO inhibitors	234-247	
amantadine	92-101	narcotic analgesics	250-268	
amantadine	92-101	meperidine	277-286	
amantadine	92-101	nitrates	290-297	
amantadine	92-101	nitrites	303-310	
amantadine	92-101	sympathomimetic agents	313-334	
amantadine	92-101	tricyclic antidepressants	337-361	
antiarrhythmic agents of class I	104-135	quinidine	144-152	
antiarrhythmic agents of class I	104-135	antihistamines	156-169	
antiarrhythmic agents of class I	104-135	antipsychotic agents	172-191	
antiarrhythmic agents of class I	104-135	phenothiazines	200-213	
antiarrhythmic agents of class I	104-135	benzodiazepines	217-231	
antiarrhythmic agents of class I	104-135	MAO inhibitors	234-247	
antiarrhythmic agents of class I	104-135	narcotic analgesics	250-268	
antiarrhythmic agents of class I	104-135	meperidine	277-286	
antiarrhythmic agents of class I	104-135	nitrates	290-297	
antiarrhythmic agents of class I	104-135	nitrites	303-310	
antiarrhythmic agents of class I	104-135	sympathomimetic agents	313-334	
antiarrhythmic agents of class I	104-135	tricyclic antidepressants	337-361	
quinidine	144-152	antihistamines	156-169	
quinidine	144-152	antipsychotic agents	172-191	
quinidine	144-152	phenothiazines	200-213	
quinidine	144-152	benzodiazepines	217-231	
quinidine	144-152	MAO inhibitors	234-247	
quinidine	144-152	narcotic analgesics	250-268	
quinidine	144-152	meperidine	277-286	
quinidine	144-152	nitrates	290-297	
quinidine	144-152	nitrites	303-310	
quinidine	144-152	sympathomimetic agents	313-334	
quinidine	144-152	tricyclic antidepressants	337-361	
antihistamines	156-169	antipsychotic agents	172-191	
antihistamines	156-169	phenothiazines	200-213	
antihistamines	156-169	benzodiazepines	217-231	
antihistamines	156-169	MAO inhibitors	234-247	
antihistamines	156-169	narcotic analgesics	250-268	
antihistamines	156-169	meperidine	277-286	
antihistamines	156-169	nitrates	290-297	
antihistamines	156-169	nitrites	303-310	
antihistamines	156-169	sympathomimetic agents	313-334	
antihistamines	156-169	tricyclic antidepressants	337-361	
antipsychotic agents	172-191	phenothiazines	200-213	
antipsychotic agents	172-191	benzodiazepines	217-231	
antipsychotic agents	172-191	MAO inhibitors	234-247	
antipsychotic agents	172-191	narcotic analgesics	250-268	
antipsychotic agents	172-191	meperidine	277-286	
antipsychotic agents	172-191	nitrates	290-297	
antipsychotic agents	172-191	nitrites	303-310	
antipsychotic agents	172-191	sympathomimetic agents	313-334	
antipsychotic agents	172-191	tricyclic antidepressants	337-361	
phenothiazines	200-213	benzodiazepines	217-231	
phenothiazines	200-213	MAO inhibitors	234-247	
phenothiazines	200-213	narcotic analgesics	250-268	
phenothiazines	200-213	meperidine	277-286	
phenothiazines	200-213	nitrates	290-297	
phenothiazines	200-213	nitrites	303-310	
phenothiazines	200-213	sympathomimetic agents	313-334	
phenothiazines	200-213	tricyclic antidepressants	337-361	
benzodiazepines	217-231	MAO inhibitors	234-247	
benzodiazepines	217-231	narcotic analgesics	250-268	
benzodiazepines	217-231	meperidine	277-286	
benzodiazepines	217-231	nitrates	290-297	
benzodiazepines	217-231	nitrites	303-310	
benzodiazepines	217-231	sympathomimetic agents	313-334	
benzodiazepines	217-231	tricyclic antidepressants	337-361	
MAO inhibitors	234-247	narcotic analgesics	250-268	
MAO inhibitors	234-247	meperidine	277-286	
MAO inhibitors	234-247	nitrates	290-297	
MAO inhibitors	234-247	nitrites	303-310	
MAO inhibitors	234-247	sympathomimetic agents	313-334	
MAO inhibitors	234-247	tricyclic antidepressants	337-361	
narcotic analgesics	250-268	meperidine	277-286	
narcotic analgesics	250-268	nitrates	290-297	
narcotic analgesics	250-268	nitrites	303-310	
narcotic analgesics	250-268	sympathomimetic agents	313-334	
narcotic analgesics	250-268	tricyclic antidepressants	337-361	
meperidine	277-286	nitrates	290-297	
meperidine	277-286	nitrites	303-310	
meperidine	277-286	sympathomimetic agents	313-334	
meperidine	277-286	tricyclic antidepressants	337-361	
nitrates	290-297	nitrites	303-310	
nitrates	290-297	sympathomimetic agents	313-334	
nitrates	290-297	tricyclic antidepressants	337-361	
nitrites	303-310	sympathomimetic agents	313-334	
nitrites	303-310	tricyclic antidepressants	337-361	
sympathomimetic agents	313-334	tricyclic antidepressants	337-361	

Anticholinergics antagonize the effects of antiglaucoma agents.
Anticholinergics	0-15	antiglaucoma agents	43-61	

Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids.
Anticholinergic drugs	0-20	corticosteroids	133-147	

Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;
Anticholinergic agents	0-21	digoxin	122-128	

Anticholinergic drugs may antagonize the effects of drugs that alter gastrointestinal motility, such as metoclopramide.
Anticholinergic drugs	0-20	metoclopramide	104-117	

Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.
antacids	8-15	anticholinergic agents	54-75	

Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
Central Nervous System Depressants	23-56	MEPERIDINE	59-68	
Central Nervous System Depressants	23-56	NARCOTIC ANALGESICS	175-193	
Central Nervous System Depressants	23-56	ANESTHETICS	204-214	
Central Nervous System Depressants	23-56	PHENOTHIAZINES	217-230	
Central Nervous System Depressants	23-56	TRANQUILIZERS	239-251	
Central Nervous System Depressants	23-56	SEDATIVE-HYPNOTICS	254-271	
Central Nervous System Depressants	23-56	BARBITURATES	284-295	
Central Nervous System Depressants	23-56	TRICYCLIC ANTIDEPRESSANTS	299-323	
Central Nervous System Depressants	23-56	CNS DEPRESSANTS	335-349	
Central Nervous System Depressants	23-56	ALCOHOL	362-368	
MEPERIDINE	59-68	NARCOTIC ANALGESICS	175-193	
MEPERIDINE	59-68	ANESTHETICS	204-214	
MEPERIDINE	59-68	PHENOTHIAZINES	217-230	
MEPERIDINE	59-68	TRANQUILIZERS	239-251	
MEPERIDINE	59-68	SEDATIVE-HYPNOTICS	254-271	
MEPERIDINE	59-68	BARBITURATES	284-295	
MEPERIDINE	59-68	TRICYCLIC ANTIDEPRESSANTS	299-323	
MEPERIDINE	59-68	CNS DEPRESSANTS	335-349	
MEPERIDINE	59-68	ALCOHOL	362-368	
NARCOTIC ANALGESICS	175-193	ANESTHETICS	204-214	
NARCOTIC ANALGESICS	175-193	PHENOTHIAZINES	217-230	
NARCOTIC ANALGESICS	175-193	TRANQUILIZERS	239-251	
NARCOTIC ANALGESICS	175-193	SEDATIVE-HYPNOTICS	254-271	
NARCOTIC ANALGESICS	175-193	BARBITURATES	284-295	
NARCOTIC ANALGESICS	175-193	TRICYCLIC ANTIDEPRESSANTS	299-323	
NARCOTIC ANALGESICS	175-193	CNS DEPRESSANTS	335-349	
NARCOTIC ANALGESICS	175-193	ALCOHOL	362-368	
ANESTHETICS	204-214	PHENOTHIAZINES	217-230	
ANESTHETICS	204-214	TRANQUILIZERS	239-251	
ANESTHETICS	204-214	SEDATIVE-HYPNOTICS	254-271	
ANESTHETICS	204-214	BARBITURATES	284-295	
ANESTHETICS	204-214	TRICYCLIC ANTIDEPRESSANTS	299-323	
ANESTHETICS	204-214	CNS DEPRESSANTS	335-349	
ANESTHETICS	204-214	ALCOHOL	362-368	
PHENOTHIAZINES	217-230	TRANQUILIZERS	239-251	
PHENOTHIAZINES	217-230	SEDATIVE-HYPNOTICS	254-271	
PHENOTHIAZINES	217-230	BARBITURATES	284-295	
PHENOTHIAZINES	217-230	TRICYCLIC ANTIDEPRESSANTS	299-323	
PHENOTHIAZINES	217-230	CNS DEPRESSANTS	335-349	
PHENOTHIAZINES	217-230	ALCOHOL	362-368	
TRANQUILIZERS	239-251	SEDATIVE-HYPNOTICS	254-271	
TRANQUILIZERS	239-251	BARBITURATES	284-295	
TRANQUILIZERS	239-251	TRICYCLIC ANTIDEPRESSANTS	299-323	
TRANQUILIZERS	239-251	CNS DEPRESSANTS	335-349	
TRANQUILIZERS	239-251	ALCOHOL	362-368	
SEDATIVE-HYPNOTICS	254-271	BARBITURATES	284-295	
SEDATIVE-HYPNOTICS	254-271	TRICYCLIC ANTIDEPRESSANTS	299-323	
SEDATIVE-HYPNOTICS	254-271	CNS DEPRESSANTS	335-349	
SEDATIVE-HYPNOTICS	254-271	ALCOHOL	362-368	
BARBITURATES	284-295	TRICYCLIC ANTIDEPRESSANTS	299-323	
BARBITURATES	284-295	CNS DEPRESSANTS	335-349	
BARBITURATES	284-295	ALCOHOL	362-368	
TRICYCLIC ANTIDEPRESSANTS	299-323	CNS DEPRESSANTS	335-349	
TRICYCLIC ANTIDEPRESSANTS	299-323	ALCOHOL	362-368	
CNS DEPRESSANTS	335-349	ALCOHOL	362-368	

Some anticonvulsants may interact with Mephenytoin.
anticonvulsants	5-19	Mephenytoin	39-49	

Those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital.
anticonvulsants	6-20	divalproex sodium	30-46	
anticonvulsants	6-20	valproic acid	49-61	
anticonvulsants	6-20	phenobarbital	68-80	
divalproex sodium	30-46	valproic acid	49-61	
divalproex sodium	30-46	phenobarbital	68-80	
valproic acid	49-61	phenobarbital	68-80	

Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
Mephenytoin	0-10	steroid medications	75-93	
Mephenytoin	0-10	warfarin	96-103	
Mephenytoin	0-10	anti-infective medicines	152-175	
Mephenytoin	0-10	furosemide	178-187	
Mephenytoin	0-10	theophylline	193-204	
Mephenytoin	0-10	Mephenytoin	223-233	
steroid medications	75-93	warfarin	96-103	
steroid medications	75-93	anti-infective medicines	152-175	
steroid medications	75-93	furosemide	178-187	
steroid medications	75-93	theophylline	193-204	
steroid medications	75-93	Mephenytoin	223-233	
warfarin	96-103	anti-infective medicines	152-175	
warfarin	96-103	furosemide	178-187	
warfarin	96-103	theophylline	193-204	
warfarin	96-103	Mephenytoin	223-233	
anti-infective medicines	152-175	furosemide	178-187	
anti-infective medicines	152-175	theophylline	193-204	
anti-infective medicines	152-175	Mephenytoin	223-233	
furosemide	178-187	theophylline	193-204	
furosemide	178-187	Mephenytoin	223-233	
theophylline	193-204	Mephenytoin	223-233	

Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.
Mequitazine	0-10	CNS depressant	30-43	
Mequitazine	0-10	antichlolinergic	46-61	
Mequitazine	0-10	TCA	64-66	
Mequitazine	0-10	MAOIs	69-73	
Mequitazine	0-10	alcohol	80-86	
CNS depressant	30-43	antichlolinergic	46-61	
CNS depressant	30-43	TCA	64-66	
CNS depressant	30-43	MAOIs	69-73	
CNS depressant	30-43	alcohol	80-86	
antichlolinergic	46-61	TCA	64-66	
antichlolinergic	46-61	MAOIs	69-73	
antichlolinergic	46-61	alcohol	80-86	
TCA	64-66	MAOIs	69-73	
TCA	64-66	alcohol	80-86	
MAOIs	69-73	alcohol	80-86	

Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem.
Probenecid	0-9	meropenem	25-33	
Probenecid	0-9	meropenem	105-113	
meropenem	25-33	meropenem	105-113	

Therefore, the coadministration of probenecid with meropenem is not recommended.
probenecid	35-44	meropenem	51-59	

There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).
meropenem	23-31	valproic acid	60-72	
meropenem	23-31	valproate	159-167	
valproic acid	60-72	valproate	159-167	

ARAMINE should be used with caution in digitalized patients, since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias.
ARAMINE	0-6	digitalis	86-94	
ARAMINE	0-6	sympathomimetic amines	100-121	
digitalis	86-94	sympathomimetic amines	100-121	

Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines.
Monoamine oxidase inhibitors	0-27	tricyclic antidepressants	32-56	
Monoamine oxidase inhibitors	0-27	sympathomimetic amines	87-108	
tricyclic antidepressants	32-56	sympathomimetic amines	87-108	

SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.
SKELAXIN	0-7	alcohol	36-42	
SKELAXIN	0-7	barbiturates	45-56	
SKELAXIN	0-7	CNS depressants	68-82	
alcohol	36-42	barbiturates	45-56	
alcohol	36-42	CNS depressants	68-82	
barbiturates	45-56	CNS depressants	68-82	

Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.
aspirin	52-58	methazolamide	64-76	
aspirin	52-58	aspirin	195-201	
aspirin	52-58	carbonic anhydrase inhibitors	207-235	
methazolamide	64-76	aspirin	195-201	
methazolamide	64-76	carbonic anhydrase inhibitors	207-235	
aspirin	195-201	carbonic anhydrase inhibitors	207-235	

Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.
Anticoagulants	0-13	anticoagulants	44-57	
Anticoagulants	0-13	methimazole	119-129	
anticoagulants	44-57	methimazole	119-129	

Digitalis glycosides: Serum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid;
Digitalis glycosides	0-19	digitalis glycoside	101-119	

Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid;
Theophylline	0-11	Theophylline	14-25	
Theophylline	0-11	theophylline	89-100	
Theophylline	14-25	theophylline	89-100	

Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids.
opioids	38-44	levomepromazine	95-109	
opioids	38-44	opioids	165-171	
levomepromazine	95-109	opioids	165-171	

Combination with tramadol (Ultram) is associated with increased risk of seizures.
tramadol	17-24	Ultram	27-32	

Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates.
levomepromazine	63-77	benzodiazepines	93-107	
levomepromazine	63-77	barbiturates	112-123	
benzodiazepines	93-107	barbiturates	112-123	

Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
levomepromazine	38-52	anticholinergic drugs	65-85	
levomepromazine	38-52	tricyclic antidepressants	88-112	
levomepromazine	38-52	antiparkinsonian-agents	118-140	
anticholinergic drugs	65-85	tricyclic antidepressants	88-112	
anticholinergic drugs	65-85	antiparkinsonian-agents	118-140	
tricyclic antidepressants	88-112	antiparkinsonian-agents	118-140	

Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine.
Caffeine	0-7	ephedrine	35-43	
Caffeine	0-7	amphetamine	45-55	
Caffeine	0-7	levomepromazine	101-115	
ephedrine	35-43	amphetamine	45-55	
ephedrine	35-43	levomepromazine	101-115	
amphetamine	45-55	levomepromazine	101-115	

Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).
Celontin	6-13	methsuximide	16-27	
Celontin	6-13	antiepileptic drugs	74-92	
Celontin	6-13	methsuximide	167-178	
Celontin	6-13	phenytoin	222-230	
Celontin	6-13	phenobarbital	236-248	
methsuximide	16-27	antiepileptic drugs	74-92	
methsuximide	16-27	methsuximide	167-178	
methsuximide	16-27	phenytoin	222-230	
methsuximide	16-27	phenobarbital	236-248	
antiepileptic drugs	74-92	methsuximide	167-178	
antiepileptic drugs	74-92	phenytoin	222-230	
antiepileptic drugs	74-92	phenobarbital	236-248	
methsuximide	167-178	phenytoin	222-230	
methsuximide	167-178	phenobarbital	236-248	
phenytoin	222-230	phenobarbital	236-248	

Hypokalemia may develop during concomitant use of steroids or ACTH.
steroids	50-57	ACTH	62-65	

Thiazides may decrease arterial responsiveness to norepinephrine.
Thiazides	0-8	norepinephrine	50-63	

Thiazide drugs may increase the responsiveness of tubocurarine.
Thiazide drugs	0-13	tubocurarine	50-61	

Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity.
Lithium	0-6	thiazides	38-46	
Lithium	0-6	lithium	72-78	
thiazides	38-46	lithium	72-78	

Thiazides may add to or potentiate the action of other antihypertensive drugs.
Thiazides	0-8	antihypertensive drugs	55-76	

Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.
ganglionic adrenergic blocking drugs	25-34;50-74	peripheral adrenergic blocking drugs	39-74	

When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur.
methyldopa	5-14	antihypertensive drugs	35-56	

Patients may require reduced doses of anesthetics when on methyldopa.
anesthetics	38-48	methyldopa	58-67	

When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity.
methyldopa	5-14	lithium	20-26	
methyldopa	5-14	lithium	110-116	
lithium	20-26	lithium	110-116	

Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate.
methyldopa	65-74	ferrous sulfate	101-115	
methyldopa	65-74	ferrous gluconate	120-136	
ferrous sulfate	101-115	ferrous gluconate	120-136	

Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended.
methyldopa	20-29	ferrous sulfate	36-50	
methyldopa	20-29	ferrous gluconate	55-71	
ferrous sulfate	36-50	ferrous gluconate	55-71	

Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin.
Methyldopa	0-9	VMA	50-52	
Methyldopa	0-9	vanillylmandelic acid	55-75	
Methyldopa	0-9	VMA	139-141	
Methyldopa	0-9	vanillin	146-153	
VMA	50-52	vanillylmandelic acid	55-75	
VMA	50-52	VMA	139-141	
VMA	50-52	vanillin	146-153	
vanillylmandelic acid	55-75	VMA	139-141	
vanillylmandelic acid	55-75	vanillin	146-153	
VMA	139-141	vanillin	146-153	

CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
Macrolide Antibiotics	25-45	Protease Inhibitors	51-69	
Macrolide Antibiotics	25-45	ergot alkaloid drugs	178-197	
Macrolide Antibiotics	25-45	dihydroergotamine	205-221	
Macrolide Antibiotics	25-45	ergotamine	227-236	
Protease Inhibitors	51-69	ergot alkaloid drugs	178-197	
Protease Inhibitors	51-69	dihydroergotamine	205-221	
Protease Inhibitors	51-69	ergotamine	227-236	
ergot alkaloid drugs	178-197	dihydroergotamine	205-221	
ergot alkaloid drugs	178-197	ergotamine	227-236	
dihydroergotamine	205-221	ergotamine	227-236	

Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
macrolide antibiotics	63-83	erythromycin	92-103	
macrolide antibiotics	63-83	troleandomycin	106-119	
macrolide antibiotics	63-83	clarithromycin	122-135	
macrolide antibiotics	63-83	HIV protease inhibitors	139-150;177-186	
macrolide antibiotics	63-83	reverse transcriptase inhibitors	155-186	
macrolide antibiotics	63-83	ritonavir	195-203	
macrolide antibiotics	63-83	indinavir	206-214	
macrolide antibiotics	63-83	nelfinavir	217-226	
macrolide antibiotics	63-83	delavirdine	229-239	
macrolide antibiotics	63-83	azole antifungals	245-261	
macrolide antibiotics	63-83	ketoconazole	270-281	
macrolide antibiotics	63-83	itraconazole	284-295	
macrolide antibiotics	63-83	voriconazole	298-309	
erythromycin	92-103	troleandomycin	106-119	
erythromycin	92-103	clarithromycin	122-135	
erythromycin	92-103	HIV protease inhibitors	139-150;177-186	
erythromycin	92-103	reverse transcriptase inhibitors	155-186	
erythromycin	92-103	ritonavir	195-203	
erythromycin	92-103	indinavir	206-214	
erythromycin	92-103	nelfinavir	217-226	
erythromycin	92-103	delavirdine	229-239	
erythromycin	92-103	azole antifungals	245-261	
erythromycin	92-103	ketoconazole	270-281	
erythromycin	92-103	itraconazole	284-295	
erythromycin	92-103	voriconazole	298-309	
troleandomycin	106-119	clarithromycin	122-135	
troleandomycin	106-119	HIV protease inhibitors	139-150;177-186	
troleandomycin	106-119	reverse transcriptase inhibitors	155-186	
troleandomycin	106-119	ritonavir	195-203	
troleandomycin	106-119	indinavir	206-214	
troleandomycin	106-119	nelfinavir	217-226	
troleandomycin	106-119	delavirdine	229-239	
troleandomycin	106-119	azole antifungals	245-261	
troleandomycin	106-119	ketoconazole	270-281	
troleandomycin	106-119	itraconazole	284-295	
troleandomycin	106-119	voriconazole	298-309	
clarithromycin	122-135	HIV protease inhibitors	139-150;177-186	
clarithromycin	122-135	reverse transcriptase inhibitors	155-186	
clarithromycin	122-135	ritonavir	195-203	
clarithromycin	122-135	indinavir	206-214	
clarithromycin	122-135	nelfinavir	217-226	
clarithromycin	122-135	delavirdine	229-239	
clarithromycin	122-135	azole antifungals	245-261	
clarithromycin	122-135	ketoconazole	270-281	
clarithromycin	122-135	itraconazole	284-295	
clarithromycin	122-135	voriconazole	298-309	
HIV protease inhibitors	139-150;177-186	reverse transcriptase inhibitors	155-186	
HIV protease inhibitors	139-150;177-186	ritonavir	195-203	
HIV protease inhibitors	139-150;177-186	indinavir	206-214	
HIV protease inhibitors	139-150;177-186	nelfinavir	217-226	
HIV protease inhibitors	139-150;177-186	delavirdine	229-239	
HIV protease inhibitors	139-150;177-186	azole antifungals	245-261	
HIV protease inhibitors	139-150;177-186	ketoconazole	270-281	
HIV protease inhibitors	139-150;177-186	itraconazole	284-295	
HIV protease inhibitors	139-150;177-186	voriconazole	298-309	
reverse transcriptase inhibitors	155-186	ritonavir	195-203	
reverse transcriptase inhibitors	155-186	indinavir	206-214	
reverse transcriptase inhibitors	155-186	nelfinavir	217-226	
reverse transcriptase inhibitors	155-186	delavirdine	229-239	
reverse transcriptase inhibitors	155-186	azole antifungals	245-261	
reverse transcriptase inhibitors	155-186	ketoconazole	270-281	
reverse transcriptase inhibitors	155-186	itraconazole	284-295	
reverse transcriptase inhibitors	155-186	voriconazole	298-309	
ritonavir	195-203	indinavir	206-214	
ritonavir	195-203	nelfinavir	217-226	
ritonavir	195-203	delavirdine	229-239	
ritonavir	195-203	azole antifungals	245-261	
ritonavir	195-203	ketoconazole	270-281	
ritonavir	195-203	itraconazole	284-295	
ritonavir	195-203	voriconazole	298-309	
indinavir	206-214	nelfinavir	217-226	
indinavir	206-214	delavirdine	229-239	
indinavir	206-214	azole antifungals	245-261	
indinavir	206-214	ketoconazole	270-281	
indinavir	206-214	itraconazole	284-295	
indinavir	206-214	voriconazole	298-309	
nelfinavir	217-226	delavirdine	229-239	
nelfinavir	217-226	azole antifungals	245-261	
nelfinavir	217-226	ketoconazole	270-281	
nelfinavir	217-226	itraconazole	284-295	
nelfinavir	217-226	voriconazole	298-309	
delavirdine	229-239	azole antifungals	245-261	
delavirdine	229-239	ketoconazole	270-281	
delavirdine	229-239	itraconazole	284-295	
delavirdine	229-239	voriconazole	298-309	
azole antifungals	245-261	ketoconazole	270-281	
azole antifungals	245-261	itraconazole	284-295	
azole antifungals	245-261	voriconazole	298-309	
ketoconazole	270-281	itraconazole	284-295	
ketoconazole	270-281	voriconazole	298-309	
itraconazole	284-295	voriconazole	298-309	

Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.
saquinavir	31-40	nefazodone	43-52	
saquinavir	31-40	fluconazole	55-65	
saquinavir	31-40	fluoxetine	86-95	
saquinavir	31-40	fluvoxamine	98-108	
saquinavir	31-40	zileuton	111-118	
saquinavir	31-40	clotrimazole	125-136	
nefazodone	43-52	fluconazole	55-65	
nefazodone	43-52	fluoxetine	86-95	
nefazodone	43-52	fluvoxamine	98-108	
nefazodone	43-52	zileuton	111-118	
nefazodone	43-52	clotrimazole	125-136	
fluconazole	55-65	fluoxetine	86-95	
fluconazole	55-65	fluvoxamine	98-108	
fluconazole	55-65	zileuton	111-118	
fluconazole	55-65	clotrimazole	125-136	
fluoxetine	86-95	fluvoxamine	98-108	
fluoxetine	86-95	zileuton	111-118	
fluoxetine	86-95	clotrimazole	125-136	
fluvoxamine	98-108	zileuton	111-118	
fluvoxamine	98-108	clotrimazole	125-136	
zileuton	111-118	clotrimazole	125-136	

Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.
Methergine	33-42	methylergonovine maleate	48-71	
Methergine	33-42	vasoconstrictors	106-121	
Methergine	33-42	ergot alkaloids	126-140	
methylergonovine maleate	48-71	vasoconstrictors	106-121	
methylergonovine maleate	48-71	ergot alkaloids	126-140	
vasoconstrictors	106-121	ergot alkaloids	126-140	

Ritalin may decrease the hypotensive effect of guanethidine.
Ritalin	0-6	guanethidine	47-58	

Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
Ritalin	44-50	coumarin anticoagulants	82-104	
Ritalin	44-50	anticonvulsants	107-121	
Ritalin	44-50	phenobarbital	124-136	
Ritalin	44-50	diphenylhydantoin	139-155	
Ritalin	44-50	primidone	158-166	
Ritalin	44-50	phenylbutazone	170-183	
Ritalin	44-50	tricyclic drugs	190-204	
Ritalin	44-50	imipramine	207-216	
Ritalin	44-50	clomipramine	219-230	
Ritalin	44-50	desipramine	233-243	
coumarin anticoagulants	82-104	anticonvulsants	107-121	
coumarin anticoagulants	82-104	phenobarbital	124-136	
coumarin anticoagulants	82-104	diphenylhydantoin	139-155	
coumarin anticoagulants	82-104	primidone	158-166	
coumarin anticoagulants	82-104	phenylbutazone	170-183	
coumarin anticoagulants	82-104	tricyclic drugs	190-204	
coumarin anticoagulants	82-104	imipramine	207-216	
coumarin anticoagulants	82-104	clomipramine	219-230	
coumarin anticoagulants	82-104	desipramine	233-243	
anticonvulsants	107-121	phenobarbital	124-136	
anticonvulsants	107-121	diphenylhydantoin	139-155	
anticonvulsants	107-121	primidone	158-166	
anticonvulsants	107-121	phenylbutazone	170-183	
anticonvulsants	107-121	tricyclic drugs	190-204	
anticonvulsants	107-121	imipramine	207-216	
anticonvulsants	107-121	clomipramine	219-230	
anticonvulsants	107-121	desipramine	233-243	
phenobarbital	124-136	diphenylhydantoin	139-155	
phenobarbital	124-136	primidone	158-166	
phenobarbital	124-136	phenylbutazone	170-183	
phenobarbital	124-136	tricyclic drugs	190-204	
phenobarbital	124-136	imipramine	207-216	
phenobarbital	124-136	clomipramine	219-230	
phenobarbital	124-136	desipramine	233-243	
diphenylhydantoin	139-155	primidone	158-166	
diphenylhydantoin	139-155	phenylbutazone	170-183	
diphenylhydantoin	139-155	tricyclic drugs	190-204	
diphenylhydantoin	139-155	imipramine	207-216	
diphenylhydantoin	139-155	clomipramine	219-230	
diphenylhydantoin	139-155	desipramine	233-243	
primidone	158-166	phenylbutazone	170-183	
primidone	158-166	tricyclic drugs	190-204	
primidone	158-166	imipramine	207-216	
primidone	158-166	clomipramine	219-230	
primidone	158-166	desipramine	233-243	
phenylbutazone	170-183	tricyclic drugs	190-204	
phenylbutazone	170-183	imipramine	207-216	
phenylbutazone	170-183	clomipramine	219-230	
phenylbutazone	170-183	desipramine	233-243	
tricyclic drugs	190-204	imipramine	207-216	
tricyclic drugs	190-204	clomipramine	219-230	
tricyclic drugs	190-204	desipramine	233-243	
imipramine	207-216	clomipramine	219-230	
imipramine	207-216	desipramine	233-243	
clomipramine	219-230	desipramine	233-243	

The safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated.
methylphenidate	20-34	clonidine	56-64	
methylphenidate	20-34	alpha-2 agonists	92-107	
clonidine	56-64	alpha-2 agonists	92-107	

Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone;
cyclosporin	62-72	methylprednisolone	78-95	

convulsions have been reported with concurrent use of methylprednisolone and cyclosporin.
methylprednisolone	54-71	cyclosporin	77-87	

Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.
phenobarbital	42-54	phenytoin	57-65	
phenobarbital	42-54	rifampin	72-79	
phenobarbital	42-54	methylprednisolone	111-128	
phenobarbital	42-54	methylprednisolone	159-176	
phenytoin	57-65	rifampin	72-79	
phenytoin	57-65	methylprednisolone	111-128	
phenytoin	57-65	methylprednisolone	159-176	
rifampin	72-79	methylprednisolone	111-128	
rifampin	72-79	methylprednisolone	159-176	
methylprednisolone	111-128	methylprednisolone	159-176	

Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance.
troleandomycin	14-27	ketoconazole	33-44	
troleandomycin	14-27	methylprednisolone	76-93	
ketoconazole	33-44	methylprednisolone	76-93	

Methylprednisolone may increase the clearance of chronic high dose aspirin.
Methylprednisolone	0-17	aspirin	67-73	

This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn.
salicylate	29-38	salicylate	77-86	
salicylate	29-38	methylprednisolone	102-119	
salicylate	77-86	methylprednisolone	102-119	

Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.
Aspirin	0-6	corticosteroids	54-68	

The effect of methylprednisolone on oral anticoagulants is variable.
methylprednisolone	14-31	anticoagulants	41-54	

There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids.
anticoagulant	63-75	corticosteroids	106-120	

Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
Methscopolamine	0-14	antidepressants	34-48	
Methscopolamine	0-14	tricyclic	51-59	
Methscopolamine	0-14	MAO inhibitors	68-81	
Methscopolamine	0-14	phenelzine	90-99	
Methscopolamine	0-14	linezolid	102-110	
Methscopolamine	0-14	tranylcypromine	113-127	
Methscopolamine	0-14	isocarboxazid	130-142	
Methscopolamine	0-14	selegiline	145-154	
Methscopolamine	0-14	furazolidone	157-168	
Methscopolamine	0-14	quinidine	172-180	
Methscopolamine	0-14	amantadine	183-192	
Methscopolamine	0-14	antihistamines	195-208	
Methscopolamine	0-14	diphenhydramine	217-231	
Methscopolamine	0-14	anticholinergics	241-256	
Methscopolamine	0-14	potassium chloride	259-276	
Methscopolamine	0-14	antacids	291-298	
Methscopolamine	0-14	absorbent-type anti-diarrhea medicines	301-338	
Methscopolamine	0-14	kaolin	347-352	
Methscopolamine	0-14	pectin	354-359	
Methscopolamine	0-14	phenothiazines	363-376	
Methscopolamine	0-14	chlorpromazine	385-398	
Methscopolamine	0-14	promethazine	401-412	
antidepressants	34-48	tricyclic	51-59	
antidepressants	34-48	MAO inhibitors	68-81	
antidepressants	34-48	phenelzine	90-99	
antidepressants	34-48	linezolid	102-110	
antidepressants	34-48	tranylcypromine	113-127	
antidepressants	34-48	isocarboxazid	130-142	
antidepressants	34-48	selegiline	145-154	
antidepressants	34-48	furazolidone	157-168	
antidepressants	34-48	quinidine	172-180	
antidepressants	34-48	amantadine	183-192	
antidepressants	34-48	antihistamines	195-208	
antidepressants	34-48	diphenhydramine	217-231	
antidepressants	34-48	anticholinergics	241-256	
antidepressants	34-48	potassium chloride	259-276	
antidepressants	34-48	antacids	291-298	
antidepressants	34-48	absorbent-type anti-diarrhea medicines	301-338	
antidepressants	34-48	kaolin	347-352	
antidepressants	34-48	pectin	354-359	
antidepressants	34-48	phenothiazines	363-376	
antidepressants	34-48	chlorpromazine	385-398	
antidepressants	34-48	promethazine	401-412	
tricyclic	51-59	MAO inhibitors	68-81	
tricyclic	51-59	phenelzine	90-99	
tricyclic	51-59	linezolid	102-110	
tricyclic	51-59	tranylcypromine	113-127	
tricyclic	51-59	isocarboxazid	130-142	
tricyclic	51-59	selegiline	145-154	
tricyclic	51-59	furazolidone	157-168	
tricyclic	51-59	quinidine	172-180	
tricyclic	51-59	amantadine	183-192	
tricyclic	51-59	antihistamines	195-208	
tricyclic	51-59	diphenhydramine	217-231	
tricyclic	51-59	anticholinergics	241-256	
tricyclic	51-59	potassium chloride	259-276	
tricyclic	51-59	antacids	291-298	
tricyclic	51-59	absorbent-type anti-diarrhea medicines	301-338	
tricyclic	51-59	kaolin	347-352	
tricyclic	51-59	pectin	354-359	
tricyclic	51-59	phenothiazines	363-376	
tricyclic	51-59	chlorpromazine	385-398	
tricyclic	51-59	promethazine	401-412	
MAO inhibitors	68-81	phenelzine	90-99	
MAO inhibitors	68-81	linezolid	102-110	
MAO inhibitors	68-81	tranylcypromine	113-127	
MAO inhibitors	68-81	isocarboxazid	130-142	
MAO inhibitors	68-81	selegiline	145-154	
MAO inhibitors	68-81	furazolidone	157-168	
MAO inhibitors	68-81	quinidine	172-180	
MAO inhibitors	68-81	amantadine	183-192	
MAO inhibitors	68-81	antihistamines	195-208	
MAO inhibitors	68-81	diphenhydramine	217-231	
MAO inhibitors	68-81	anticholinergics	241-256	
MAO inhibitors	68-81	potassium chloride	259-276	
MAO inhibitors	68-81	antacids	291-298	
MAO inhibitors	68-81	absorbent-type anti-diarrhea medicines	301-338	
MAO inhibitors	68-81	kaolin	347-352	
MAO inhibitors	68-81	pectin	354-359	
MAO inhibitors	68-81	phenothiazines	363-376	
MAO inhibitors	68-81	chlorpromazine	385-398	
MAO inhibitors	68-81	promethazine	401-412	
phenelzine	90-99	linezolid	102-110	
phenelzine	90-99	tranylcypromine	113-127	
phenelzine	90-99	isocarboxazid	130-142	
phenelzine	90-99	selegiline	145-154	
phenelzine	90-99	furazolidone	157-168	
phenelzine	90-99	quinidine	172-180	
phenelzine	90-99	amantadine	183-192	
phenelzine	90-99	antihistamines	195-208	
phenelzine	90-99	diphenhydramine	217-231	
phenelzine	90-99	anticholinergics	241-256	
phenelzine	90-99	potassium chloride	259-276	
phenelzine	90-99	antacids	291-298	
phenelzine	90-99	absorbent-type anti-diarrhea medicines	301-338	
phenelzine	90-99	kaolin	347-352	
phenelzine	90-99	pectin	354-359	
phenelzine	90-99	phenothiazines	363-376	
phenelzine	90-99	chlorpromazine	385-398	
phenelzine	90-99	promethazine	401-412	
linezolid	102-110	tranylcypromine	113-127	
linezolid	102-110	isocarboxazid	130-142	
linezolid	102-110	selegiline	145-154	
linezolid	102-110	furazolidone	157-168	
linezolid	102-110	quinidine	172-180	
linezolid	102-110	amantadine	183-192	
linezolid	102-110	antihistamines	195-208	
linezolid	102-110	diphenhydramine	217-231	
linezolid	102-110	anticholinergics	241-256	
linezolid	102-110	potassium chloride	259-276	
linezolid	102-110	antacids	291-298	
linezolid	102-110	absorbent-type anti-diarrhea medicines	301-338	
linezolid	102-110	kaolin	347-352	
linezolid	102-110	pectin	354-359	
linezolid	102-110	phenothiazines	363-376	
linezolid	102-110	chlorpromazine	385-398	
linezolid	102-110	promethazine	401-412	
tranylcypromine	113-127	isocarboxazid	130-142	
tranylcypromine	113-127	selegiline	145-154	
tranylcypromine	113-127	furazolidone	157-168	
tranylcypromine	113-127	quinidine	172-180	
tranylcypromine	113-127	amantadine	183-192	
tranylcypromine	113-127	antihistamines	195-208	
tranylcypromine	113-127	diphenhydramine	217-231	
tranylcypromine	113-127	anticholinergics	241-256	
tranylcypromine	113-127	potassium chloride	259-276	
tranylcypromine	113-127	antacids	291-298	
tranylcypromine	113-127	absorbent-type anti-diarrhea medicines	301-338	
tranylcypromine	113-127	kaolin	347-352	
tranylcypromine	113-127	pectin	354-359	
tranylcypromine	113-127	phenothiazines	363-376	
tranylcypromine	113-127	chlorpromazine	385-398	
tranylcypromine	113-127	promethazine	401-412	
isocarboxazid	130-142	selegiline	145-154	
isocarboxazid	130-142	furazolidone	157-168	
isocarboxazid	130-142	quinidine	172-180	
isocarboxazid	130-142	amantadine	183-192	
isocarboxazid	130-142	antihistamines	195-208	
isocarboxazid	130-142	diphenhydramine	217-231	
isocarboxazid	130-142	anticholinergics	241-256	
isocarboxazid	130-142	potassium chloride	259-276	
isocarboxazid	130-142	antacids	291-298	
isocarboxazid	130-142	absorbent-type anti-diarrhea medicines	301-338	
isocarboxazid	130-142	kaolin	347-352	
isocarboxazid	130-142	pectin	354-359	
isocarboxazid	130-142	phenothiazines	363-376	
isocarboxazid	130-142	chlorpromazine	385-398	
isocarboxazid	130-142	promethazine	401-412	
selegiline	145-154	furazolidone	157-168	
selegiline	145-154	quinidine	172-180	
selegiline	145-154	amantadine	183-192	
selegiline	145-154	antihistamines	195-208	
selegiline	145-154	diphenhydramine	217-231	
selegiline	145-154	anticholinergics	241-256	
selegiline	145-154	potassium chloride	259-276	
selegiline	145-154	antacids	291-298	
selegiline	145-154	absorbent-type anti-diarrhea medicines	301-338	
selegiline	145-154	kaolin	347-352	
selegiline	145-154	pectin	354-359	
selegiline	145-154	phenothiazines	363-376	
selegiline	145-154	chlorpromazine	385-398	
selegiline	145-154	promethazine	401-412	
furazolidone	157-168	quinidine	172-180	
furazolidone	157-168	amantadine	183-192	
furazolidone	157-168	antihistamines	195-208	
furazolidone	157-168	diphenhydramine	217-231	
furazolidone	157-168	anticholinergics	241-256	
furazolidone	157-168	potassium chloride	259-276	
furazolidone	157-168	antacids	291-298	
furazolidone	157-168	absorbent-type anti-diarrhea medicines	301-338	
furazolidone	157-168	kaolin	347-352	
furazolidone	157-168	pectin	354-359	
furazolidone	157-168	phenothiazines	363-376	
furazolidone	157-168	chlorpromazine	385-398	
furazolidone	157-168	promethazine	401-412	
quinidine	172-180	amantadine	183-192	
quinidine	172-180	antihistamines	195-208	
quinidine	172-180	diphenhydramine	217-231	
quinidine	172-180	anticholinergics	241-256	
quinidine	172-180	potassium chloride	259-276	
quinidine	172-180	antacids	291-298	
quinidine	172-180	absorbent-type anti-diarrhea medicines	301-338	
quinidine	172-180	kaolin	347-352	
quinidine	172-180	pectin	354-359	
quinidine	172-180	phenothiazines	363-376	
quinidine	172-180	chlorpromazine	385-398	
quinidine	172-180	promethazine	401-412	
amantadine	183-192	antihistamines	195-208	
amantadine	183-192	diphenhydramine	217-231	
amantadine	183-192	anticholinergics	241-256	
amantadine	183-192	potassium chloride	259-276	
amantadine	183-192	antacids	291-298	
amantadine	183-192	absorbent-type anti-diarrhea medicines	301-338	
amantadine	183-192	kaolin	347-352	
amantadine	183-192	pectin	354-359	
amantadine	183-192	phenothiazines	363-376	
amantadine	183-192	chlorpromazine	385-398	
amantadine	183-192	promethazine	401-412	
antihistamines	195-208	diphenhydramine	217-231	
antihistamines	195-208	anticholinergics	241-256	
antihistamines	195-208	potassium chloride	259-276	
antihistamines	195-208	antacids	291-298	
antihistamines	195-208	absorbent-type anti-diarrhea medicines	301-338	
antihistamines	195-208	kaolin	347-352	
antihistamines	195-208	pectin	354-359	
antihistamines	195-208	phenothiazines	363-376	
antihistamines	195-208	chlorpromazine	385-398	
antihistamines	195-208	promethazine	401-412	
diphenhydramine	217-231	anticholinergics	241-256	
diphenhydramine	217-231	potassium chloride	259-276	
diphenhydramine	217-231	antacids	291-298	
diphenhydramine	217-231	absorbent-type anti-diarrhea medicines	301-338	
diphenhydramine	217-231	kaolin	347-352	
diphenhydramine	217-231	pectin	354-359	
diphenhydramine	217-231	phenothiazines	363-376	
diphenhydramine	217-231	chlorpromazine	385-398	
diphenhydramine	217-231	promethazine	401-412	
anticholinergics	241-256	potassium chloride	259-276	
anticholinergics	241-256	antacids	291-298	
anticholinergics	241-256	absorbent-type anti-diarrhea medicines	301-338	
anticholinergics	241-256	kaolin	347-352	
anticholinergics	241-256	pectin	354-359	
anticholinergics	241-256	phenothiazines	363-376	
anticholinergics	241-256	chlorpromazine	385-398	
anticholinergics	241-256	promethazine	401-412	
potassium chloride	259-276	antacids	291-298	
potassium chloride	259-276	absorbent-type anti-diarrhea medicines	301-338	
potassium chloride	259-276	kaolin	347-352	
potassium chloride	259-276	pectin	354-359	
potassium chloride	259-276	phenothiazines	363-376	
potassium chloride	259-276	chlorpromazine	385-398	
potassium chloride	259-276	promethazine	401-412	
antacids	291-298	absorbent-type anti-diarrhea medicines	301-338	
antacids	291-298	kaolin	347-352	
antacids	291-298	pectin	354-359	
antacids	291-298	phenothiazines	363-376	
antacids	291-298	chlorpromazine	385-398	
antacids	291-298	promethazine	401-412	
absorbent-type anti-diarrhea medicines	301-338	kaolin	347-352	
absorbent-type anti-diarrhea medicines	301-338	pectin	354-359	
absorbent-type anti-diarrhea medicines	301-338	phenothiazines	363-376	
absorbent-type anti-diarrhea medicines	301-338	chlorpromazine	385-398	
absorbent-type anti-diarrhea medicines	301-338	promethazine	401-412	
kaolin	347-352	pectin	354-359	
kaolin	347-352	phenothiazines	363-376	
kaolin	347-352	chlorpromazine	385-398	
kaolin	347-352	promethazine	401-412	
pectin	354-359	phenothiazines	363-376	
pectin	354-359	chlorpromazine	385-398	
pectin	354-359	promethazine	401-412	
phenothiazines	363-376	chlorpromazine	385-398	
phenothiazines	363-376	promethazine	401-412	
chlorpromazine	385-398	promethazine	401-412	

Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.
alcohol	18-24	CNS depression-producing drugs	36-65	
alcohol	18-24	methyprylon	110-120	
CNS depression-producing drugs	36-65	methyprylon	110-120	

Methysergide may reverse the analgesic activity of narcotic analgesics.
Methysergide	0-11	narcotic analgesics	51-69	

Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.
vasoconstrictor agents	20-41	ergot alkaloids	53-67	
vasoconstrictor agents	20-41	sumatriptan	70-80	
vasoconstrictor agents	20-41	nicotine	87-94	
ergot alkaloids	53-67	sumatriptan	70-80	
ergot alkaloids	53-67	nicotine	87-94	
sumatriptan	70-80	nicotine	87-94	

The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics.
metoclopramide	15-28	anticholinergic drugs	78-98	
metoclopramide	15-28	narcotic analgesics	104-122	
anticholinergic drugs	78-98	narcotic analgesics	104-122	

Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.
metoclopramide	41-54	alcohol	70-76	
metoclopramide	41-54	sedatives	79-87	
metoclopramide	41-54	hypnotics	90-98	
metoclopramide	41-54	narcotics	101-109	
metoclopramide	41-54	tranquilizers	115-127	
alcohol	70-76	sedatives	79-87	
alcohol	70-76	hypnotics	90-98	
alcohol	70-76	narcotics	101-109	
alcohol	70-76	tranquilizers	115-127	
sedatives	79-87	hypnotics	90-98	
sedatives	79-87	narcotics	101-109	
sedatives	79-87	tranquilizers	115-127	
hypnotics	90-98	narcotics	101-109	
hypnotics	90-98	tranquilizers	115-127	
narcotics	101-109	tranquilizers	115-127	

The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxi-dase inhibitors.
metoclopramide	17-30	monoamine oxi-dase inhibitors	173-201	

Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).
digoxin	62-68	metoclopramide	74-87	
digoxin	62-68	acetaminophen	189-201	
digoxin	62-68	tetracycline	204-215	
digoxin	62-68	levodopa	218-225	
digoxin	62-68	ethanol	228-234	
digoxin	62-68	cyclosporine	237-248	
metoclopramide	74-87	acetaminophen	189-201	
metoclopramide	74-87	tetracycline	204-215	
metoclopramide	74-87	levodopa	218-225	
metoclopramide	74-87	ethanol	228-234	
metoclopramide	74-87	cyclosporine	237-248	
acetaminophen	189-201	tetracycline	204-215	
acetaminophen	189-201	levodopa	218-225	
acetaminophen	189-201	ethanol	228-234	
acetaminophen	189-201	cyclosporine	237-248	
tetracycline	204-215	levodopa	218-225	
tetracycline	204-215	ethanol	228-234	
tetracycline	204-215	cyclosporine	237-248	
levodopa	218-225	ethanol	228-234	
levodopa	218-225	cyclosporine	237-248	
ethanol	228-234	cyclosporine	237-248	

Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.
metoclopramide	22-35	insulin	124-130	

Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.
Diuretics	0-8	Furosemide	11-20	
Diuretics	0-8	loop diuretics	41-54	
Diuretics	0-8	metolazone	81-90	
Furosemide	11-20	loop diuretics	41-54	
Furosemide	11-20	metolazone	81-90	
loop diuretics	41-54	metolazone	81-90	

Other Antihypertensives: When MYKROX Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy.
Antihypertensives	6-22	MYKROX	30-35	
Antihypertensives	6-22	antihypertensive drugs	65-86	
MYKROX	30-35	antihypertensive drugs	65-86	

Alcohol, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy.
Alcohol	0-6	Barbiturates	9-20	
Alcohol	0-6	Narcotics	27-35	
Alcohol	0-6	metolazone	150-159	
Barbiturates	9-20	Narcotics	27-35	
Barbiturates	9-20	metolazone	150-159	
Narcotics	27-35	metolazone	150-159	

Digitalis Glycosides: Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis.
Digitalis Glycosides	0-19	Diuretic	22-29	
Digitalis Glycosides	0-19	digitalis	101-109	
Diuretic	22-29	digitalis	101-109	

Corticosteroids or ACTH: May increase the risk of hypokalemia and increase salt and water retention.
Corticosteroids	0-14	ACTH	19-22	

Lithium: Serum lithium levels may increase.
Lithium	0-6	lithium	15-21	

Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.
Curariform Drugs	0-15	Diuretic	18-25	
Curariform Drugs	0-15	curariform drugs	93-108	
Curariform Drugs	0-15	tubocurarine	119-130	
Diuretic	18-25	curariform drugs	93-108	
Diuretic	18-25	tubocurarine	119-130	
curariform drugs	93-108	tubocurarine	119-130	

Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of MYKROX Tablets.
Salicylates	0-10	Non-Steroidal Anti-Inflammatory Drugs	22-58	
Salicylates	0-10	MYKROX	106-111	
Non-Steroidal Anti-Inflammatory Drugs	22-58	MYKROX	106-111	

Sympathomimetics: Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.
Sympathomimetics	0-15	Metolazone	18-27	
Sympathomimetics	0-15	norepinephrine	69-82	
Metolazone	18-27	norepinephrine	69-82	

Methenamine: Efficacy may be decreased due to urinary alkalizing effect of metolazone.
Methenamine	0-10	metolazone	75-84	

Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants;
Anticoagulants	0-13	Metolazone	16-25	
Anticoagulants	0-13	thiazide-like diuretics	45-67	
Anticoagulants	0-13	anticoagulants	117-130	
Metolazone	16-25	thiazide-like diuretics	45-67	
Metolazone	16-25	anticoagulants	117-130	
thiazide-like diuretics	45-67	anticoagulants	117-130	

Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.
reserpine	37-45	beta-blocking agents	92-111	

Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time.
metronidazole	5-17	coumarin	79-86	
metronidazole	5-17	warfarin	92-99	
coumarin	79-86	warfarin	92-99	

Drug interactions should be kept in mind when METROGEL (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.
METROGEL	46-53	metronidazole	56-68	
METROGEL	46-53	metronidazole	201-213	
metronidazole	56-68	metronidazole	201-213	

The metabolism of Metopirone is accelerated by phenytoin;
Metopirone	18-27	phenytoin	47-55	

Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.
Metopirone	0-9	acetaminophen	43-55	
Metopirone	0-9	acetaminophen	87-99	
acetaminophen	43-55	acetaminophen	87-99	

Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.
DEMSER	44-49	phenothiazines	73-86	
DEMSER	44-49	haloperidol	91-101	
phenothiazines	73-86	haloperidol	91-101	

Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.
DEMSER	18-23	alcohol	30-36	
DEMSER	18-23	CNS depressants	47-61	
alcohol	30-36	CNS depressants	47-61	

Since MEXITIL is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter mexiletine plasma concentrations.
MEXITIL	6-12	mexiletine	171-180	

In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2.
mexiletine	74-83	fluvoxamine	140-150	

In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group.
propafenone	101-111	mexiletine	143-152	

In this crossover steady state study, the pharmacokinetics of propafenone were unaffected in either phenotype by the coadministration of mexiletine.
propafenone	62-72	mexiletine	137-146	

Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone.
mexiletine	12-21	propafenone	26-36	
mexiletine	12-21	propafenone	141-151	
propafenone	26-36	propafenone	141-151	

When concomitant administration of either of these two drugs with mexiletine is initiated, the dose of mexiletine should be slowly titrated to desired effect.
mexiletine	66-75	mexiletine	103-112	

In a large compassionate use program Mexitil    has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions.
Mexitil	37-43	antihypertensive	111-126	
Mexitil	37-43	anticoagulant drugs	133-151	
antihypertensive	111-126	anticoagulant drugs	133-151	

A variety of antiarrhythmics such as quinidine or propranolol were also added, sometimes with improved control of ventricular ectopy.
antiarrhythmics	13-27	quinidine	37-45	
antiarrhythmics	13-27	propranolol	50-60	
quinidine	37-45	propranolol	50-60	

When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported.
phenytoin	5-13	rifampin	56-63	
phenytoin	5-13	phenobarbital	69-81	
phenytoin	5-13	Mexitil	117-123	
phenytoin	5-13	Mexitil	137-143	
rifampin	56-63	phenobarbital	69-81	
rifampin	56-63	Mexitil	117-123	
rifampin	56-63	Mexitil	137-143	
phenobarbital	69-81	Mexitil	117-123	
phenobarbital	69-81	Mexitil	137-143	
Mexitil	117-123	Mexitil	137-143	

In a formal study, benzodiazepines were shown not to affect Mexitil    plasma concentrations.
benzodiazepines	19-33	Mexitil	60-66	

ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol.
Mexitil	64-70	digoxin	79-85	
Mexitil	64-70	diuretics	88-96	
Mexitil	64-70	propranolol	102-112	
digoxin	79-85	diuretics	88-96	
digoxin	79-85	propranolol	102-112	
diuretics	88-96	propranolol	102-112	

Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels;
cimetidine	29-38	Mexitil	44-50	
cimetidine	29-38	Mexitil	115-121	
Mexitil	44-50	Mexitil	115-121	

Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels.
Mexitil	0-6	digoxin	32-38	
Mexitil	0-6	magnesium-aluminum hydroxide	51-78	
Mexitil	0-6	Mexitil	133-139	
Mexitil	0-6	digoxin	178-184	
digoxin	32-38	magnesium-aluminum hydroxide	51-78	
digoxin	32-38	Mexitil	133-139	
digoxin	32-38	digoxin	178-184	
magnesium-aluminum hydroxide	51-78	Mexitil	133-139	
magnesium-aluminum hydroxide	51-78	digoxin	178-184	
Mexitil	133-139	digoxin	178-184	

Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels.
Mexitil	18-24	theophylline	33-44	
Mexitil	18-24	theophylline	75-86	
theophylline	33-44	theophylline	75-86	

This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
Mexitil	91-97	Theophylline	103-114	
Mexitil	91-97	Mexitil	146-152	
Mexitil	91-97	Mexitil	200-206	
Mexitil	91-97	Mexitil	215-221	
Mexitil	91-97	theophylline	227-238	
Mexitil	91-97	theophylline	269-280	
Mexitil	91-97	Mexitil	338-344	
Theophylline	103-114	Mexitil	146-152	
Theophylline	103-114	Mexitil	200-206	
Theophylline	103-114	Mexitil	215-221	
Theophylline	103-114	theophylline	227-238	
Theophylline	103-114	theophylline	269-280	
Theophylline	103-114	Mexitil	338-344	
Mexitil	146-152	Mexitil	200-206	
Mexitil	146-152	Mexitil	215-221	
Mexitil	146-152	theophylline	227-238	
Mexitil	146-152	theophylline	269-280	
Mexitil	146-152	Mexitil	338-344	
Mexitil	200-206	Mexitil	215-221	
Mexitil	200-206	theophylline	227-238	
Mexitil	200-206	theophylline	269-280	
Mexitil	200-206	Mexitil	338-344	
Mexitil	215-221	theophylline	227-238	
Mexitil	215-221	theophylline	269-280	
Mexitil	215-221	Mexitil	338-344	
theophylline	227-238	theophylline	269-280	
theophylline	227-238	Mexitil	338-344	
theophylline	269-280	Mexitil	338-344	

Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of Mexitil   .
caffeine	99-106	Mexitil	158-164	

Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.
Posicor	0-6	terfenadine	78-88	
Posicor	0-6	astemizole	91-100	
Posicor	0-6	cisapride	103-111	
Posicor	0-6	cyclosporine	114-125	
Posicor	0-6	tricyclic antidepressants	132-156	
terfenadine	78-88	astemizole	91-100	
terfenadine	78-88	cisapride	103-111	
terfenadine	78-88	cyclosporine	114-125	
terfenadine	78-88	tricyclic antidepressants	132-156	
astemizole	91-100	cisapride	103-111	
astemizole	91-100	cyclosporine	114-125	
astemizole	91-100	tricyclic antidepressants	132-156	
cisapride	103-111	cyclosporine	114-125	
cisapride	103-111	tricyclic antidepressants	132-156	
cyclosporine	114-125	tricyclic antidepressants	132-156	

A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.
MYCAMINE	140-147	mycophenolate mofetil	153-173	
MYCAMINE	140-147	cyclosporine	176-187	
MYCAMINE	140-147	tacrolimus	190-199	
MYCAMINE	140-147	prednisolone	202-213	
MYCAMINE	140-147	sirolimus	216-224	
MYCAMINE	140-147	nifedipine	227-236	
MYCAMINE	140-147	fluconazole	239-249	
MYCAMINE	140-147	ritonavir	252-260	
MYCAMINE	140-147	rifampin	267-274	
mycophenolate mofetil	153-173	cyclosporine	176-187	
mycophenolate mofetil	153-173	tacrolimus	190-199	
mycophenolate mofetil	153-173	prednisolone	202-213	
mycophenolate mofetil	153-173	sirolimus	216-224	
mycophenolate mofetil	153-173	nifedipine	227-236	
mycophenolate mofetil	153-173	fluconazole	239-249	
mycophenolate mofetil	153-173	ritonavir	252-260	
mycophenolate mofetil	153-173	rifampin	267-274	
cyclosporine	176-187	tacrolimus	190-199	
cyclosporine	176-187	prednisolone	202-213	
cyclosporine	176-187	sirolimus	216-224	
cyclosporine	176-187	nifedipine	227-236	
cyclosporine	176-187	fluconazole	239-249	
cyclosporine	176-187	ritonavir	252-260	
cyclosporine	176-187	rifampin	267-274	
tacrolimus	190-199	prednisolone	202-213	
tacrolimus	190-199	sirolimus	216-224	
tacrolimus	190-199	nifedipine	227-236	
tacrolimus	190-199	fluconazole	239-249	
tacrolimus	190-199	ritonavir	252-260	
tacrolimus	190-199	rifampin	267-274	
prednisolone	202-213	sirolimus	216-224	
prednisolone	202-213	nifedipine	227-236	
prednisolone	202-213	fluconazole	239-249	
prednisolone	202-213	ritonavir	252-260	
prednisolone	202-213	rifampin	267-274	
sirolimus	216-224	nifedipine	227-236	
sirolimus	216-224	fluconazole	239-249	
sirolimus	216-224	ritonavir	252-260	
sirolimus	216-224	rifampin	267-274	
nifedipine	227-236	fluconazole	239-249	
nifedipine	227-236	ritonavir	252-260	
nifedipine	227-236	rifampin	267-274	
fluconazole	239-249	ritonavir	252-260	
fluconazole	239-249	rifampin	267-274	
ritonavir	252-260	rifampin	267-274	

There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.
MYCAMINE	58-65	mycophenolate mofetil	70-90	
MYCAMINE	58-65	cyclosporine	93-104	
MYCAMINE	58-65	tacrolimus	107-116	
MYCAMINE	58-65	prednisolone	119-130	
MYCAMINE	58-65	fluconazole	137-147	
mycophenolate mofetil	70-90	cyclosporine	93-104	
mycophenolate mofetil	70-90	tacrolimus	107-116	
mycophenolate mofetil	70-90	prednisolone	119-130	
mycophenolate mofetil	70-90	fluconazole	137-147	
cyclosporine	93-104	tacrolimus	107-116	
cyclosporine	93-104	prednisolone	119-130	
cyclosporine	93-104	fluconazole	137-147	
tacrolimus	107-116	prednisolone	119-130	
tacrolimus	107-116	fluconazole	137-147	
prednisolone	119-130	fluconazole	137-147	

Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone.
Sirolimus	0-8	MYCAMINE	90-97	
Sirolimus	0-8	sirolimus	113-121	
MYCAMINE	90-97	sirolimus	113-121	

Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone.
Nifedipine	0-9	MYCAMINE	101-108	
Nifedipine	0-9	nifedipine	124-133	
MYCAMINE	101-108	nifedipine	124-133	

Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
sirolimus	19-27	nifedipine	32-41	
sirolimus	19-27	MYCAMINE	63-70	
sirolimus	19-27	sirolimus	96-104	
sirolimus	19-27	nifedipine	109-118	
sirolimus	19-27	sirolimus	133-141	
sirolimus	19-27	nifedipine	146-155	
nifedipine	32-41	MYCAMINE	63-70	
nifedipine	32-41	sirolimus	96-104	
nifedipine	32-41	nifedipine	109-118	
nifedipine	32-41	sirolimus	133-141	
nifedipine	32-41	nifedipine	146-155	
MYCAMINE	63-70	sirolimus	96-104	
MYCAMINE	63-70	nifedipine	109-118	
MYCAMINE	63-70	sirolimus	133-141	
MYCAMINE	63-70	nifedipine	146-155	
sirolimus	96-104	nifedipine	109-118	
sirolimus	96-104	sirolimus	133-141	
sirolimus	96-104	nifedipine	146-155	
nifedipine	109-118	sirolimus	133-141	
nifedipine	109-118	nifedipine	146-155	
sirolimus	133-141	nifedipine	146-155	

Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).
midazolam	74-82	azole antimycotics	228-245	
midazolam	74-82	protease inhibitors	248-266	
midazolam	74-82	calcium channel antagonists	269-295	
midazolam	74-82	macrolide antibiotics	302-322	
azole antimycotics	228-245	protease inhibitors	248-266	
azole antimycotics	228-245	calcium channel antagonists	269-295	
azole antimycotics	228-245	macrolide antibiotics	302-322	
protease inhibitors	248-266	calcium channel antagonists	269-295	
protease inhibitors	248-266	macrolide antibiotics	302-322	
calcium channel antagonists	269-295	macrolide antibiotics	302-322	

Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.
erythromycin	14-25	diltiazem	28-36	
erythromycin	14-25	verapamil	39-47	
erythromycin	14-25	ketoconazole	50-61	
erythromycin	14-25	fluconazole	64-74	
erythromycin	14-25	itraconazole	80-91	
erythromycin	14-25	midazolam	171-179	
diltiazem	28-36	verapamil	39-47	
diltiazem	28-36	ketoconazole	50-61	
diltiazem	28-36	fluconazole	64-74	
diltiazem	28-36	itraconazole	80-91	
diltiazem	28-36	midazolam	171-179	
verapamil	39-47	ketoconazole	50-61	
verapamil	39-47	fluconazole	64-74	
verapamil	39-47	itraconazole	80-91	
verapamil	39-47	midazolam	171-179	
ketoconazole	50-61	fluconazole	64-74	
ketoconazole	50-61	itraconazole	80-91	
ketoconazole	50-61	midazolam	171-179	
fluconazole	64-74	itraconazole	80-91	
fluconazole	64-74	midazolam	171-179	
itraconazole	80-91	midazolam	171-179	

Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam.
ritonavir	64-72	nelfinavir	78-87	
ritonavir	64-72	midazolam	198-206	
nelfinavir	78-87	midazolam	198-206	

Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies.
rifampin	63-70	carbamazepine	73-85	
rifampin	63-70	phenytoin	92-100	
rifampin	63-70	midazolam	175-183	
carbamazepine	73-85	phenytoin	92-100	
carbamazepine	73-85	midazolam	175-183	
phenytoin	92-100	midazolam	175-183	

The difficulty in achieving adequate sedation may have been the result of decreased absorption of the sedatives due to both the gastrointestinal effects and stimulant effects of methylphenidate.
sedatives	102-110	methylphenidate	178-192	

The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
VERSED Syrup	23-34	narcotics	153-161	
VERSED Syrup	23-34	morphine	168-175	
VERSED Syrup	23-34	meperidine	178-187	
VERSED Syrup	23-34	fentanyl	193-200	
VERSED Syrup	23-34	propofol	204-211	
VERSED Syrup	23-34	ketamine	214-221	
VERSED Syrup	23-34	nitrous oxide	224-236	
VERSED Syrup	23-34	secobarbital	239-250	
VERSED Syrup	23-34	droperidol	256-265	
narcotics	153-161	morphine	168-175	
narcotics	153-161	meperidine	178-187	
narcotics	153-161	fentanyl	193-200	
narcotics	153-161	propofol	204-211	
narcotics	153-161	ketamine	214-221	
narcotics	153-161	nitrous oxide	224-236	
narcotics	153-161	secobarbital	239-250	
narcotics	153-161	droperidol	256-265	
morphine	168-175	meperidine	178-187	
morphine	168-175	fentanyl	193-200	
morphine	168-175	propofol	204-211	
morphine	168-175	ketamine	214-221	
morphine	168-175	nitrous oxide	224-236	
morphine	168-175	secobarbital	239-250	
morphine	168-175	droperidol	256-265	
meperidine	178-187	fentanyl	193-200	
meperidine	178-187	propofol	204-211	
meperidine	178-187	ketamine	214-221	
meperidine	178-187	nitrous oxide	224-236	
meperidine	178-187	secobarbital	239-250	
meperidine	178-187	droperidol	256-265	
fentanyl	193-200	propofol	204-211	
fentanyl	193-200	ketamine	214-221	
fentanyl	193-200	nitrous oxide	224-236	
fentanyl	193-200	secobarbital	239-250	
fentanyl	193-200	droperidol	256-265	
propofol	204-211	ketamine	214-221	
propofol	204-211	nitrous oxide	224-236	
propofol	204-211	secobarbital	239-250	
propofol	204-211	droperidol	256-265	
ketamine	214-221	nitrous oxide	224-236	
ketamine	214-221	secobarbital	239-250	
ketamine	214-221	droperidol	256-265	
nitrous oxide	224-236	secobarbital	239-250	
nitrous oxide	224-236	droperidol	256-265	
secobarbital	239-250	droperidol	256-265	

No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.
atropine	72-79	scopolamine	82-92	
atropine	72-79	glycopyrrolate	95-108	
atropine	72-79	diazepam	111-118	
atropine	72-79	hydroxyzine	121-131	
atropine	72-79	muscle relaxants	144-159	
atropine	72-79	anesthetics	171-181	
scopolamine	82-92	glycopyrrolate	95-108	
scopolamine	82-92	diazepam	111-118	
scopolamine	82-92	hydroxyzine	121-131	
scopolamine	82-92	muscle relaxants	144-159	
scopolamine	82-92	anesthetics	171-181	
glycopyrrolate	95-108	diazepam	111-118	
glycopyrrolate	95-108	hydroxyzine	121-131	
glycopyrrolate	95-108	muscle relaxants	144-159	
glycopyrrolate	95-108	anesthetics	171-181	
diazepam	111-118	hydroxyzine	121-131	
diazepam	111-118	muscle relaxants	144-159	
diazepam	111-118	anesthetics	171-181	
hydroxyzine	121-131	muscle relaxants	144-159	
hydroxyzine	121-131	anesthetics	171-181	
muscle relaxants	144-159	anesthetics	171-181	

When administered concomitantly with ProAmatine   , cardiac glycosides may enhance or precipitate bradycardia, A.V.
ProAmatine	37-46	cardiac glycosides	52-69	

The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
phenylephrine	66-78	pseudoephedrine	81-95	
phenylephrine	66-78	ephedrine	98-106	
phenylephrine	66-78	phenylpropanolamine	109-127	
phenylephrine	66-78	dihydroergotamine	132-148	
phenylephrine	66-78	ProAmatine	200-209	
phenylephrine	66-78	ProAmatine	254-263	
pseudoephedrine	81-95	ephedrine	98-106	
pseudoephedrine	81-95	phenylpropanolamine	109-127	
pseudoephedrine	81-95	dihydroergotamine	132-148	
pseudoephedrine	81-95	ProAmatine	200-209	
pseudoephedrine	81-95	ProAmatine	254-263	
ephedrine	98-106	phenylpropanolamine	109-127	
ephedrine	98-106	dihydroergotamine	132-148	
ephedrine	98-106	ProAmatine	200-209	
ephedrine	98-106	ProAmatine	254-263	
phenylpropanolamine	109-127	dihydroergotamine	132-148	
phenylpropanolamine	109-127	ProAmatine	200-209	
phenylpropanolamine	109-127	ProAmatine	254-263	
dihydroergotamine	132-148	ProAmatine	200-209	
dihydroergotamine	132-148	ProAmatine	254-263	
ProAmatine	200-209	ProAmatine	254-263	

ProAmatine    has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation.
ProAmatine	0-9	fludrocortisone acetate	105-127	

ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
ProAmatine	0-9	Alpha-adrenergic blocking agents	12-43	
ProAmatine	0-9	prazosin	54-61	
ProAmatine	0-9	terazosin	64-72	
ProAmatine	0-9	doxazosin	79-87	
ProAmatine	0-9	ProAmatine	120-129	
ProAmatine	0-9	desglymidodrine	274-288	
ProAmatine	0-9	metformin	415-423	
ProAmatine	0-9	cimetidine	426-435	
ProAmatine	0-9	ranitidine	438-447	
ProAmatine	0-9	procainamide	450-461	
ProAmatine	0-9	triamterene	464-474	
ProAmatine	0-9	flecainide	477-486	
ProAmatine	0-9	quinidine	493-501	
Alpha-adrenergic blocking agents	12-43	prazosin	54-61	
Alpha-adrenergic blocking agents	12-43	terazosin	64-72	
Alpha-adrenergic blocking agents	12-43	doxazosin	79-87	
Alpha-adrenergic blocking agents	12-43	ProAmatine	120-129	
Alpha-adrenergic blocking agents	12-43	desglymidodrine	274-288	
Alpha-adrenergic blocking agents	12-43	metformin	415-423	
Alpha-adrenergic blocking agents	12-43	cimetidine	426-435	
Alpha-adrenergic blocking agents	12-43	ranitidine	438-447	
Alpha-adrenergic blocking agents	12-43	procainamide	450-461	
Alpha-adrenergic blocking agents	12-43	triamterene	464-474	
Alpha-adrenergic blocking agents	12-43	flecainide	477-486	
Alpha-adrenergic blocking agents	12-43	quinidine	493-501	
prazosin	54-61	terazosin	64-72	
prazosin	54-61	doxazosin	79-87	
prazosin	54-61	ProAmatine	120-129	
prazosin	54-61	desglymidodrine	274-288	
prazosin	54-61	metformin	415-423	
prazosin	54-61	cimetidine	426-435	
prazosin	54-61	ranitidine	438-447	
prazosin	54-61	procainamide	450-461	
prazosin	54-61	triamterene	464-474	
prazosin	54-61	flecainide	477-486	
prazosin	54-61	quinidine	493-501	
terazosin	64-72	doxazosin	79-87	
terazosin	64-72	ProAmatine	120-129	
terazosin	64-72	desglymidodrine	274-288	
terazosin	64-72	metformin	415-423	
terazosin	64-72	cimetidine	426-435	
terazosin	64-72	ranitidine	438-447	
terazosin	64-72	procainamide	450-461	
terazosin	64-72	triamterene	464-474	
terazosin	64-72	flecainide	477-486	
terazosin	64-72	quinidine	493-501	
doxazosin	79-87	ProAmatine	120-129	
doxazosin	79-87	desglymidodrine	274-288	
doxazosin	79-87	metformin	415-423	
doxazosin	79-87	cimetidine	426-435	
doxazosin	79-87	ranitidine	438-447	
doxazosin	79-87	procainamide	450-461	
doxazosin	79-87	triamterene	464-474	
doxazosin	79-87	flecainide	477-486	
doxazosin	79-87	quinidine	493-501	
ProAmatine	120-129	desglymidodrine	274-288	
ProAmatine	120-129	metformin	415-423	
ProAmatine	120-129	cimetidine	426-435	
ProAmatine	120-129	ranitidine	438-447	
ProAmatine	120-129	procainamide	450-461	
ProAmatine	120-129	triamterene	464-474	
ProAmatine	120-129	flecainide	477-486	
ProAmatine	120-129	quinidine	493-501	
desglymidodrine	274-288	metformin	415-423	
desglymidodrine	274-288	cimetidine	426-435	
desglymidodrine	274-288	ranitidine	438-447	
desglymidodrine	274-288	procainamide	450-461	
desglymidodrine	274-288	triamterene	464-474	
desglymidodrine	274-288	flecainide	477-486	
desglymidodrine	274-288	quinidine	493-501	
metformin	415-423	cimetidine	426-435	
metformin	415-423	ranitidine	438-447	
metformin	415-423	procainamide	450-461	
metformin	415-423	triamterene	464-474	
metformin	415-423	flecainide	477-486	
metformin	415-423	quinidine	493-501	
cimetidine	426-435	ranitidine	438-447	
cimetidine	426-435	procainamide	450-461	
cimetidine	426-435	triamterene	464-474	
cimetidine	426-435	flecainide	477-486	
cimetidine	426-435	quinidine	493-501	
ranitidine	438-447	procainamide	450-461	
ranitidine	438-447	triamterene	464-474	
ranitidine	438-447	flecainide	477-486	
ranitidine	438-447	quinidine	493-501	
procainamide	450-461	triamterene	464-474	
procainamide	450-461	flecainide	477-486	
procainamide	450-461	quinidine	493-501	
triamterene	464-474	flecainide	477-486	
triamterene	464-474	quinidine	493-501	
flecainide	477-486	quinidine	493-501	

Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).
mifepristone	49-60	ketoconazole	158-169	
mifepristone	49-60	itraconazole	172-183	
mifepristone	49-60	erythromycin	186-197	
mifepristone	49-60	mifepristone	276-287	
ketoconazole	158-169	itraconazole	172-183	
ketoconazole	158-169	erythromycin	186-197	
ketoconazole	158-169	mifepristone	276-287	
itraconazole	172-183	erythromycin	186-197	
itraconazole	172-183	mifepristone	276-287	
erythromycin	186-197	mifepristone	276-287	

Furthermore, rifampin, dexamethasone, St.
rifampin	13-20	dexamethasone	23-35	

John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).
anticonvulsants	27-41	phenytoin	44-52	
anticonvulsants	27-41	phenobarbital	55-67	
anticonvulsants	27-41	carbamazepine	70-82	
anticonvulsants	27-41	mifepristone	96-107	
anticonvulsants	27-41	mifepristone	146-157	
phenytoin	44-52	phenobarbital	55-67	
phenytoin	44-52	carbamazepine	70-82	
phenytoin	44-52	mifepristone	96-107	
phenytoin	44-52	mifepristone	146-157	
phenobarbital	55-67	carbamazepine	70-82	
phenobarbital	55-67	mifepristone	96-107	
phenobarbital	55-67	mifepristone	146-157	
carbamazepine	70-82	mifepristone	96-107	
carbamazepine	70-82	mifepristone	146-157	
mifepristone	96-107	mifepristone	146-157	

While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme.
ZAVESCA	27-33	Cerezyme	76-83	
ZAVESCA	27-33	Cerezyme	218-225	
Cerezyme	76-83	Cerezyme	218-225	

Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.
Cerezyme	25-32	imiglucerase	38-49	
Cerezyme	25-32	ZAVESCA	56-62	
imiglucerase	38-49	ZAVESCA	56-62	

Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
tetracyclines	8-20	anticoagulant	98-110	
tetracyclines	8-20	anticoagulant	161-173	
anticoagulant	98-110	anticoagulant	161-173	

Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin.
penicillin	73-82	tetracycline class drugs	117-140	
penicillin	73-82	penicillin	162-171	
tetracycline class drugs	117-140	penicillin	162-171	

Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.
tetracyclines	14-26	antacids	43-50	
tetracyclines	14-26	aluminum	63-70	
tetracyclines	14-26	calcium	73-79	
tetracyclines	14-26	magnesium	84-92	
tetracyclines	14-26	iron	99-102	
antacids	43-50	aluminum	63-70	
antacids	43-50	calcium	73-79	
antacids	43-50	magnesium	84-92	
antacids	43-50	iron	99-102	
aluminum	63-70	calcium	73-79	
aluminum	63-70	magnesium	84-92	
aluminum	63-70	iron	99-102	
calcium	73-79	magnesium	84-92	
calcium	73-79	iron	99-102	
magnesium	84-92	iron	99-102	

The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.
tetracycline	22-33	methoxyflurane	39-52	

Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.
tetracyclines	18-30	contraceptives	42-55	
tetracyclines	18-30	contraceptives	73-86	
contraceptives	42-55	contraceptives	73-86	

Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects.
Guanethidine	17-28	minoxidil	40-48	
Guanethidine	17-28	guanethidine	146-157	
minoxidil	40-48	guanethidine	146-157	

If at all possible guanethidine should be discontinued well before minoxidil is begun.
guanethidine	19-30	minoxidil	67-75	

Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of REMERON SolTab    (mirtazapine) Orally Disintegrating Tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes.
REMERON SolTab	74-87	mirtazapine	93-103	

While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied.
mirtazapine	39-49	mirtazapine	121-131	
mirtazapine	39-49	REMERON SolTab	309-322	
mirtazapine	121-131	REMERON SolTab	309-322	

Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects.
Alcohol	0-6	alcohol	39-45	
Alcohol	0-6	mirtazapine	109-119	
alcohol	39-45	mirtazapine	109-119	

However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol.
REMERON	66-72	alcohol	126-132	

Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.
alcohol	49-55	REMERON SolTab	70-83	
alcohol	49-55	Diazepam	86-93	
alcohol	49-55	diazepam	126-133	
alcohol	49-55	mirtazapine	184-194	
REMERON SolTab	70-83	Diazepam	86-93	
REMERON SolTab	70-83	diazepam	126-133	
REMERON SolTab	70-83	mirtazapine	184-194	
Diazepam	86-93	diazepam	126-133	
Diazepam	86-93	mirtazapine	184-194	
diazepam	126-133	mirtazapine	184-194	

However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam.
REMERON	52-58	diazepam	111-118	

Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON SolTab.
diazepam	49-56	REMERON SolTab	95-108	

Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin.
Mitotane	0-7	warfarin	59-66	
Mitotane	0-7	warfarin	175-182	
warfarin	59-66	warfarin	175-182	

Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants.
anticoagulant	70-82	Mitotane	123-130	
anticoagulant	70-82	coumarin-type anticoagulants	147-174	
Mitotane	123-130	coumarin-type anticoagulants	147-174	

Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and succinylcholine has not been systematically studied.
MIVACRON	9-16	MIVACRON	165-172	
MIVACRON	9-16	succinylcholine	178-192	
MIVACRON	165-172	succinylcholine	178-192	

Prior administration of succinylcholine can potentiate the neuromuscular blocking effects of nondepolarizing agents.
succinylcholine	24-38	nondepolarizing agents	93-114	

Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON.
succinylcholine	38-52	MIVACRON	102-109	

The use of MIVACRON before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.
MIVACRON	11-18	succinylcholine	27-41	
MIVACRON	11-18	succinylcholine	84-98	
succinylcholine	27-41	succinylcholine	84-98	

There are no clinical data on the use of MIVACRON with other nondepolarizing neuromuscular blocking agents.
MIVACRON	41-48	nondepolarizing neuromuscular blocking agents	61-105	

Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C.
Isoflurane	0-9	enflurane	15-23	
Isoflurane	0-9	nitrous oxide	44-56	
Isoflurane	0-9	oxygen	58-63	
enflurane	15-23	nitrous oxide	44-56	
enflurane	15-23	oxygen	58-63	
nitrous oxide	44-56	oxygen	58-63	

A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of enflurane or isoflurane.
MIVACRON	64-71	enflurane	119-127	
MIVACRON	64-71	isoflurane	132-141	
enflurane	119-127	isoflurane	132-141	

Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
nondepolarizing agents	67-88	MIVACRON	98-105	
nondepolarizing agents	67-88	antibiotics	123-133	
nondepolarizing agents	67-88	aminoglycosides	142-156	
nondepolarizing agents	67-88	tetracyclines	159-171	
nondepolarizing agents	67-88	bacitracin	174-183	
nondepolarizing agents	67-88	polymyxins	186-195	
nondepolarizing agents	67-88	lincomycin	198-207	
nondepolarizing agents	67-88	clindamycin	210-220	
nondepolarizing agents	67-88	colistin	223-230	
nondepolarizing agents	67-88	sodium colistimethate	237-257	
nondepolarizing agents	67-88	magnesium	261-269	
nondepolarizing agents	67-88	lithium	278-284	
nondepolarizing agents	67-88	anesthetics	293-303	
nondepolarizing agents	67-88	procainamide	306-317	
nondepolarizing agents	67-88	quinidine	324-332	
MIVACRON	98-105	antibiotics	123-133	
MIVACRON	98-105	aminoglycosides	142-156	
MIVACRON	98-105	tetracyclines	159-171	
MIVACRON	98-105	bacitracin	174-183	
MIVACRON	98-105	polymyxins	186-195	
MIVACRON	98-105	lincomycin	198-207	
MIVACRON	98-105	clindamycin	210-220	
MIVACRON	98-105	colistin	223-230	
MIVACRON	98-105	sodium colistimethate	237-257	
MIVACRON	98-105	magnesium	261-269	
MIVACRON	98-105	lithium	278-284	
MIVACRON	98-105	anesthetics	293-303	
MIVACRON	98-105	procainamide	306-317	
MIVACRON	98-105	quinidine	324-332	
antibiotics	123-133	aminoglycosides	142-156	
antibiotics	123-133	tetracyclines	159-171	
antibiotics	123-133	bacitracin	174-183	
antibiotics	123-133	polymyxins	186-195	
antibiotics	123-133	lincomycin	198-207	
antibiotics	123-133	clindamycin	210-220	
antibiotics	123-133	colistin	223-230	
antibiotics	123-133	sodium colistimethate	237-257	
antibiotics	123-133	magnesium	261-269	
antibiotics	123-133	lithium	278-284	
antibiotics	123-133	anesthetics	293-303	
antibiotics	123-133	procainamide	306-317	
antibiotics	123-133	quinidine	324-332	
aminoglycosides	142-156	tetracyclines	159-171	
aminoglycosides	142-156	bacitracin	174-183	
aminoglycosides	142-156	polymyxins	186-195	
aminoglycosides	142-156	lincomycin	198-207	
aminoglycosides	142-156	clindamycin	210-220	
aminoglycosides	142-156	colistin	223-230	
aminoglycosides	142-156	sodium colistimethate	237-257	
aminoglycosides	142-156	magnesium	261-269	
aminoglycosides	142-156	lithium	278-284	
aminoglycosides	142-156	anesthetics	293-303	
aminoglycosides	142-156	procainamide	306-317	
aminoglycosides	142-156	quinidine	324-332	
tetracyclines	159-171	bacitracin	174-183	
tetracyclines	159-171	polymyxins	186-195	
tetracyclines	159-171	lincomycin	198-207	
tetracyclines	159-171	clindamycin	210-220	
tetracyclines	159-171	colistin	223-230	
tetracyclines	159-171	sodium colistimethate	237-257	
tetracyclines	159-171	magnesium	261-269	
tetracyclines	159-171	lithium	278-284	
tetracyclines	159-171	anesthetics	293-303	
tetracyclines	159-171	procainamide	306-317	
tetracyclines	159-171	quinidine	324-332	
bacitracin	174-183	polymyxins	186-195	
bacitracin	174-183	lincomycin	198-207	
bacitracin	174-183	clindamycin	210-220	
bacitracin	174-183	colistin	223-230	
bacitracin	174-183	sodium colistimethate	237-257	
bacitracin	174-183	magnesium	261-269	
bacitracin	174-183	lithium	278-284	
bacitracin	174-183	anesthetics	293-303	
bacitracin	174-183	procainamide	306-317	
bacitracin	174-183	quinidine	324-332	
polymyxins	186-195	lincomycin	198-207	
polymyxins	186-195	clindamycin	210-220	
polymyxins	186-195	colistin	223-230	
polymyxins	186-195	sodium colistimethate	237-257	
polymyxins	186-195	magnesium	261-269	
polymyxins	186-195	lithium	278-284	
polymyxins	186-195	anesthetics	293-303	
polymyxins	186-195	procainamide	306-317	
polymyxins	186-195	quinidine	324-332	
lincomycin	198-207	clindamycin	210-220	
lincomycin	198-207	colistin	223-230	
lincomycin	198-207	sodium colistimethate	237-257	
lincomycin	198-207	magnesium	261-269	
lincomycin	198-207	lithium	278-284	
lincomycin	198-207	anesthetics	293-303	
lincomycin	198-207	procainamide	306-317	
lincomycin	198-207	quinidine	324-332	
clindamycin	210-220	colistin	223-230	
clindamycin	210-220	sodium colistimethate	237-257	
clindamycin	210-220	magnesium	261-269	
clindamycin	210-220	lithium	278-284	
clindamycin	210-220	anesthetics	293-303	
clindamycin	210-220	procainamide	306-317	
clindamycin	210-220	quinidine	324-332	
colistin	223-230	sodium colistimethate	237-257	
colistin	223-230	magnesium	261-269	
colistin	223-230	lithium	278-284	
colistin	223-230	anesthetics	293-303	
colistin	223-230	procainamide	306-317	
colistin	223-230	quinidine	324-332	
sodium colistimethate	237-257	magnesium	261-269	
sodium colistimethate	237-257	lithium	278-284	
sodium colistimethate	237-257	anesthetics	293-303	
sodium colistimethate	237-257	procainamide	306-317	
sodium colistimethate	237-257	quinidine	324-332	
magnesium	261-269	lithium	278-284	
magnesium	261-269	anesthetics	293-303	
magnesium	261-269	procainamide	306-317	
magnesium	261-269	quinidine	324-332	
lithium	278-284	anesthetics	293-303	
lithium	278-284	procainamide	306-317	
lithium	278-284	quinidine	324-332	
anesthetics	293-303	procainamide	306-317	
anesthetics	293-303	quinidine	324-332	
procainamide	306-317	quinidine	324-332	

The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
MIVACRON	37-44	contraceptives	151-164	
MIVACRON	37-44	glucocorticoids	167-181	
MIVACRON	37-44	monoamine oxidase inhibitors	195-222	
MIVACRON	37-44	neuromuscular blocking agents	354-382	
MIVACRON	37-44	phenytoin	443-451	
MIVACRON	37-44	carbamazepine	456-468	
contraceptives	151-164	glucocorticoids	167-181	
contraceptives	151-164	monoamine oxidase inhibitors	195-222	
contraceptives	151-164	neuromuscular blocking agents	354-382	
contraceptives	151-164	phenytoin	443-451	
contraceptives	151-164	carbamazepine	456-468	
glucocorticoids	167-181	monoamine oxidase inhibitors	195-222	
glucocorticoids	167-181	neuromuscular blocking agents	354-382	
glucocorticoids	167-181	phenytoin	443-451	
glucocorticoids	167-181	carbamazepine	456-468	
monoamine oxidase inhibitors	195-222	neuromuscular blocking agents	354-382	
monoamine oxidase inhibitors	195-222	phenytoin	443-451	
monoamine oxidase inhibitors	195-222	carbamazepine	456-468	
neuromuscular blocking agents	354-382	phenytoin	443-451	
neuromuscular blocking agents	354-382	carbamazepine	456-468	
phenytoin	443-451	carbamazepine	456-468	

While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
phenytoin	29-37	carbamazepine	42-54	
phenytoin	29-37	MIVACRON	81-88	
carbamazepine	42-54	MIVACRON	81-88	

Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
corticosteroids	53-67	phenytoin	176-184	
corticosteroids	53-67	carbamazepine	189-201	
corticosteroids	53-67	antibiotics	213-223	
corticosteroids	53-67	cisplatin	246-254	
corticosteroids	53-67	edrophonium	258-268	
corticosteroids	53-67	neostigmine	272-282	
corticosteroids	53-67	polymyxin B	286-296	
corticosteroids	53-67	bacitracin	301-310	
corticosteroids	53-67	anesthetics	320-330	
corticosteroids	53-67	procaine	340-347	
corticosteroids	53-67	anesthetics	359-369	
corticosteroids	53-67	succinylcholine	373-387	
corticosteroids	53-67	muscle relaxants	398-413	
phenytoin	176-184	carbamazepine	189-201	
phenytoin	176-184	antibiotics	213-223	
phenytoin	176-184	cisplatin	246-254	
phenytoin	176-184	edrophonium	258-268	
phenytoin	176-184	neostigmine	272-282	
phenytoin	176-184	polymyxin B	286-296	
phenytoin	176-184	bacitracin	301-310	
phenytoin	176-184	anesthetics	320-330	
phenytoin	176-184	procaine	340-347	
phenytoin	176-184	anesthetics	359-369	
phenytoin	176-184	succinylcholine	373-387	
phenytoin	176-184	muscle relaxants	398-413	
carbamazepine	189-201	antibiotics	213-223	
carbamazepine	189-201	cisplatin	246-254	
carbamazepine	189-201	edrophonium	258-268	
carbamazepine	189-201	neostigmine	272-282	
carbamazepine	189-201	polymyxin B	286-296	
carbamazepine	189-201	bacitracin	301-310	
carbamazepine	189-201	anesthetics	320-330	
carbamazepine	189-201	procaine	340-347	
carbamazepine	189-201	anesthetics	359-369	
carbamazepine	189-201	succinylcholine	373-387	
carbamazepine	189-201	muscle relaxants	398-413	
antibiotics	213-223	cisplatin	246-254	
antibiotics	213-223	edrophonium	258-268	
antibiotics	213-223	neostigmine	272-282	
antibiotics	213-223	polymyxin B	286-296	
antibiotics	213-223	bacitracin	301-310	
antibiotics	213-223	anesthetics	320-330	
antibiotics	213-223	procaine	340-347	
antibiotics	213-223	anesthetics	359-369	
antibiotics	213-223	succinylcholine	373-387	
antibiotics	213-223	muscle relaxants	398-413	
cisplatin	246-254	edrophonium	258-268	
cisplatin	246-254	neostigmine	272-282	
cisplatin	246-254	polymyxin B	286-296	
cisplatin	246-254	bacitracin	301-310	
cisplatin	246-254	anesthetics	320-330	
cisplatin	246-254	procaine	340-347	
cisplatin	246-254	anesthetics	359-369	
cisplatin	246-254	succinylcholine	373-387	
cisplatin	246-254	muscle relaxants	398-413	
edrophonium	258-268	neostigmine	272-282	
edrophonium	258-268	polymyxin B	286-296	
edrophonium	258-268	bacitracin	301-310	
edrophonium	258-268	anesthetics	320-330	
edrophonium	258-268	procaine	340-347	
edrophonium	258-268	anesthetics	359-369	
edrophonium	258-268	succinylcholine	373-387	
edrophonium	258-268	muscle relaxants	398-413	
neostigmine	272-282	polymyxin B	286-296	
neostigmine	272-282	bacitracin	301-310	
neostigmine	272-282	anesthetics	320-330	
neostigmine	272-282	procaine	340-347	
neostigmine	272-282	anesthetics	359-369	
neostigmine	272-282	succinylcholine	373-387	
neostigmine	272-282	muscle relaxants	398-413	
polymyxin B	286-296	bacitracin	301-310	
polymyxin B	286-296	anesthetics	320-330	
polymyxin B	286-296	procaine	340-347	
polymyxin B	286-296	anesthetics	359-369	
polymyxin B	286-296	succinylcholine	373-387	
polymyxin B	286-296	muscle relaxants	398-413	
bacitracin	301-310	anesthetics	320-330	
bacitracin	301-310	procaine	340-347	
bacitracin	301-310	anesthetics	359-369	
bacitracin	301-310	succinylcholine	373-387	
bacitracin	301-310	muscle relaxants	398-413	
anesthetics	320-330	procaine	340-347	
anesthetics	320-330	anesthetics	359-369	
anesthetics	320-330	succinylcholine	373-387	
anesthetics	320-330	muscle relaxants	398-413	
procaine	340-347	anesthetics	359-369	
procaine	340-347	succinylcholine	373-387	
procaine	340-347	muscle relaxants	398-413	
anesthetics	359-369	succinylcholine	373-387	
anesthetics	359-369	muscle relaxants	398-413	
succinylcholine	373-387	muscle relaxants	398-413	

Diuretics: Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started.
Diuretics	0-8	ACE inhibitors	97-110	

The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of moexpril should be reduced..
UNIVASC	44-50	UNIVASC	196-202	
UNIVASC	44-50	moexpril	254-261	
UNIVASC	196-202	moexpril	254-261	

Potassium Supplements and Potassium-Sparing Diuretics: UNIVASC    can increase serum potassium because it decreases aldosterone secretion.
Potassium	0-8	Potassium-Sparing Diuretics	26-52	
Potassium	0-8	UNIVASC	55-61	
Potassium-Sparing Diuretics	26-52	UNIVASC	55-61	

Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
potassium-sparing diuretics	7-33	spironolactone	36-49	
potassium-sparing diuretics	7-33	triamterene	52-62	
potassium-sparing diuretics	7-33	amiloride	65-73	
potassium-sparing diuretics	7-33	potassium	79-87	
potassium-sparing diuretics	7-33	ACE inhibitors	120-133	
spironolactone	36-49	triamterene	52-62	
spironolactone	36-49	amiloride	65-73	
spironolactone	36-49	potassium	79-87	
spironolactone	36-49	ACE inhibitors	120-133	
triamterene	52-62	amiloride	65-73	
triamterene	52-62	potassium	79-87	
triamterene	52-62	ACE inhibitors	120-133	
amiloride	65-73	potassium	79-87	
amiloride	65-73	ACE inhibitors	120-133	
potassium	79-87	ACE inhibitors	120-133	

Oral Anticoagulants: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect.
Anticoagulants	5-18	warfarin	46-53	
Anticoagulants	5-18	anticoagulant	141-153	
warfarin	46-53	anticoagulant	141-153	

Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
Lithium	0-6	lithium	25-31	
Lithium	0-6	lithium	56-62	
Lithium	0-6	ACE inhibitors	114-127	
Lithium	0-6	lithium	149-155	
lithium	25-31	lithium	56-62	
lithium	25-31	ACE inhibitors	114-127	
lithium	25-31	lithium	149-155	
lithium	56-62	ACE inhibitors	114-127	
lithium	56-62	lithium	149-155	
ACE inhibitors	114-127	lithium	149-155	

If a diuretic is also used, the risk of lithium toxicity may be increased.
diuretic	5-12	lithium	40-46	

Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine.
UNIVASC	81-87	hydrochlorothiazide	128-146	
UNIVASC	81-87	digoxin	149-155	
UNIVASC	81-87	cimetidine	161-170	
hydrochlorothiazide	128-146	digoxin	149-155	
hydrochlorothiazide	128-146	cimetidine	161-170	
digoxin	149-155	cimetidine	161-170	

UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.
UNIVASC	0-6	calcium-channel-blocking agents	63-93	
UNIVASC	0-6	diuretics	96-104	
UNIVASC	0-6	H2 blockers	107-117	
UNIVASC	0-6	digoxin	120-126	
UNIVASC	0-6	hypoglycemic agents	134-152	
calcium-channel-blocking agents	63-93	diuretics	96-104	
calcium-channel-blocking agents	63-93	H2 blockers	107-117	
calcium-channel-blocking agents	63-93	digoxin	120-126	
calcium-channel-blocking agents	63-93	hypoglycemic agents	134-152	
diuretics	96-104	H2 blockers	107-117	
diuretics	96-104	digoxin	120-126	
diuretics	96-104	hypoglycemic agents	134-152	
H2 blockers	107-117	digoxin	120-126	
H2 blockers	107-117	hypoglycemic agents	134-152	
digoxin	120-126	hypoglycemic agents	134-152	

However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.
ketoconazole	9-20	mometasone furoate	96-113	

Montelukast at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State  - did not cause clinically significant changes in the kinetics of a single intravenous dose of theophylline (predominantly a cytochrome P450 1A2 substrate).
Montelukast	0-10	theophylline	176-187	

- did not change the pharmacokinetic profile of warfarin (a substrate of cytochromes P450 2A6 and 2C9) or influence the effect of a single 30-mg oral dose of warfarin on prothrombin time or the INR (International Normalized Ratio).
warfarin	48-55	warfarin	158-165	

- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily.
terfenadine	53-63	fexofenadine	105-116	
terfenadine	53-63	terfenadine	218-228	
fexofenadine	105-116	terfenadine	218-228	

Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg.
Montelukast	0-10	contraceptive	167-179	
Montelukast	0-10	norethindrone	192-204	
Montelukast	0-10	estradiol	219-227	
contraceptive	167-179	norethindrone	192-204	
contraceptive	167-179	estradiol	219-227	
norethindrone	192-204	estradiol	219-227	

- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.
prednisone	72-81	prednisolone	86-97	
prednisone	72-81	prednisone	139-148	
prednisone	72-81	prednisolone	165-176	
prednisolone	86-97	prednisone	139-148	
prednisolone	86-97	prednisolone	165-176	
prednisone	139-148	prednisolone	165-176	

Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast.
Phenobarbital	0-12	montelukast	70-80	
Phenobarbital	0-12	montelukast	133-143	
montelukast	70-80	montelukast	133-143	

It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.
phenobarbital	112-124	rifampin	129-136	
phenobarbital	112-124	montelukast	164-174	
rifampin	129-136	montelukast	164-174	

In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
montelukast	62-72	theophylline	164-175	
montelukast	62-72	prednisone	178-187	
montelukast	62-72	prednisolone	190-201	
montelukast	62-72	contraceptives	209-222	
montelukast	62-72	norethindrone	225-237	
montelukast	62-72	ethinyl estradiol	244-260	
montelukast	62-72	terfenadine	271-281	
montelukast	62-72	digoxin	284-290	
montelukast	62-72	warfarin	297-304	
theophylline	164-175	prednisone	178-187	
theophylline	164-175	prednisolone	190-201	
theophylline	164-175	contraceptives	209-222	
theophylline	164-175	norethindrone	225-237	
theophylline	164-175	ethinyl estradiol	244-260	
theophylline	164-175	terfenadine	271-281	
theophylline	164-175	digoxin	284-290	
theophylline	164-175	warfarin	297-304	
prednisone	178-187	prednisolone	190-201	
prednisone	178-187	contraceptives	209-222	
prednisone	178-187	norethindrone	225-237	
prednisone	178-187	ethinyl estradiol	244-260	
prednisone	178-187	terfenadine	271-281	
prednisone	178-187	digoxin	284-290	
prednisone	178-187	warfarin	297-304	
prednisolone	190-201	contraceptives	209-222	
prednisolone	190-201	norethindrone	225-237	
prednisolone	190-201	ethinyl estradiol	244-260	
prednisolone	190-201	terfenadine	271-281	
prednisolone	190-201	digoxin	284-290	
prednisolone	190-201	warfarin	297-304	
contraceptives	209-222	norethindrone	225-237	
contraceptives	209-222	ethinyl estradiol	244-260	
contraceptives	209-222	terfenadine	271-281	
contraceptives	209-222	digoxin	284-290	
contraceptives	209-222	warfarin	297-304	
norethindrone	225-237	ethinyl estradiol	244-260	
norethindrone	225-237	terfenadine	271-281	
norethindrone	225-237	digoxin	284-290	
norethindrone	225-237	warfarin	297-304	
ethinyl estradiol	244-260	terfenadine	271-281	
ethinyl estradiol	244-260	digoxin	284-290	
ethinyl estradiol	244-260	warfarin	297-304	
terfenadine	271-281	digoxin	284-290	
terfenadine	271-281	warfarin	297-304	
digoxin	284-290	warfarin	297-304	

These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants.
thyroid hormones	27-42	sedative hypnotics	45-62	
thyroid hormones	27-42	non-steroidal anti-inflammatory agents	65-102	
thyroid hormones	27-42	benzodiazepines	105-119	
thyroid hormones	27-42	decongestants	126-138	
sedative hypnotics	45-62	non-steroidal anti-inflammatory agents	65-102	
sedative hypnotics	45-62	benzodiazepines	105-119	
sedative hypnotics	45-62	decongestants	126-138	
non-steroidal anti-inflammatory agents	65-102	benzodiazepines	105-119	
non-steroidal anti-inflammatory agents	65-102	decongestants	126-138	
benzodiazepines	105-119	decongestants	126-138	

Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast.
Phenobarbital	0-12	montelukast	70-80	
Phenobarbital	0-12	montelukast	133-143	
montelukast	70-80	montelukast	133-143	

It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.
phenobarbital	112-124	rifampin	129-136	
phenobarbital	112-124	montelukast	164-174	
rifampin	129-136	montelukast	164-174	

Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.
Central Nervous System Depressants	15-48	morphine	77-84	
Central Nervous System Depressants	15-48	CNS depressants	127-141	
Central Nervous System Depressants	15-48	alcohol	151-157	
Central Nervous System Depressants	15-48	sedatives	160-168	
Central Nervous System Depressants	15-48	antihistaminics	171-185	
Central Nervous System Depressants	15-48	psychotropic drugs	191-208	
morphine	77-84	CNS depressants	127-141	
morphine	77-84	alcohol	151-157	
morphine	77-84	sedatives	160-168	
morphine	77-84	antihistaminics	171-185	
morphine	77-84	psychotropic drugs	191-208	
CNS depressants	127-141	alcohol	151-157	
CNS depressants	127-141	sedatives	160-168	
CNS depressants	127-141	antihistaminics	171-185	
CNS depressants	127-141	psychotropic drugs	191-208	
alcohol	151-157	sedatives	160-168	
alcohol	151-157	antihistaminics	171-185	
alcohol	151-157	psychotropic drugs	191-208	
sedatives	160-168	antihistaminics	171-185	
sedatives	160-168	psychotropic drugs	191-208	
antihistaminics	171-185	psychotropic drugs	191-208	

Use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression, hypotension and profound sedation or coma.
neuroleptics	7-18	morphine	45-52	

Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
Mixed Agonist/Antagonist Opioid Analgesics	17-58	Agonist/antagonist analgesics	61-89	
Mixed Agonist/Antagonist Opioid Analgesics	17-58	pentazocine	98-108	
Mixed Agonist/Antagonist Opioid Analgesics	17-58	nalbuphine	111-120	
Mixed Agonist/Antagonist Opioid Analgesics	17-58	butorphanol	123-133	
Mixed Agonist/Antagonist Opioid Analgesics	17-58	buprenorphine	139-151	
Mixed Agonist/Antagonist Opioid Analgesics	17-58	opioid agonist analgesic	261-284	
Agonist/antagonist analgesics	61-89	pentazocine	98-108	
Agonist/antagonist analgesics	61-89	nalbuphine	111-120	
Agonist/antagonist analgesics	61-89	butorphanol	123-133	
Agonist/antagonist analgesics	61-89	buprenorphine	139-151	
Agonist/antagonist analgesics	61-89	opioid agonist analgesic	261-284	
pentazocine	98-108	nalbuphine	111-120	
pentazocine	98-108	butorphanol	123-133	
pentazocine	98-108	buprenorphine	139-151	
pentazocine	98-108	opioid agonist analgesic	261-284	
nalbuphine	111-120	butorphanol	123-133	
nalbuphine	111-120	buprenorphine	139-151	
nalbuphine	111-120	opioid agonist analgesic	261-284	
butorphanol	123-133	buprenorphine	139-151	
butorphanol	123-133	opioid agonist analgesic	261-284	
buprenorphine	139-151	opioid agonist analgesic	261-284	

Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
Antacids	0-7	Myfortic	41-48	
Antacids	0-7	magnesium	133-141	
Antacids	0-7	aluminum	143-150	
Antacids	0-7	antacids	163-170	
Antacids	0-7	Myfortic	271-278	
Myfortic	41-48	magnesium	133-141	
Myfortic	41-48	aluminum	143-150	
Myfortic	41-48	antacids	163-170	
Myfortic	41-48	Myfortic	271-278	
magnesium	133-141	aluminum	143-150	
magnesium	133-141	antacids	163-170	
magnesium	133-141	Myfortic	271-278	
aluminum	143-150	antacids	163-170	
aluminum	143-150	Myfortic	271-278	
antacids	163-170	Myfortic	271-278	

It is recommended that Myfortic and antacids not be administered simultaneously.
Myfortic	23-30	antacids	36-43	

Cyclosporine: When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of Myfortic.
Cyclosporine	0-11	cyclosporine	64-75	
Cyclosporine	0-11	Myfortic	152-159	
cyclosporine	64-75	Myfortic	152-159	

Acyclovir/Ganciclovir: may be taken with Myfortic;
Acyclovir	0-8	Ganciclovir	10-20	
Acyclovir	0-8	Myfortic	41-48	
Ganciclovir	10-20	Myfortic	41-48	

Both acyclovir/ganciclovir and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.
acyclovir	5-13	ganciclovir	15-25	
acyclovir	5-13	MPAG	31-34	
ganciclovir	15-25	MPAG	31-34	

Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.
Azathioprine	0-11	Mycophenolate Mofetil	13-33	
Azathioprine	0-11	azathioprine	47-58	
Azathioprine	0-11	mycophenolate mofetil	64-84	
Azathioprine	0-11	Myfortic	136-143	
Azathioprine	0-11	azathioprine	184-195	
Azathioprine	0-11	mycophenolate mofetil	200-220	
Mycophenolate Mofetil	13-33	azathioprine	47-58	
Mycophenolate Mofetil	13-33	mycophenolate mofetil	64-84	
Mycophenolate Mofetil	13-33	Myfortic	136-143	
Mycophenolate Mofetil	13-33	azathioprine	184-195	
Mycophenolate Mofetil	13-33	mycophenolate mofetil	200-220	
azathioprine	47-58	mycophenolate mofetil	64-84	
azathioprine	47-58	Myfortic	136-143	
azathioprine	47-58	azathioprine	184-195	
azathioprine	47-58	mycophenolate mofetil	200-220	
mycophenolate mofetil	64-84	Myfortic	136-143	
mycophenolate mofetil	64-84	azathioprine	184-195	
mycophenolate mofetil	64-84	mycophenolate mofetil	200-220	
Myfortic	136-143	azathioprine	184-195	
Myfortic	136-143	mycophenolate mofetil	200-220	
azathioprine	184-195	mycophenolate mofetil	200-220	

Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil.
Cholestyramine	0-13	MPA	108-110	
Cholestyramine	0-13	mycophenolate mofetil	146-166	
MPA	108-110	mycophenolate mofetil	146-166	

Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic.
Myfortic	29-36	cholestyramine	43-56	
Myfortic	29-36	activated charcoal	204-221	
Myfortic	29-36	Myfortic	275-282	
cholestyramine	43-56	activated charcoal	204-221	
cholestyramine	43-56	Myfortic	275-282	
activated charcoal	204-221	Myfortic	275-282	

Oral Contraceptives: Given the different metabolism of Myfortic and oral contraceptives, no drug interaction between these two classes of drug is expected.
Contraceptives	5-18	Myfortic	55-62	
Contraceptives	5-18	contraceptives	73-86	
Myfortic	55-62	contraceptives	73-86	

However, in a drug-drug interaction study, mean levonorgesterol AUC was decreased by 15% when coadministered with mycophenolate mofetil.
levonorgesterol	48-62	mycophenolate mofetil	114-134	

Therefore, it is recommended that oral contraceptives are co- administered with Myfortic with caution and additional birth control methods be considered.
contraceptives	39-52	Myfortic	80-87	

Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective.
Live Vaccines	0-12	Myfortic	37-44	
Live Vaccines	0-12	live attenuated vaccines	58-81	
Myfortic	37-44	live attenuated vaccines	58-81	

Interference of MPAG hydrolysis may lead to less MPA available for absorption.
MPAG	16-19	MPA	49-51	

Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron.
ondansetron	8-18	ondansetron	209-219	

Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
Phenytoin	0-8	Carbamazepine	11-23	
Phenytoin	0-8	Rifampicin	30-39	
Phenytoin	0-8	phenytoin	100-108	
Phenytoin	0-8	carbamazepine	111-123	
Phenytoin	0-8	rifampicin	130-139	
Phenytoin	0-8	ondansetron	160-170	
Phenytoin	0-8	ondansetron	204-214	
Carbamazepine	11-23	Rifampicin	30-39	
Carbamazepine	11-23	phenytoin	100-108	
Carbamazepine	11-23	carbamazepine	111-123	
Carbamazepine	11-23	rifampicin	130-139	
Carbamazepine	11-23	ondansetron	160-170	
Carbamazepine	11-23	ondansetron	204-214	
Rifampicin	30-39	phenytoin	100-108	
Rifampicin	30-39	carbamazepine	111-123	
Rifampicin	30-39	rifampicin	130-139	
Rifampicin	30-39	ondansetron	160-170	
Rifampicin	30-39	ondansetron	204-214	
phenytoin	100-108	carbamazepine	111-123	
phenytoin	100-108	rifampicin	130-139	
phenytoin	100-108	ondansetron	160-170	
phenytoin	100-108	ondansetron	204-214	
carbamazepine	111-123	rifampicin	130-139	
carbamazepine	111-123	ondansetron	160-170	
carbamazepine	111-123	ondansetron	204-214	
rifampicin	130-139	ondansetron	160-170	
rifampicin	130-139	ondansetron	204-214	
ondansetron	160-170	ondansetron	204-214	

However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.
ondansetron	66-76	Tramadol	126-133	
ondansetron	66-76	ondansetron	189-199	
ondansetron	66-76	tramadol	205-212	
ondansetron	66-76	ondansetron	273-283	
ondansetron	66-76	tramadol	360-367	
ondansetron	66-76	ondansetron	472-482	
Tramadol	126-133	ondansetron	189-199	
Tramadol	126-133	tramadol	205-212	
Tramadol	126-133	ondansetron	273-283	
Tramadol	126-133	tramadol	360-367	
Tramadol	126-133	ondansetron	472-482	
ondansetron	189-199	tramadol	205-212	
ondansetron	189-199	ondansetron	273-283	
ondansetron	189-199	tramadol	360-367	
ondansetron	189-199	ondansetron	472-482	
tramadol	205-212	ondansetron	273-283	
tramadol	205-212	tramadol	360-367	
tramadol	205-212	ondansetron	472-482	
ondansetron	273-283	tramadol	360-367	
ondansetron	273-283	ondansetron	472-482	
tramadol	360-367	ondansetron	472-482	

In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.
carmustine	11-20	etoposide	23-31	
carmustine	11-20	cisplatin	38-46	
carmustine	11-20	ondansetron	86-96	
etoposide	23-31	cisplatin	38-46	
etoposide	23-31	ondansetron	86-96	
cisplatin	38-46	ondansetron	86-96	

ondansetron did not increase blood levels of high-dose methotrexate.
ondansetron	0-10	methotrexate	55-66	

Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects.
beta adrenergic aerosol bronchodilators	6-44	Alupent	84-90	
beta adrenergic aerosol bronchodilators	6-44	metaproterenol sulfate	96-117	
Alupent	84-90	metaproterenol sulfate	96-117	

Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.
Beta adrenergic agonists	0-23	monoamine oxidase inhibitors	92-119	
Beta adrenergic agonists	0-23	tricyclic antidepressants	124-148	
Beta adrenergic agonists	0-23	beta adrenergic agonists	171-194	
monoamine oxidase inhibitors	92-119	tricyclic antidepressants	124-148	
monoamine oxidase inhibitors	92-119	beta adrenergic agonists	171-194	
tricyclic antidepressants	124-148	beta adrenergic agonists	171-194	

Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.
Alcohol	0-6	XENICAL	84-90	
Alcohol	0-6	alcohol	108-114	
Alcohol	0-6	alcohol	188-194	
Alcohol	0-6	orlistat	214-221	
Alcohol	0-6	orlistat	287-294	
XENICAL	84-90	alcohol	108-114	
XENICAL	84-90	alcohol	188-194	
XENICAL	84-90	orlistat	214-221	
XENICAL	84-90	orlistat	287-294	
alcohol	108-114	alcohol	188-194	
alcohol	108-114	orlistat	214-221	
alcohol	108-114	orlistat	287-294	
alcohol	188-194	orlistat	214-221	
alcohol	188-194	orlistat	287-294	
orlistat	214-221	orlistat	287-294	

Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine.
Cyclosporine	0-11	XENICAL	38-44	
Cyclosporine	0-11	cyclosporine	50-61	
Cyclosporine	0-11	cyclosporine	110-121	
Cyclosporine	0-11	XENICAL	142-148	
Cyclosporine	0-11	cyclosporine	174-185	
XENICAL	38-44	cyclosporine	50-61	
XENICAL	38-44	cyclosporine	110-121	
XENICAL	38-44	XENICAL	142-148	
XENICAL	38-44	cyclosporine	174-185	
cyclosporine	50-61	cyclosporine	110-121	
cyclosporine	50-61	XENICAL	142-148	
cyclosporine	50-61	cyclosporine	174-185	
cyclosporine	110-121	XENICAL	142-148	
cyclosporine	110-121	cyclosporine	174-185	
XENICAL	142-148	cyclosporine	174-185	

Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin.
Digoxin	0-6	XENICAL	48-54	
Digoxin	0-6	XENICAL	93-99	
Digoxin	0-6	digoxin	156-162	
XENICAL	48-54	XENICAL	93-99	
XENICAL	48-54	digoxin	156-162	
XENICAL	93-99	digoxin	156-162	

Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL.
Fat-soluble Vitamin Supplements	0-30	beta-carotene	109-121	
Fat-soluble Vitamin Supplements	0-30	XENICAL	182-188	
beta-carotene	109-121	XENICAL	182-188	

XENICAL inhibited absorption of a vitamin E acetate supplement by approximately 60%.
XENICAL	0-6	vitamin E acetate	34-50	

The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time.
orlistat	14-21	vitamin D	57-65	
orlistat	14-21	vitamin A	68-76	
orlistat	14-21	vitamin K	105-113	
vitamin D	57-65	vitamin A	68-76	
vitamin D	57-65	vitamin K	105-113	
vitamin A	68-76	vitamin K	105-113	

Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide.
Glyburide	0-8	orlistat	50-57	
Glyburide	0-8	orlistat	95-102	
Glyburide	0-8	glyburide	187-195	
orlistat	50-57	orlistat	95-102	
orlistat	50-57	glyburide	187-195	
orlistat	95-102	glyburide	187-195	

Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets).
Nifedipine	0-9	XENICAL	78-84	
Nifedipine	0-9	XENICAL	123-129	
Nifedipine	0-9	nifedipine	168-177	
XENICAL	78-84	XENICAL	123-129	
XENICAL	78-84	nifedipine	168-177	
XENICAL	123-129	nifedipine	168-177	

Oral Contraceptives: In 20 normal-weight female subjects, the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives.
Contraceptives	5-18	XENICAL	75-81	
Contraceptives	5-18	contraceptives	187-200	
XENICAL	75-81	contraceptives	187-200	

Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin.
Phenytoin	0-8	XENICAL	50-56	
Phenytoin	0-8	XENICAL	95-101	
Phenytoin	0-8	phenytoin	165-173	
XENICAL	50-56	XENICAL	95-101	
XENICAL	50-56	phenytoin	165-173	
XENICAL	95-101	phenytoin	165-173	

Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin.
Pravastatin	0-10	XENICAL	108-114	
Pravastatin	0-10	XENICAL	153-159	
Pravastatin	0-10	pravastatin	200-210	
XENICAL	108-114	XENICAL	153-159	
XENICAL	108-114	pravastatin	200-210	
XENICAL	153-159	pravastatin	200-210	

Warfarin: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII).
Warfarin	0-7	XENICAL	58-64	
Warfarin	0-7	warfarin	142-149	
XENICAL	58-64	warfarin	142-149	

Although undercarboxylated osteocalcin, a marker of vitamin K nutritional status, was unaltered with XENICAL administration, vitamin K levels tended to decline in subjects taking XENICAL.
XENICAL	101-107	XENICAL	179-185	

Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.
vitamin K	14-22	XENICAL	57-63	
vitamin K	14-22	warfarin	102-109	
vitamin K	14-22	XENICAL	130-136	
XENICAL	57-63	warfarin	102-109	
XENICAL	57-63	XENICAL	130-136	
warfarin	102-109	XENICAL	130-136	

Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.
Tetracycline	0-11	antibiotic	31-40	
Tetracycline	0-11	penicillin	85-94	
antibiotic	31-40	penicillin	85-94	

No pharmacokinetic interaction between 85 mg/m2 ELOXATIN and infusional 5-FU has been observed in patients treated every 2 weeks.
ELOXATIN	48-55	5-FU	72-75	

Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks.
5-FU	13-16	ELOXATIN	104-111	

Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants.
Anticoagulants	0-13	Anabolic steroids	15-31	
Anticoagulants	0-13	anticoagulants	66-79	
Anabolic steroids	15-31	anticoagulants	66-79	

Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.
Warfarin	0-7	oxandrolone	31-41	
Warfarin	0-7	warfarin	117-124	
Warfarin	0-7	S-warfarin	158-167	
Warfarin	0-7	R-warfarin	257-266	
oxandrolone	31-41	warfarin	117-124	
oxandrolone	31-41	S-warfarin	158-167	
oxandrolone	31-41	R-warfarin	257-266	
warfarin	117-124	S-warfarin	158-167	
warfarin	117-124	R-warfarin	257-266	
S-warfarin	158-167	R-warfarin	257-266	

A 5.5-fold decrease in the mean warfarin dose from 6.13 mg/day to 1.13 mg/day (approximately 80-85% reduction of warfarin dose), was necessary to maintain a target INR of 1.5.
warfarin	32-39	warfarin	113-120	

When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved.
oxandrolone	5-15	warfarin	84-91	
oxandrolone	5-15	warfarin	171-178	
warfarin	84-91	warfarin	171-178	

Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued.
warfarin	106-113	oxandrolone	160-170	

Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents.
hypoglycemic agents	5-23	Oxandrolone	25-35	
hypoglycemic agents	5-23	hypoglycemic agents	72-90	
Oxandrolone	25-35	hypoglycemic agents	72-90	

Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema.
Adrenal steroids	0-15	ACTH	20-23	
Adrenal steroids	0-15	adrenal cortical steroids	81-105	
Adrenal steroids	0-15	ACTH	110-113	
ACTH	20-23	adrenal cortical steroids	81-105	
ACTH	20-23	ACTH	110-113	
adrenal cortical steroids	81-105	ACTH	110-113	

The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.
oxybutynin	23-32	anticholinergic drugs	45-65	

Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor.
oxybutynin chloride	5-23	DITROPAN XL	85-95	
oxybutynin chloride	5-23	ketoconazole	119-130	
DITROPAN XL	85-95	ketoconazole	119-130	

Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
antimycotic agents	67-84	itraconazole	93-104	
antimycotic agents	67-84	miconazole	110-119	
antimycotic agents	67-84	macrolide antibiotics	125-145	
antimycotic agents	67-84	erythromycin	154-165	
antimycotic agents	67-84	clarithromycin	171-184	
antimycotic agents	67-84	oxybutynin	198-207	
itraconazole	93-104	miconazole	110-119	
itraconazole	93-104	macrolide antibiotics	125-145	
itraconazole	93-104	erythromycin	154-165	
itraconazole	93-104	clarithromycin	171-184	
itraconazole	93-104	oxybutynin	198-207	
miconazole	110-119	macrolide antibiotics	125-145	
miconazole	110-119	erythromycin	154-165	
miconazole	110-119	clarithromycin	171-184	
miconazole	110-119	oxybutynin	198-207	
macrolide antibiotics	125-145	erythromycin	154-165	
macrolide antibiotics	125-145	clarithromycin	171-184	
macrolide antibiotics	125-145	oxybutynin	198-207	
erythromycin	154-165	clarithromycin	171-184	
erythromycin	154-165	oxybutynin	198-207	
clarithromycin	171-184	oxybutynin	198-207	

Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.
antacid	24-30	antacid	42-48	
antacid	24-30	aluminum hydroxide	61-78	
antacid	24-30	magnesium hydroxide	81-99	
antacid	24-30	simethicone	106-116	
antacid	24-30	oxybutynin	164-173	
antacid	24-30	desethyloxybutynin	178-195	
antacid	42-48	aluminum hydroxide	61-78	
antacid	42-48	magnesium hydroxide	81-99	
antacid	42-48	simethicone	106-116	
antacid	42-48	oxybutynin	164-173	
antacid	42-48	desethyloxybutynin	178-195	
aluminum hydroxide	61-78	magnesium hydroxide	81-99	
aluminum hydroxide	61-78	simethicone	106-116	
aluminum hydroxide	61-78	oxybutynin	164-173	
aluminum hydroxide	61-78	desethyloxybutynin	178-195	
magnesium hydroxide	81-99	simethicone	106-116	
magnesium hydroxide	81-99	oxybutynin	164-173	
magnesium hydroxide	81-99	desethyloxybutynin	178-195	
simethicone	106-116	oxybutynin	164-173	
simethicone	106-116	desethyloxybutynin	178-195	
oxybutynin	164-173	desethyloxybutynin	178-195	

The CNS depressant effects of oxycodone hydrochloride may be additive with that of other CNS depressants..
oxycodone hydrochloride	30-52	CNS depressants	89-103	

The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
CNS depressants	29-43	sedatives	55-63	
CNS depressants	29-43	hypnotics	66-74	
CNS depressants	29-43	tranquilizers	77-89	
CNS depressants	29-43	anesthetics	100-110	
CNS depressants	29-43	phenothiazines	113-126	
CNS depressants	29-43	opioids	135-141	
CNS depressants	29-43	tricyclic antidepressants	144-168	
CNS depressants	29-43	monoamine oxidase (MAO) inhibitors	171-204	
CNS depressants	29-43	alcohol	211-217	
sedatives	55-63	hypnotics	66-74	
sedatives	55-63	tranquilizers	77-89	
sedatives	55-63	anesthetics	100-110	
sedatives	55-63	phenothiazines	113-126	
sedatives	55-63	opioids	135-141	
sedatives	55-63	tricyclic antidepressants	144-168	
sedatives	55-63	monoamine oxidase (MAO) inhibitors	171-204	
sedatives	55-63	alcohol	211-217	
hypnotics	66-74	tranquilizers	77-89	
hypnotics	66-74	anesthetics	100-110	
hypnotics	66-74	phenothiazines	113-126	
hypnotics	66-74	opioids	135-141	
hypnotics	66-74	tricyclic antidepressants	144-168	
hypnotics	66-74	monoamine oxidase (MAO) inhibitors	171-204	
hypnotics	66-74	alcohol	211-217	
tranquilizers	77-89	anesthetics	100-110	
tranquilizers	77-89	phenothiazines	113-126	
tranquilizers	77-89	opioids	135-141	
tranquilizers	77-89	tricyclic antidepressants	144-168	
tranquilizers	77-89	monoamine oxidase (MAO) inhibitors	171-204	
tranquilizers	77-89	alcohol	211-217	
anesthetics	100-110	phenothiazines	113-126	
anesthetics	100-110	opioids	135-141	
anesthetics	100-110	tricyclic antidepressants	144-168	
anesthetics	100-110	monoamine oxidase (MAO) inhibitors	171-204	
anesthetics	100-110	alcohol	211-217	
phenothiazines	113-126	opioids	135-141	
phenothiazines	113-126	tricyclic antidepressants	144-168	
phenothiazines	113-126	monoamine oxidase (MAO) inhibitors	171-204	
phenothiazines	113-126	alcohol	211-217	
opioids	135-141	tricyclic antidepressants	144-168	
opioids	135-141	monoamine oxidase (MAO) inhibitors	171-204	
opioids	135-141	alcohol	211-217	
tricyclic antidepressants	144-168	monoamine oxidase (MAO) inhibitors	171-204	
tricyclic antidepressants	144-168	alcohol	211-217	
monoamine oxidase (MAO) inhibitors	171-204	alcohol	211-217	

Anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.
Anticholinergics	0-15	opioid analgesics	96-112	

It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia.
oxymorphone	74-84	propofol	104-111	

In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of cimetidine with opioid analgesics;
cimetidine	143-152	opioid analgesics	159-175	

Potential for INVEGA    to Affect Other Drugs Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes.
INVEGA	14-19	Paliperidone	46-57	

Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol.
paliperidone	33-44	INVEGA	47-52	
paliperidone	33-44	centrally acting drugs	111-132	
paliperidone	33-44	alcohol	138-144	
INVEGA	47-52	centrally acting drugs	111-132	
INVEGA	47-52	alcohol	138-144	
centrally acting drugs	111-132	alcohol	138-144	

Paliperidone may antagonize the effect of levodopa and other dopamine agonists.
Paliperidone	0-11	levodopa	42-49	
Paliperidone	0-11	dopamine agonists	61-77	
levodopa	42-49	dopamine agonists	61-77	

Potential for Other Drugs to Affect INVEGA    Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely.
INVEGA	36-41	Paliperidone	46-57	

Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
pantoprazole	53-64	theophylline	154-165	
pantoprazole	53-64	cisapride	168-176	
pantoprazole	53-64	antipyrine	179-188	
pantoprazole	53-64	caffeine	191-198	
pantoprazole	53-64	carbamazepine	201-213	
pantoprazole	53-64	diazepam	216-223	
pantoprazole	53-64	desmethyldiazepam	253-269	
pantoprazole	53-64	diclofenac	273-282	
pantoprazole	53-64	naproxen	285-292	
pantoprazole	53-64	piroxicam	295-303	
pantoprazole	53-64	digoxin	306-312	
pantoprazole	53-64	ethanol	315-321	
pantoprazole	53-64	glyburide	324-332	
pantoprazole	53-64	contraceptive	343-355	
pantoprazole	53-64	levonorgestrel	358-371	
pantoprazole	53-64	ethinyl estradiol	373-389	
pantoprazole	53-64	metoprolol	393-402	
pantoprazole	53-64	nifedipine	405-414	
pantoprazole	53-64	phenytoin	417-425	
pantoprazole	53-64	warfarin	428-435	
pantoprazole	53-64	midazolam	438-446	
pantoprazole	53-64	clarithromycin	449-462	
pantoprazole	53-64	metronidazole	465-477	
pantoprazole	53-64	amoxicillin	483-493	
theophylline	154-165	cisapride	168-176	
theophylline	154-165	antipyrine	179-188	
theophylline	154-165	caffeine	191-198	
theophylline	154-165	carbamazepine	201-213	
theophylline	154-165	diazepam	216-223	
theophylline	154-165	desmethyldiazepam	253-269	
theophylline	154-165	diclofenac	273-282	
theophylline	154-165	naproxen	285-292	
theophylline	154-165	piroxicam	295-303	
theophylline	154-165	digoxin	306-312	
theophylline	154-165	ethanol	315-321	
theophylline	154-165	glyburide	324-332	
theophylline	154-165	contraceptive	343-355	
theophylline	154-165	levonorgestrel	358-371	
theophylline	154-165	ethinyl estradiol	373-389	
theophylline	154-165	metoprolol	393-402	
theophylline	154-165	nifedipine	405-414	
theophylline	154-165	phenytoin	417-425	
theophylline	154-165	warfarin	428-435	
theophylline	154-165	midazolam	438-446	
theophylline	154-165	clarithromycin	449-462	
theophylline	154-165	metronidazole	465-477	
theophylline	154-165	amoxicillin	483-493	
cisapride	168-176	antipyrine	179-188	
cisapride	168-176	caffeine	191-198	
cisapride	168-176	carbamazepine	201-213	
cisapride	168-176	diazepam	216-223	
cisapride	168-176	desmethyldiazepam	253-269	
cisapride	168-176	diclofenac	273-282	
cisapride	168-176	naproxen	285-292	
cisapride	168-176	piroxicam	295-303	
cisapride	168-176	digoxin	306-312	
cisapride	168-176	ethanol	315-321	
cisapride	168-176	glyburide	324-332	
cisapride	168-176	contraceptive	343-355	
cisapride	168-176	levonorgestrel	358-371	
cisapride	168-176	ethinyl estradiol	373-389	
cisapride	168-176	metoprolol	393-402	
cisapride	168-176	nifedipine	405-414	
cisapride	168-176	phenytoin	417-425	
cisapride	168-176	warfarin	428-435	
cisapride	168-176	midazolam	438-446	
cisapride	168-176	clarithromycin	449-462	
cisapride	168-176	metronidazole	465-477	
cisapride	168-176	amoxicillin	483-493	
antipyrine	179-188	caffeine	191-198	
antipyrine	179-188	carbamazepine	201-213	
antipyrine	179-188	diazepam	216-223	
antipyrine	179-188	desmethyldiazepam	253-269	
antipyrine	179-188	diclofenac	273-282	
antipyrine	179-188	naproxen	285-292	
antipyrine	179-188	piroxicam	295-303	
antipyrine	179-188	digoxin	306-312	
antipyrine	179-188	ethanol	315-321	
antipyrine	179-188	glyburide	324-332	
antipyrine	179-188	contraceptive	343-355	
antipyrine	179-188	levonorgestrel	358-371	
antipyrine	179-188	ethinyl estradiol	373-389	
antipyrine	179-188	metoprolol	393-402	
antipyrine	179-188	nifedipine	405-414	
antipyrine	179-188	phenytoin	417-425	
antipyrine	179-188	warfarin	428-435	
antipyrine	179-188	midazolam	438-446	
antipyrine	179-188	clarithromycin	449-462	
antipyrine	179-188	metronidazole	465-477	
antipyrine	179-188	amoxicillin	483-493	
caffeine	191-198	carbamazepine	201-213	
caffeine	191-198	diazepam	216-223	
caffeine	191-198	desmethyldiazepam	253-269	
caffeine	191-198	diclofenac	273-282	
caffeine	191-198	naproxen	285-292	
caffeine	191-198	piroxicam	295-303	
caffeine	191-198	digoxin	306-312	
caffeine	191-198	ethanol	315-321	
caffeine	191-198	glyburide	324-332	
caffeine	191-198	contraceptive	343-355	
caffeine	191-198	levonorgestrel	358-371	
caffeine	191-198	ethinyl estradiol	373-389	
caffeine	191-198	metoprolol	393-402	
caffeine	191-198	nifedipine	405-414	
caffeine	191-198	phenytoin	417-425	
caffeine	191-198	warfarin	428-435	
caffeine	191-198	midazolam	438-446	
caffeine	191-198	clarithromycin	449-462	
caffeine	191-198	metronidazole	465-477	
caffeine	191-198	amoxicillin	483-493	
carbamazepine	201-213	diazepam	216-223	
carbamazepine	201-213	desmethyldiazepam	253-269	
carbamazepine	201-213	diclofenac	273-282	
carbamazepine	201-213	naproxen	285-292	
carbamazepine	201-213	piroxicam	295-303	
carbamazepine	201-213	digoxin	306-312	
carbamazepine	201-213	ethanol	315-321	
carbamazepine	201-213	glyburide	324-332	
carbamazepine	201-213	contraceptive	343-355	
carbamazepine	201-213	levonorgestrel	358-371	
carbamazepine	201-213	ethinyl estradiol	373-389	
carbamazepine	201-213	metoprolol	393-402	
carbamazepine	201-213	nifedipine	405-414	
carbamazepine	201-213	phenytoin	417-425	
carbamazepine	201-213	warfarin	428-435	
carbamazepine	201-213	midazolam	438-446	
carbamazepine	201-213	clarithromycin	449-462	
carbamazepine	201-213	metronidazole	465-477	
carbamazepine	201-213	amoxicillin	483-493	
diazepam	216-223	desmethyldiazepam	253-269	
diazepam	216-223	diclofenac	273-282	
diazepam	216-223	naproxen	285-292	
diazepam	216-223	piroxicam	295-303	
diazepam	216-223	digoxin	306-312	
diazepam	216-223	ethanol	315-321	
diazepam	216-223	glyburide	324-332	
diazepam	216-223	contraceptive	343-355	
diazepam	216-223	levonorgestrel	358-371	
diazepam	216-223	ethinyl estradiol	373-389	
diazepam	216-223	metoprolol	393-402	
diazepam	216-223	nifedipine	405-414	
diazepam	216-223	phenytoin	417-425	
diazepam	216-223	warfarin	428-435	
diazepam	216-223	midazolam	438-446	
diazepam	216-223	clarithromycin	449-462	
diazepam	216-223	metronidazole	465-477	
diazepam	216-223	amoxicillin	483-493	
desmethyldiazepam	253-269	diclofenac	273-282	
desmethyldiazepam	253-269	naproxen	285-292	
desmethyldiazepam	253-269	piroxicam	295-303	
desmethyldiazepam	253-269	digoxin	306-312	
desmethyldiazepam	253-269	ethanol	315-321	
desmethyldiazepam	253-269	glyburide	324-332	
desmethyldiazepam	253-269	contraceptive	343-355	
desmethyldiazepam	253-269	levonorgestrel	358-371	
desmethyldiazepam	253-269	ethinyl estradiol	373-389	
desmethyldiazepam	253-269	metoprolol	393-402	
desmethyldiazepam	253-269	nifedipine	405-414	
desmethyldiazepam	253-269	phenytoin	417-425	
desmethyldiazepam	253-269	warfarin	428-435	
desmethyldiazepam	253-269	midazolam	438-446	
desmethyldiazepam	253-269	clarithromycin	449-462	
desmethyldiazepam	253-269	metronidazole	465-477	
desmethyldiazepam	253-269	amoxicillin	483-493	
diclofenac	273-282	naproxen	285-292	
diclofenac	273-282	piroxicam	295-303	
diclofenac	273-282	digoxin	306-312	
diclofenac	273-282	ethanol	315-321	
diclofenac	273-282	glyburide	324-332	
diclofenac	273-282	contraceptive	343-355	
diclofenac	273-282	levonorgestrel	358-371	
diclofenac	273-282	ethinyl estradiol	373-389	
diclofenac	273-282	metoprolol	393-402	
diclofenac	273-282	nifedipine	405-414	
diclofenac	273-282	phenytoin	417-425	
diclofenac	273-282	warfarin	428-435	
diclofenac	273-282	midazolam	438-446	
diclofenac	273-282	clarithromycin	449-462	
diclofenac	273-282	metronidazole	465-477	
diclofenac	273-282	amoxicillin	483-493	
naproxen	285-292	piroxicam	295-303	
naproxen	285-292	digoxin	306-312	
naproxen	285-292	ethanol	315-321	
naproxen	285-292	glyburide	324-332	
naproxen	285-292	contraceptive	343-355	
naproxen	285-292	levonorgestrel	358-371	
naproxen	285-292	ethinyl estradiol	373-389	
naproxen	285-292	metoprolol	393-402	
naproxen	285-292	nifedipine	405-414	
naproxen	285-292	phenytoin	417-425	
naproxen	285-292	warfarin	428-435	
naproxen	285-292	midazolam	438-446	
naproxen	285-292	clarithromycin	449-462	
naproxen	285-292	metronidazole	465-477	
naproxen	285-292	amoxicillin	483-493	
piroxicam	295-303	digoxin	306-312	
piroxicam	295-303	ethanol	315-321	
piroxicam	295-303	glyburide	324-332	
piroxicam	295-303	contraceptive	343-355	
piroxicam	295-303	levonorgestrel	358-371	
piroxicam	295-303	ethinyl estradiol	373-389	
piroxicam	295-303	metoprolol	393-402	
piroxicam	295-303	nifedipine	405-414	
piroxicam	295-303	phenytoin	417-425	
piroxicam	295-303	warfarin	428-435	
piroxicam	295-303	midazolam	438-446	
piroxicam	295-303	clarithromycin	449-462	
piroxicam	295-303	metronidazole	465-477	
piroxicam	295-303	amoxicillin	483-493	
digoxin	306-312	ethanol	315-321	
digoxin	306-312	glyburide	324-332	
digoxin	306-312	contraceptive	343-355	
digoxin	306-312	levonorgestrel	358-371	
digoxin	306-312	ethinyl estradiol	373-389	
digoxin	306-312	metoprolol	393-402	
digoxin	306-312	nifedipine	405-414	
digoxin	306-312	phenytoin	417-425	
digoxin	306-312	warfarin	428-435	
digoxin	306-312	midazolam	438-446	
digoxin	306-312	clarithromycin	449-462	
digoxin	306-312	metronidazole	465-477	
digoxin	306-312	amoxicillin	483-493	
ethanol	315-321	glyburide	324-332	
ethanol	315-321	contraceptive	343-355	
ethanol	315-321	levonorgestrel	358-371	
ethanol	315-321	ethinyl estradiol	373-389	
ethanol	315-321	metoprolol	393-402	
ethanol	315-321	nifedipine	405-414	
ethanol	315-321	phenytoin	417-425	
ethanol	315-321	warfarin	428-435	
ethanol	315-321	midazolam	438-446	
ethanol	315-321	clarithromycin	449-462	
ethanol	315-321	metronidazole	465-477	
ethanol	315-321	amoxicillin	483-493	
glyburide	324-332	contraceptive	343-355	
glyburide	324-332	levonorgestrel	358-371	
glyburide	324-332	ethinyl estradiol	373-389	
glyburide	324-332	metoprolol	393-402	
glyburide	324-332	nifedipine	405-414	
glyburide	324-332	phenytoin	417-425	
glyburide	324-332	warfarin	428-435	
glyburide	324-332	midazolam	438-446	
glyburide	324-332	clarithromycin	449-462	
glyburide	324-332	metronidazole	465-477	
glyburide	324-332	amoxicillin	483-493	
contraceptive	343-355	levonorgestrel	358-371	
contraceptive	343-355	ethinyl estradiol	373-389	
contraceptive	343-355	metoprolol	393-402	
contraceptive	343-355	nifedipine	405-414	
contraceptive	343-355	phenytoin	417-425	
contraceptive	343-355	warfarin	428-435	
contraceptive	343-355	midazolam	438-446	
contraceptive	343-355	clarithromycin	449-462	
contraceptive	343-355	metronidazole	465-477	
contraceptive	343-355	amoxicillin	483-493	
levonorgestrel	358-371	ethinyl estradiol	373-389	
levonorgestrel	358-371	metoprolol	393-402	
levonorgestrel	358-371	nifedipine	405-414	
levonorgestrel	358-371	phenytoin	417-425	
levonorgestrel	358-371	warfarin	428-435	
levonorgestrel	358-371	midazolam	438-446	
levonorgestrel	358-371	clarithromycin	449-462	
levonorgestrel	358-371	metronidazole	465-477	
levonorgestrel	358-371	amoxicillin	483-493	
ethinyl estradiol	373-389	metoprolol	393-402	
ethinyl estradiol	373-389	nifedipine	405-414	
ethinyl estradiol	373-389	phenytoin	417-425	
ethinyl estradiol	373-389	warfarin	428-435	
ethinyl estradiol	373-389	midazolam	438-446	
ethinyl estradiol	373-389	clarithromycin	449-462	
ethinyl estradiol	373-389	metronidazole	465-477	
ethinyl estradiol	373-389	amoxicillin	483-493	
metoprolol	393-402	nifedipine	405-414	
metoprolol	393-402	phenytoin	417-425	
metoprolol	393-402	warfarin	428-435	
metoprolol	393-402	midazolam	438-446	
metoprolol	393-402	clarithromycin	449-462	
metoprolol	393-402	metronidazole	465-477	
metoprolol	393-402	amoxicillin	483-493	
nifedipine	405-414	phenytoin	417-425	
nifedipine	405-414	warfarin	428-435	
nifedipine	405-414	midazolam	438-446	
nifedipine	405-414	clarithromycin	449-462	
nifedipine	405-414	metronidazole	465-477	
nifedipine	405-414	amoxicillin	483-493	
phenytoin	417-425	warfarin	428-435	
phenytoin	417-425	midazolam	438-446	
phenytoin	417-425	clarithromycin	449-462	
phenytoin	417-425	metronidazole	465-477	
phenytoin	417-425	amoxicillin	483-493	
warfarin	428-435	midazolam	438-446	
warfarin	428-435	clarithromycin	449-462	
warfarin	428-435	metronidazole	465-477	
warfarin	428-435	amoxicillin	483-493	
midazolam	438-446	clarithromycin	449-462	
midazolam	438-446	metronidazole	465-477	
midazolam	438-446	amoxicillin	483-493	
clarithromycin	449-462	metronidazole	465-477	
clarithromycin	449-462	amoxicillin	483-493	
metronidazole	465-477	amoxicillin	483-493	

Therefore, when coadministered with pantoprazole, adjustment of the dosage of pantoprazole or of such drugs may not be necessary.
pantoprazole	36-47	pantoprazole	78-89	

There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly.
proton pump inhibitors	98-119	pantoprazole	132-143	
proton pump inhibitors	98-119	warfarin	150-157	
pantoprazole	132-143	warfarin	150-157	

Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time.
proton pump inhibitors	22-43	warfarin	49-56	

Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).
pantoprazole	75-86	ketoconazole	202-213	
pantoprazole	75-86	ampicillin	216-225	
pantoprazole	75-86	iron	239-242	
ketoconazole	202-213	ampicillin	216-225	
ketoconazole	202-213	iron	239-242	
ampicillin	216-225	iron	239-242	

Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole.
tetrahydrocannabinol	85-104	THC	107-109	
tetrahydrocannabinol	85-104	proton pump inhibitors	139-160	
tetrahydrocannabinol	85-104	pantoprazole	173-184	
THC	107-109	proton pump inhibitors	139-160	
THC	107-109	pantoprazole	173-184	
proton pump inhibitors	139-160	pantoprazole	173-184	

A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
ketoconazole	62-73	paricalcitol	97-108	
ketoconazole	62-73	paricalcitol	126-137	
ketoconazole	62-73	ketoconazole	177-188	
ketoconazole	62-73	paricalcitol	291-302	
ketoconazole	62-73	ketoconazole	309-320	
ketoconazole	62-73	atazanavir	368-377	
ketoconazole	62-73	clarithromycin	380-393	
ketoconazole	62-73	indinavir	396-404	
ketoconazole	62-73	itraconazole	407-418	
ketoconazole	62-73	nefazodone	421-430	
ketoconazole	62-73	nelfinavir	433-442	
ketoconazole	62-73	ritonavir	445-453	
ketoconazole	62-73	saquinavir	456-465	
ketoconazole	62-73	telithromycin	468-480	
ketoconazole	62-73	voriconazole	485-496	
paricalcitol	97-108	paricalcitol	126-137	
paricalcitol	97-108	ketoconazole	177-188	
paricalcitol	97-108	paricalcitol	291-302	
paricalcitol	97-108	ketoconazole	309-320	
paricalcitol	97-108	atazanavir	368-377	
paricalcitol	97-108	clarithromycin	380-393	
paricalcitol	97-108	indinavir	396-404	
paricalcitol	97-108	itraconazole	407-418	
paricalcitol	97-108	nefazodone	421-430	
paricalcitol	97-108	nelfinavir	433-442	
paricalcitol	97-108	ritonavir	445-453	
paricalcitol	97-108	saquinavir	456-465	
paricalcitol	97-108	telithromycin	468-480	
paricalcitol	97-108	voriconazole	485-496	
paricalcitol	126-137	ketoconazole	177-188	
paricalcitol	126-137	paricalcitol	291-302	
paricalcitol	126-137	ketoconazole	309-320	
paricalcitol	126-137	atazanavir	368-377	
paricalcitol	126-137	clarithromycin	380-393	
paricalcitol	126-137	indinavir	396-404	
paricalcitol	126-137	itraconazole	407-418	
paricalcitol	126-137	nefazodone	421-430	
paricalcitol	126-137	nelfinavir	433-442	
paricalcitol	126-137	ritonavir	445-453	
paricalcitol	126-137	saquinavir	456-465	
paricalcitol	126-137	telithromycin	468-480	
paricalcitol	126-137	voriconazole	485-496	
ketoconazole	177-188	paricalcitol	291-302	
ketoconazole	177-188	ketoconazole	309-320	
ketoconazole	177-188	atazanavir	368-377	
ketoconazole	177-188	clarithromycin	380-393	
ketoconazole	177-188	indinavir	396-404	
ketoconazole	177-188	itraconazole	407-418	
ketoconazole	177-188	nefazodone	421-430	
ketoconazole	177-188	nelfinavir	433-442	
ketoconazole	177-188	ritonavir	445-453	
ketoconazole	177-188	saquinavir	456-465	
ketoconazole	177-188	telithromycin	468-480	
ketoconazole	177-188	voriconazole	485-496	
paricalcitol	291-302	ketoconazole	309-320	
paricalcitol	291-302	atazanavir	368-377	
paricalcitol	291-302	clarithromycin	380-393	
paricalcitol	291-302	indinavir	396-404	
paricalcitol	291-302	itraconazole	407-418	
paricalcitol	291-302	nefazodone	421-430	
paricalcitol	291-302	nelfinavir	433-442	
paricalcitol	291-302	ritonavir	445-453	
paricalcitol	291-302	saquinavir	456-465	
paricalcitol	291-302	telithromycin	468-480	
paricalcitol	291-302	voriconazole	485-496	
ketoconazole	309-320	atazanavir	368-377	
ketoconazole	309-320	clarithromycin	380-393	
ketoconazole	309-320	indinavir	396-404	
ketoconazole	309-320	itraconazole	407-418	
ketoconazole	309-320	nefazodone	421-430	
ketoconazole	309-320	nelfinavir	433-442	
ketoconazole	309-320	ritonavir	445-453	
ketoconazole	309-320	saquinavir	456-465	
ketoconazole	309-320	telithromycin	468-480	
ketoconazole	309-320	voriconazole	485-496	
atazanavir	368-377	clarithromycin	380-393	
atazanavir	368-377	indinavir	396-404	
atazanavir	368-377	itraconazole	407-418	
atazanavir	368-377	nefazodone	421-430	
atazanavir	368-377	nelfinavir	433-442	
atazanavir	368-377	ritonavir	445-453	
atazanavir	368-377	saquinavir	456-465	
atazanavir	368-377	telithromycin	468-480	
atazanavir	368-377	voriconazole	485-496	
clarithromycin	380-393	indinavir	396-404	
clarithromycin	380-393	itraconazole	407-418	
clarithromycin	380-393	nefazodone	421-430	
clarithromycin	380-393	nelfinavir	433-442	
clarithromycin	380-393	ritonavir	445-453	
clarithromycin	380-393	saquinavir	456-465	
clarithromycin	380-393	telithromycin	468-480	
clarithromycin	380-393	voriconazole	485-496	
indinavir	396-404	itraconazole	407-418	
indinavir	396-404	nefazodone	421-430	
indinavir	396-404	nelfinavir	433-442	
indinavir	396-404	ritonavir	445-453	
indinavir	396-404	saquinavir	456-465	
indinavir	396-404	telithromycin	468-480	
indinavir	396-404	voriconazole	485-496	
itraconazole	407-418	nefazodone	421-430	
itraconazole	407-418	nelfinavir	433-442	
itraconazole	407-418	ritonavir	445-453	
itraconazole	407-418	saquinavir	456-465	
itraconazole	407-418	telithromycin	468-480	
itraconazole	407-418	voriconazole	485-496	
nefazodone	421-430	nelfinavir	433-442	
nefazodone	421-430	ritonavir	445-453	
nefazodone	421-430	saquinavir	456-465	
nefazodone	421-430	telithromycin	468-480	
nefazodone	421-430	voriconazole	485-496	
nelfinavir	433-442	ritonavir	445-453	
nelfinavir	433-442	saquinavir	456-465	
nelfinavir	433-442	telithromycin	468-480	
nelfinavir	433-442	voriconazole	485-496	
ritonavir	445-453	saquinavir	456-465	
ritonavir	445-453	telithromycin	468-480	
ritonavir	445-453	voriconazole	485-496	
saquinavir	456-465	telithromycin	468-480	
saquinavir	456-465	voriconazole	485-496	
telithromycin	468-480	voriconazole	485-496	

Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole.
Zemplar	19-25	ketoconazole	209-220	

Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.
fat-soluble vitamins	43-62	cholestyramine	73-86	
fat-soluble vitamins	43-62	Zemplar	126-132	
cholestyramine	73-86	Zemplar	126-132	

patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.
lithium	19-25	Neulasta	31-38	

In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC;
methadone	86-94	PEG-Intron	112-121	
methadone	86-94	methadone	193-201	
PEG-Intron	112-121	methadone	193-201	

Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT.
insulin	63-69	hypoglycemic	83-94	
insulin	63-69	SOMAVERT	196-203	
hypoglycemic	83-94	SOMAVERT	196-203	

In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids.
opioids	33-39	pegvisomant	67-77	
opioids	33-39	opioids	172-178	
pegvisomant	67-77	opioids	172-178	

Concomitant administration of substances that are also tubularly secreted (e.g., probenecid) could potentially result in delayed clearance of ALIMTA.
probenecid	81-90	ALIMTA	142-147	

Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).
ibuprofen	9-17	ALIMTA	57-62	
ibuprofen	9-17	ibuprofen	182-190	
ibuprofen	9-17	ALIMTA	210-215	
ALIMTA	57-62	ibuprofen	182-190	
ALIMTA	57-62	ALIMTA	210-215	
ibuprofen	182-190	ALIMTA	210-215	

Patients with mild to moderate renal insufficiency should avoid taking NSAIDs with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of ALIMTA.
NSAIDs	71-76	ALIMTA	194-199	

In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration.
ALIMTA	63-68	NSAIDs	74-79	
ALIMTA	63-68	NSAIDs	131-136	
ALIMTA	63-68	ALIMTA	223-228	
NSAIDs	74-79	NSAIDs	131-136	
NSAIDs	74-79	ALIMTA	223-228	
NSAIDs	131-136	ALIMTA	223-228	

The interaction of CYLERT (pemoline) with other drugs has not been studied in humans.
CYLERT	19-24	pemoline	27-34	

Decreased seizure threshold has been reported in patients receiving CYLERT concomitantly with antiepileptic medications.
CYLERT	68-73	antiepileptic medications	94-118	

Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.
bacteriostatic antibiotics	29-54	erythromycin	63-74	
bacteriostatic antibiotics	29-54	tetracycline	77-88	
bacteriostatic antibiotics	29-54	penicillins	132-142	
erythromycin	63-74	tetracycline	77-88	
erythromycin	63-74	penicillins	132-142	
tetracycline	77-88	penicillins	132-142	

Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins.
Penicillin	0-9	probenecid	73-82	
Penicillin	0-9	penicillins	128-138	
probenecid	73-82	penicillins	128-138	

Displacement of penicillin from plasma protein binding sites will elevate the level of free penicillin in the serum.
penicillin	16-25	penicillin	92-101	

Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.
Alcohol	11-17	alcohol	80-86	
Alcohol	11-17	pentazocine	156-166	
alcohol	80-86	pentazocine	156-166	

Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors.
TRENTAL	152-158	anticoagulants	177-190	
TRENTAL	152-158	platelet aggregation inhibitors	195-225	
anticoagulants	177-190	platelet aggregation inhibitors	195-225	

Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals.
TRENTAL	30-36	theophylline	42-53	
TRENTAL	30-36	theophylline	91-102	
TRENTAL	30-36	theophylline	115-126	
theophylline	42-53	theophylline	91-102	
theophylline	42-53	theophylline	115-126	
theophylline	91-102	theophylline	115-126	

TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.
TRENTAL	0-6	antihypertensive drugs	40-61	
TRENTAL	0-6	beta blockers	64-76	
TRENTAL	0-6	digitalis	79-87	
TRENTAL	0-6	diuretics	90-98	
TRENTAL	0-6	antidiabetic agents	101-119	
TRENTAL	0-6	antiarrhythmics	126-140	
antihypertensive drugs	40-61	beta blockers	64-76	
antihypertensive drugs	40-61	digitalis	79-87	
antihypertensive drugs	40-61	diuretics	90-98	
antihypertensive drugs	40-61	antidiabetic agents	101-119	
antihypertensive drugs	40-61	antiarrhythmics	126-140	
beta blockers	64-76	digitalis	79-87	
beta blockers	64-76	diuretics	90-98	
beta blockers	64-76	antidiabetic agents	101-119	
beta blockers	64-76	antiarrhythmics	126-140	
digitalis	79-87	diuretics	90-98	
digitalis	79-87	antidiabetic agents	101-119	
digitalis	79-87	antiarrhythmics	126-140	
diuretics	90-98	antidiabetic agents	101-119	
diuretics	90-98	antiarrhythmics	126-140	
antidiabetic agents	101-119	antiarrhythmics	126-140	

Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
Dopamine antagonists	0-19	neuroleptics	34-45	
Dopamine antagonists	0-19	phenothiazines	48-61	
Dopamine antagonists	0-19	butyrophenones	64-77	
Dopamine antagonists	0-19	thioxanthines	80-92	
Dopamine antagonists	0-19	metoclopramide	99-112	
Dopamine antagonists	0-19	Permax	171-176	
Dopamine antagonists	0-19	dopamine agonist	181-196	
neuroleptics	34-45	phenothiazines	48-61	
neuroleptics	34-45	butyrophenones	64-77	
neuroleptics	34-45	thioxanthines	80-92	
neuroleptics	34-45	metoclopramide	99-112	
neuroleptics	34-45	Permax	171-176	
neuroleptics	34-45	dopamine agonist	181-196	
phenothiazines	48-61	butyrophenones	64-77	
phenothiazines	48-61	thioxanthines	80-92	
phenothiazines	48-61	metoclopramide	99-112	
phenothiazines	48-61	Permax	171-176	
phenothiazines	48-61	dopamine agonist	181-196	
butyrophenones	64-77	thioxanthines	80-92	
butyrophenones	64-77	metoclopramide	99-112	
butyrophenones	64-77	Permax	171-176	
butyrophenones	64-77	dopamine agonist	181-196	
thioxanthines	80-92	metoclopramide	99-112	
thioxanthines	80-92	Permax	171-176	
thioxanthines	80-92	dopamine agonist	181-196	
metoclopramide	99-112	Permax	171-176	
metoclopramide	99-112	dopamine agonist	181-196	
Permax	171-176	dopamine agonist	181-196	

Because pergolide mesylate is approximately 90% bound to plasma proteins, caution should be exercised if pergolide mesylate is coadministered with other drugs known to affect protein binding.
pergolide mesylate	8-25	pergolide mesylate	105-122	

Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy.
Diuretics	0-8	diuretics	23-31	
Diuretics	0-8	ACEON	162-166	
diuretics	23-31	ACEON	162-166	

The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril.
diuretic	84-91	perindopril	161-171	

If diuretics cannot be interrupted, close medical supervision should be provided with the first dose of ACEON    Tablets, for at least two hours and until blood pressure has stabilized for another hour.
diuretics	3-11	ACEON	104-108	

The rate and extent of perindopril absorption and elimination are not affected by concomitant diuretics.
perindopril	23-33	diuretics	94-102	

The bioavailability of perindoprilat was reduced by diuretics, however, and this was associated with a decrease in plasma ACE inhibition.
perindoprilat	23-35	diuretics	52-60	

Potassium Supplements and Potassium-Sparing Diuretics: ACEON    Tablets may increase serum potassium because of its potential to decrease aldosterone production.
Potassium	0-8	Potassium-Sparing Diuretics	26-52	
Potassium	0-8	ACEON	55-59	
Potassium-Sparing Diuretics	26-52	ACEON	55-59	

Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.
potassium-sparing diuretics	7-33	spironolactone	36-49	
potassium-sparing diuretics	7-33	amiloride	52-60	
potassium-sparing diuretics	7-33	triamterene	63-73	
potassium-sparing diuretics	7-33	potassium	88-96	
potassium-sparing diuretics	7-33	indomethacin	164-175	
potassium-sparing diuretics	7-33	heparin	178-184	
potassium-sparing diuretics	7-33	cyclosporine	187-198	
spironolactone	36-49	amiloride	52-60	
spironolactone	36-49	triamterene	63-73	
spironolactone	36-49	potassium	88-96	
spironolactone	36-49	indomethacin	164-175	
spironolactone	36-49	heparin	178-184	
spironolactone	36-49	cyclosporine	187-198	
amiloride	52-60	triamterene	63-73	
amiloride	52-60	potassium	88-96	
amiloride	52-60	indomethacin	164-175	
amiloride	52-60	heparin	178-184	
amiloride	52-60	cyclosporine	187-198	
triamterene	63-73	potassium	88-96	
triamterene	63-73	indomethacin	164-175	
triamterene	63-73	heparin	178-184	
triamterene	63-73	cyclosporine	187-198	
potassium	88-96	indomethacin	164-175	
potassium	88-96	heparin	178-184	
potassium	88-96	cyclosporine	187-198	
indomethacin	164-175	heparin	178-184	
indomethacin	164-175	cyclosporine	187-198	
heparin	178-184	cyclosporine	187-198	

Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.
Lithium	0-6	lithium	25-31	
Lithium	0-6	lithium	49-55	
Lithium	0-6	lithium	119-125	
lithium	25-31	lithium	49-55	
lithium	25-31	lithium	119-125	
lithium	49-55	lithium	119-125	

Use of a diuretic may further increase the risk of lithium toxicity.
diuretic	9-16	lithium	51-57	

Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.
Digoxin	0-6	digoxin	74-80	
Digoxin	0-6	ACEON	122-126	
Digoxin	0-6	digoxin	157-163	
Digoxin	0-6	perindopril	196-206	
Digoxin	0-6	perindoprilat	208-220	
digoxin	74-80	ACEON	122-126	
digoxin	74-80	digoxin	157-163	
digoxin	74-80	perindopril	196-206	
digoxin	74-80	perindoprilat	208-220	
ACEON	122-126	digoxin	157-163	
ACEON	122-126	perindopril	196-206	
ACEON	122-126	perindoprilat	208-220	
digoxin	157-163	perindopril	196-206	
digoxin	157-163	perindoprilat	208-220	
perindopril	196-206	perindoprilat	208-220	

Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin.
Gentamicin	0-9	perindopril	78-88	
Gentamicin	0-9	gentamicin	94-103	
perindopril	78-88	gentamicin	94-103	

Food Interaction: Oral administration of ACEON    Tablets with food does not significantly lower the rate or extent of perindopril absorption relative to the fasted state.
ACEON	41-45	perindopril	119-129	

However, the extent of biotransformation of perindopril to the active metabolite, perindoprilat, is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant.
perindopril	44-54	perindoprilat	82-94	

Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction.
alcohol	19-25	phentermine hydrochloride	32-56	

Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.
Vasopressors	0-11	metaraminol	27-37	
Vasopressors	0-11	halothane	85-93	
metaraminol	27-37	halothane	85-93	

MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).
MAO Inhibitors	0-13	sympathomimetic pressor amines	38-67	
MAO Inhibitors	0-13	monoamine oxidase inhibitors	115-142	
MAO Inhibitors	0-13	MAOI	145-148	
sympathomimetic pressor amines	38-67	monoamine oxidase inhibitors	115-142	
sympathomimetic pressor amines	38-67	MAOI	145-148	
monoamine oxidase inhibitors	115-142	MAOI	145-148	

The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.
adrenergic agents	24-40	tricyclic antidepressants	69-93	

Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.
Vasopressors	0-11	metaraminol	27-37	
Vasopressors	0-11	halothane	85-93	
metaraminol	27-37	halothane	85-93	

MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).
MAO Inhibitors	0-13	sympathomimetic pressor amines	39-68	
MAO Inhibitors	0-13	monoamine oxidase inhibitors	116-143	
MAO Inhibitors	0-13	MAOI	146-149	
sympathomimetic pressor amines	39-68	monoamine oxidase inhibitors	116-143	
sympathomimetic pressor amines	39-68	MAOI	146-149	
monoamine oxidase inhibitors	116-143	MAOI	146-149	

The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.
adrenergic agents	24-40	tricyclic antidepressants	69-93	

Pilocarpine should be administered with caution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances.
Pilocarpine	0-10	beta adrenergic antagonists	67-93	

These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium).
atropine	146-153	ipratropium	164-174	

While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
acetylsalicylic acid	179-198	calcium	219-225	
acetylsalicylic acid	179-198	conjugated estrogens	228-247	
acetylsalicylic acid	179-198	hydroxychloroquine sulfate	250-275	
acetylsalicylic acid	179-198	ibuprofen	278-286	
acetylsalicylic acid	179-198	levothyroxine sodium	289-308	
acetylsalicylic acid	179-198	medroxyprogesterone acetate	311-337	
acetylsalicylic acid	179-198	methotrexate	340-351	
acetylsalicylic acid	179-198	multivitamins	354-366	
acetylsalicylic acid	179-198	naproxen	369-376	
acetylsalicylic acid	179-198	omeprazole	379-388	
acetylsalicylic acid	179-198	paracetamol	391-401	
acetylsalicylic acid	179-198	prednisone	408-417	
calcium	219-225	conjugated estrogens	228-247	
calcium	219-225	hydroxychloroquine sulfate	250-275	
calcium	219-225	ibuprofen	278-286	
calcium	219-225	levothyroxine sodium	289-308	
calcium	219-225	medroxyprogesterone acetate	311-337	
calcium	219-225	methotrexate	340-351	
calcium	219-225	multivitamins	354-366	
calcium	219-225	naproxen	369-376	
calcium	219-225	omeprazole	379-388	
calcium	219-225	paracetamol	391-401	
calcium	219-225	prednisone	408-417	
conjugated estrogens	228-247	hydroxychloroquine sulfate	250-275	
conjugated estrogens	228-247	ibuprofen	278-286	
conjugated estrogens	228-247	levothyroxine sodium	289-308	
conjugated estrogens	228-247	medroxyprogesterone acetate	311-337	
conjugated estrogens	228-247	methotrexate	340-351	
conjugated estrogens	228-247	multivitamins	354-366	
conjugated estrogens	228-247	naproxen	369-376	
conjugated estrogens	228-247	omeprazole	379-388	
conjugated estrogens	228-247	paracetamol	391-401	
conjugated estrogens	228-247	prednisone	408-417	
hydroxychloroquine sulfate	250-275	ibuprofen	278-286	
hydroxychloroquine sulfate	250-275	levothyroxine sodium	289-308	
hydroxychloroquine sulfate	250-275	medroxyprogesterone acetate	311-337	
hydroxychloroquine sulfate	250-275	methotrexate	340-351	
hydroxychloroquine sulfate	250-275	multivitamins	354-366	
hydroxychloroquine sulfate	250-275	naproxen	369-376	
hydroxychloroquine sulfate	250-275	omeprazole	379-388	
hydroxychloroquine sulfate	250-275	paracetamol	391-401	
hydroxychloroquine sulfate	250-275	prednisone	408-417	
ibuprofen	278-286	levothyroxine sodium	289-308	
ibuprofen	278-286	medroxyprogesterone acetate	311-337	
ibuprofen	278-286	methotrexate	340-351	
ibuprofen	278-286	multivitamins	354-366	
ibuprofen	278-286	naproxen	369-376	
ibuprofen	278-286	omeprazole	379-388	
ibuprofen	278-286	paracetamol	391-401	
ibuprofen	278-286	prednisone	408-417	
levothyroxine sodium	289-308	medroxyprogesterone acetate	311-337	
levothyroxine sodium	289-308	methotrexate	340-351	
levothyroxine sodium	289-308	multivitamins	354-366	
levothyroxine sodium	289-308	naproxen	369-376	
levothyroxine sodium	289-308	omeprazole	379-388	
levothyroxine sodium	289-308	paracetamol	391-401	
levothyroxine sodium	289-308	prednisone	408-417	
medroxyprogesterone acetate	311-337	methotrexate	340-351	
medroxyprogesterone acetate	311-337	multivitamins	354-366	
medroxyprogesterone acetate	311-337	naproxen	369-376	
medroxyprogesterone acetate	311-337	omeprazole	379-388	
medroxyprogesterone acetate	311-337	paracetamol	391-401	
medroxyprogesterone acetate	311-337	prednisone	408-417	
methotrexate	340-351	multivitamins	354-366	
methotrexate	340-351	naproxen	369-376	
methotrexate	340-351	omeprazole	379-388	
methotrexate	340-351	paracetamol	391-401	
methotrexate	340-351	prednisone	408-417	
multivitamins	354-366	naproxen	369-376	
multivitamins	354-366	omeprazole	379-388	
multivitamins	354-366	paracetamol	391-401	
multivitamins	354-366	prednisone	408-417	
naproxen	369-376	omeprazole	379-388	
naproxen	369-376	paracetamol	391-401	
naproxen	369-376	prednisone	408-417	
omeprazole	379-388	paracetamol	391-401	
omeprazole	379-388	prednisone	408-417	
paracetamol	391-401	prednisone	408-417	

Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.
reserpine	37-45	beta-blocking agents	92-111	

Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions.
Pindolol	0-7	antihypertensive agents	41-63	
Pindolol	0-7	hydrochlorothiazide	76-94	
Pindolol	0-7	hydralazine	97-107	
Pindolol	0-7	guanethidine	114-125	
antihypertensive agents	41-63	hydrochlorothiazide	76-94	
antihypertensive agents	41-63	hydralazine	97-107	
antihypertensive agents	41-63	guanethidine	114-125	
hydrochlorothiazide	76-94	hydralazine	97-107	
hydrochlorothiazide	76-94	guanethidine	114-125	
hydralazine	97-107	guanethidine	114-125	

Pindolol has been shown to increase serum thioridazine levels when both drugs are co-administered.
Pindolol	0-7	thioridazine	42-53	

Other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects.
short-acting beta adrenergic aerosol bronchodilators	6-57	MAXAIR AUTOHALER	97-112	

Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs.
coumarin-type anticoagulants	56-83	coumarin-type anticoagulants	104-131	
coumarin-type anticoagulants	56-83	FELDENE	157-163	
coumarin-type anticoagulants	56-83	FELDENE	291-297	
coumarin-type anticoagulants	56-83	coumarin-type anticoagulants	314-341	
coumarin-type anticoagulants	104-131	FELDENE	157-163	
coumarin-type anticoagulants	104-131	FELDENE	291-297	
coumarin-type anticoagulants	104-131	coumarin-type anticoagulants	314-341	
FELDENE	157-163	FELDENE	291-297	
FELDENE	157-163	coumarin-type anticoagulants	314-341	
FELDENE	291-297	coumarin-type anticoagulants	314-341	

Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.
piroxicam	17-25	FELDENE	90-96	
piroxicam	17-25	aspirin	134-140	
piroxicam	17-25	antacids	191-198	
piroxicam	17-25	piroxicam	217-225	
piroxicam	17-25	Nonsteroidal anti-inflammatory agents	243-279	
piroxicam	17-25	FELDENE	292-298	
piroxicam	17-25	lithium	352-358	
FELDENE	90-96	aspirin	134-140	
FELDENE	90-96	antacids	191-198	
FELDENE	90-96	piroxicam	217-225	
FELDENE	90-96	Nonsteroidal anti-inflammatory agents	243-279	
FELDENE	90-96	FELDENE	292-298	
FELDENE	90-96	lithium	352-358	
aspirin	134-140	antacids	191-198	
aspirin	134-140	piroxicam	217-225	
aspirin	134-140	Nonsteroidal anti-inflammatory agents	243-279	
aspirin	134-140	FELDENE	292-298	
aspirin	134-140	lithium	352-358	
antacids	191-198	piroxicam	217-225	
antacids	191-198	Nonsteroidal anti-inflammatory agents	243-279	
antacids	191-198	FELDENE	292-298	
antacids	191-198	lithium	352-358	
piroxicam	217-225	Nonsteroidal anti-inflammatory agents	243-279	
piroxicam	217-225	FELDENE	292-298	
piroxicam	217-225	lithium	352-358	
Nonsteroidal anti-inflammatory agents	243-279	FELDENE	292-298	
Nonsteroidal anti-inflammatory agents	243-279	lithium	352-358	
FELDENE	292-298	lithium	352-358	

It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.
lithium	30-36	FELDENE	103-109	

When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone.
atropine	5-12	pralidoxime	18-28	
atropine	5-12	atropine	189-196	
pralidoxime	18-28	atropine	189-196	

This is especially true if the total dose of atropine has been large and the administration of pralidoxime has been delayed.
atropine	45-52	pralidoxime	95-105	

2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions;
pralidoxime	154-164	barbiturates	173-184	
pralidoxime	154-164	anticholinesterases	209-227	
barbiturates	173-184	anticholinesterases	209-227	

morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.
morphine	0-7	theophylline	10-21	
morphine	0-7	aminophylline	24-36	
morphine	0-7	succinylcholine	39-53	
morphine	0-7	reserpine	56-64	
morphine	0-7	phenothiazine-type tranquilizers	71-102	
theophylline	10-21	aminophylline	24-36	
theophylline	10-21	succinylcholine	39-53	
theophylline	10-21	reserpine	56-64	
theophylline	10-21	phenothiazine-type tranquilizers	71-102	
aminophylline	24-36	succinylcholine	39-53	
aminophylline	24-36	reserpine	56-64	
aminophylline	24-36	phenothiazine-type tranquilizers	71-102	
succinylcholine	39-53	reserpine	56-64	
succinylcholine	39-53	phenothiazine-type tranquilizers	71-102	
reserpine	56-64	phenothiazine-type tranquilizers	71-102	

Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).
Carbidopa	0-8	Levodopa	10-17	
Carbidopa	0-8	Carbidopa	20-28	
Carbidopa	0-8	Levodopa	30-37	
Carbidopa	0-8	pramipexole	82-92	
Levodopa	10-17	Carbidopa	20-28	
Levodopa	10-17	Levodopa	30-37	
Levodopa	10-17	pramipexole	82-92	
Carbidopa	20-28	Levodopa	30-37	
Carbidopa	20-28	pramipexole	82-92	
Levodopa	30-37	pramipexole	82-92	

Selegiline: In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of pramipexole.
Selegiline	0-9	selegiline	43-52	
Selegiline	0-9	pramipexole	96-106	
selegiline	43-52	pramipexole	96-106	

Amantadine: Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole (N= 54).
Amantadine	0-9	amantadine	62-71	
Amantadine	0-9	pramipexole	116-126	
amantadine	62-71	pramipexole	116-126	

Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12).
Cimetidine	0-9	Cimetidine	12-21	
Cimetidine	0-9	pramipexole	146-156	
Cimetidine	12-21	pramipexole	146-156	

Probenecid: Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12).
Probenecid	0-9	Probenecid	12-21	
Probenecid	0-9	pramipexole	144-154	
Probenecid	12-21	pramipexole	144-154	

Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
cimetidine	178-187	ranitidine	190-199	
cimetidine	178-187	diltiazem	202-210	
cimetidine	178-187	triamterene	213-223	
cimetidine	178-187	verapamil	226-234	
cimetidine	178-187	quinidine	237-245	
cimetidine	178-187	quinine	252-258	
cimetidine	178-187	pramipexole	293-303	
cimetidine	178-187	cephalosporins	379-392	
cimetidine	178-187	penicillins	395-405	
cimetidine	178-187	indomethacin	408-419	
cimetidine	178-187	hydrochlorothiazide	422-440	
cimetidine	178-187	chlorpropamide	447-460	
cimetidine	178-187	pramipexole	521-531	
ranitidine	190-199	diltiazem	202-210	
ranitidine	190-199	triamterene	213-223	
ranitidine	190-199	verapamil	226-234	
ranitidine	190-199	quinidine	237-245	
ranitidine	190-199	quinine	252-258	
ranitidine	190-199	pramipexole	293-303	
ranitidine	190-199	cephalosporins	379-392	
ranitidine	190-199	penicillins	395-405	
ranitidine	190-199	indomethacin	408-419	
ranitidine	190-199	hydrochlorothiazide	422-440	
ranitidine	190-199	chlorpropamide	447-460	
ranitidine	190-199	pramipexole	521-531	
diltiazem	202-210	triamterene	213-223	
diltiazem	202-210	verapamil	226-234	
diltiazem	202-210	quinidine	237-245	
diltiazem	202-210	quinine	252-258	
diltiazem	202-210	pramipexole	293-303	
diltiazem	202-210	cephalosporins	379-392	
diltiazem	202-210	penicillins	395-405	
diltiazem	202-210	indomethacin	408-419	
diltiazem	202-210	hydrochlorothiazide	422-440	
diltiazem	202-210	chlorpropamide	447-460	
diltiazem	202-210	pramipexole	521-531	
triamterene	213-223	verapamil	226-234	
triamterene	213-223	quinidine	237-245	
triamterene	213-223	quinine	252-258	
triamterene	213-223	pramipexole	293-303	
triamterene	213-223	cephalosporins	379-392	
triamterene	213-223	penicillins	395-405	
triamterene	213-223	indomethacin	408-419	
triamterene	213-223	hydrochlorothiazide	422-440	
triamterene	213-223	chlorpropamide	447-460	
triamterene	213-223	pramipexole	521-531	
verapamil	226-234	quinidine	237-245	
verapamil	226-234	quinine	252-258	
verapamil	226-234	pramipexole	293-303	
verapamil	226-234	cephalosporins	379-392	
verapamil	226-234	penicillins	395-405	
verapamil	226-234	indomethacin	408-419	
verapamil	226-234	hydrochlorothiazide	422-440	
verapamil	226-234	chlorpropamide	447-460	
verapamil	226-234	pramipexole	521-531	
quinidine	237-245	quinine	252-258	
quinidine	237-245	pramipexole	293-303	
quinidine	237-245	cephalosporins	379-392	
quinidine	237-245	penicillins	395-405	
quinidine	237-245	indomethacin	408-419	
quinidine	237-245	hydrochlorothiazide	422-440	
quinidine	237-245	chlorpropamide	447-460	
quinidine	237-245	pramipexole	521-531	
quinine	252-258	pramipexole	293-303	
quinine	252-258	cephalosporins	379-392	
quinine	252-258	penicillins	395-405	
quinine	252-258	indomethacin	408-419	
quinine	252-258	hydrochlorothiazide	422-440	
quinine	252-258	chlorpropamide	447-460	
quinine	252-258	pramipexole	521-531	
pramipexole	293-303	cephalosporins	379-392	
pramipexole	293-303	penicillins	395-405	
pramipexole	293-303	indomethacin	408-419	
pramipexole	293-303	hydrochlorothiazide	422-440	
pramipexole	293-303	chlorpropamide	447-460	
pramipexole	293-303	pramipexole	521-531	
cephalosporins	379-392	penicillins	395-405	
cephalosporins	379-392	indomethacin	408-419	
cephalosporins	379-392	hydrochlorothiazide	422-440	
cephalosporins	379-392	chlorpropamide	447-460	
cephalosporins	379-392	pramipexole	521-531	
penicillins	395-405	indomethacin	408-419	
penicillins	395-405	hydrochlorothiazide	422-440	
penicillins	395-405	chlorpropamide	447-460	
penicillins	395-405	pramipexole	521-531	
indomethacin	408-419	hydrochlorothiazide	422-440	
indomethacin	408-419	chlorpropamide	447-460	
indomethacin	408-419	pramipexole	521-531	
hydrochlorothiazide	422-440	chlorpropamide	447-460	
hydrochlorothiazide	422-440	pramipexole	521-531	
chlorpropamide	447-460	pramipexole	521-531	

CYP interactions: Inhibitors of cytochrome P450 enzymes would not be expected to affect pramipexole elimination because pramipexole is not appreciably metabolized by these enzymes in vivo or in vitro.
pramipexole	88-98	pramipexole	120-130	

Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
Dopamine antagonists	0-19	pramipexole	28-38	
Dopamine antagonists	0-19	dopamine agonist	45-60	
Dopamine antagonists	0-19	dopamine antagonists	83-102	
Dopamine antagonists	0-19	neuroleptics	117-128	
Dopamine antagonists	0-19	phenothiazines	131-144	
Dopamine antagonists	0-19	butyrophenones	147-160	
Dopamine antagonists	0-19	thioxanthenes	163-175	
Dopamine antagonists	0-19	metoclopramide	181-194	
Dopamine antagonists	0-19	MIRAPEX	231-237	
pramipexole	28-38	dopamine agonist	45-60	
pramipexole	28-38	dopamine antagonists	83-102	
pramipexole	28-38	neuroleptics	117-128	
pramipexole	28-38	phenothiazines	131-144	
pramipexole	28-38	butyrophenones	147-160	
pramipexole	28-38	thioxanthenes	163-175	
pramipexole	28-38	metoclopramide	181-194	
pramipexole	28-38	MIRAPEX	231-237	
dopamine agonist	45-60	dopamine antagonists	83-102	
dopamine agonist	45-60	neuroleptics	117-128	
dopamine agonist	45-60	phenothiazines	131-144	
dopamine agonist	45-60	butyrophenones	147-160	
dopamine agonist	45-60	thioxanthenes	163-175	
dopamine agonist	45-60	metoclopramide	181-194	
dopamine agonist	45-60	MIRAPEX	231-237	
dopamine antagonists	83-102	neuroleptics	117-128	
dopamine antagonists	83-102	phenothiazines	131-144	
dopamine antagonists	83-102	butyrophenones	147-160	
dopamine antagonists	83-102	thioxanthenes	163-175	
dopamine antagonists	83-102	metoclopramide	181-194	
dopamine antagonists	83-102	MIRAPEX	231-237	
neuroleptics	117-128	phenothiazines	131-144	
neuroleptics	117-128	butyrophenones	147-160	
neuroleptics	117-128	thioxanthenes	163-175	
neuroleptics	117-128	metoclopramide	181-194	
neuroleptics	117-128	MIRAPEX	231-237	
phenothiazines	131-144	butyrophenones	147-160	
phenothiazines	131-144	thioxanthenes	163-175	
phenothiazines	131-144	metoclopramide	181-194	
phenothiazines	131-144	MIRAPEX	231-237	
butyrophenones	147-160	thioxanthenes	163-175	
butyrophenones	147-160	metoclopramide	181-194	
butyrophenones	147-160	MIRAPEX	231-237	
thioxanthenes	163-175	metoclopramide	181-194	
thioxanthenes	163-175	MIRAPEX	231-237	
metoclopramide	181-194	MIRAPEX	231-237	

Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).
SYMLIN	40-45	anticholinergic agents	150-171	
SYMLIN	40-45	atropine	181-188	
SYMLIN	40-45	alpha glucosidase inhibitors	258-285	
anticholinergic agents	150-171	atropine	181-188	
anticholinergic agents	150-171	alpha glucosidase inhibitors	258-285	
atropine	181-188	alpha glucosidase inhibitors	258-285	

When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as analgesics), the agent should be administered at least 1 hour prior to or 2 hours after SYMLIN injection.
analgesics	116-125	SYMLIN	204-209	

In clinical trials, the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of SYMLIN.
sulfonylureas	43-55	biguanides	60-69	
sulfonylureas	43-55	SYMLIN	114-119	
biguanides	60-69	SYMLIN	114-119	

No formal interaction studies have been performed to assess the effect of SYMLIN on the kinetics of oral antidiabetic agents.
SYMLIN	74-79	antidiabetic agents	105-123	

Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.
SYMLIN	7-12	Insulin	18-24	
SYMLIN	7-12	SYMLIN	60-65	
SYMLIN	7-12	human insulin	157-169	
Insulin	18-24	SYMLIN	60-65	
Insulin	18-24	human insulin	157-169	
SYMLIN	60-65	human insulin	157-169	

Thus, SYMLIN and insulin should not be mixed and must be administered separately.
SYMLIN	6-11	insulin	17-23	

Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
phenobarbital	42-54	phenytoin	57-65	
phenobarbital	42-54	rifampin	71-78	
phenobarbital	42-54	corticosteroids	110-124	
phenobarbital	42-54	corticosteroid	155-168	
phenytoin	57-65	rifampin	71-78	
phenytoin	57-65	corticosteroids	110-124	
phenytoin	57-65	corticosteroid	155-168	
rifampin	71-78	corticosteroids	110-124	
rifampin	71-78	corticosteroid	155-168	
corticosteroids	110-124	corticosteroid	155-168	

Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.
troleandomycin	14-27	ketoconazole	33-44	
troleandomycin	14-27	corticosteroids	76-90	
ketoconazole	33-44	corticosteroids	76-90	

Corticosteroids may increase the clearance of chronic high dose aspirin.
Corticosteroids	0-14	aspirin	64-70	

This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.
salicylate	29-38	salicylate	77-86	
salicylate	29-38	corticosteroid	102-115	
salicylate	77-86	corticosteroid	102-115	

Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.
Aspirin	0-6	corticosteroids	54-68	

The effect of corticosteroids on oral anticoagulants is variable.
corticosteroids	14-28	anticoagulants	38-51	

There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.
anticoagulants	63-76	corticosteroids	107-121	

Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.
Anticholinesterases	0-18	procaine hydrochloride	39-60	
Anticholinesterases	0-18	anticholinesterase agents	66-90	
Anticholinesterases	0-18	anticholinesterases	140-158	
Anticholinesterases	0-18	procaine hydrochloride	185-206	
procaine hydrochloride	39-60	anticholinesterase agents	66-90	
procaine hydrochloride	39-60	anticholinesterases	140-158	
procaine hydrochloride	39-60	procaine hydrochloride	185-206	
anticholinesterase agents	66-90	anticholinesterases	140-158	
anticholinesterase agents	66-90	procaine hydrochloride	185-206	
anticholinesterases	140-158	procaine hydrochloride	185-206	

CNS depressant medications: Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects.
CNS depressant	0-13	procaine hydrochloride	46-67	
CNS depressant	0-13	CNS depressant medications	73-98	
procaine hydrochloride	46-67	CNS depressant medications	73-98	

Hyaluronidase: Hyaluronidase may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity.
Hyaluronidase	0-12	Hyaluronidase	15-27	
Hyaluronidase	0-12	procaine hydrochloride	64-85	
Hyaluronidase	15-27	procaine hydrochloride	64-85	

Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.
Neuromuscular blocking agents	0-28	suxamethonium chloride	39-60	
Neuromuscular blocking agents	0-28	procaine hydrochloride	82-103	
Neuromuscular blocking agents	0-28	neuromuscular blocking agents	109-137	
suxamethonium chloride	39-60	procaine hydrochloride	82-103	
suxamethonium chloride	39-60	neuromuscular blocking agents	109-137	
procaine hydrochloride	82-103	neuromuscular blocking agents	109-137	

Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide.
Sulfonamides	0-11	procaine hydrochloride	32-53	
Sulfonamides	0-11	sulfonamides	59-70	
Sulfonamides	0-11	sulfonamide	133-143	
procaine hydrochloride	32-53	sulfonamides	59-70	
procaine hydrochloride	32-53	sulfonamide	133-143	
sulfonamides	59-70	sulfonamide	133-143	

Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.
Acetazolamide	0-12	acetazolamide	33-45	
Acetazolamide	0-12	procaine hydrochloride	51-72	
Acetazolamide	0-12	procaine	109-116	
acetazolamide	33-45	procaine hydrochloride	51-72	
acetazolamide	33-45	procaine	109-116	
procaine hydrochloride	51-72	procaine	109-116	

To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution.
barbiturates	54-65	antihistamines	68-81	
barbiturates	54-65	narcotics	84-92	
barbiturates	54-65	hypotensive agents	95-112	
barbiturates	54-65	phenothiazines	117-130	
antihistamines	68-81	narcotics	84-92	
antihistamines	68-81	hypotensive agents	95-112	
antihistamines	68-81	phenothiazines	117-130	
narcotics	84-92	hypotensive agents	95-112	
narcotics	84-92	phenothiazines	117-130	
hypotensive agents	95-112	phenothiazines	117-130	

Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
Matulane	8-15	sympathomimetic drugs	70-90	
Matulane	8-15	tricyclic antidepressant	93-116	
Matulane	8-15	amitriptyline HCl	131-147	
Matulane	8-15	imipramine HCl	150-163	
Matulane	8-15	tyramine	208-215	
sympathomimetic drugs	70-90	tricyclic antidepressant	93-116	
sympathomimetic drugs	70-90	amitriptyline HCl	131-147	
sympathomimetic drugs	70-90	imipramine HCl	150-163	
sympathomimetic drugs	70-90	tyramine	208-215	
tricyclic antidepressant	93-116	amitriptyline HCl	131-147	
tricyclic antidepressant	93-116	imipramine HCl	150-163	
tricyclic antidepressant	93-116	tyramine	208-215	
amitriptyline HCl	131-147	imipramine HCl	150-163	
amitriptyline HCl	131-147	tyramine	208-215	
imipramine HCl	150-163	tyramine	208-215	

No cross-resistance with other chemotherapeutic agents, radiotherapy or steroids has been demonstrated.
chemotherapeutic agents	31-53	steroids	72-79	

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines.
Thiazide diuretics	0-17	phenothiazines	82-95	

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly.
guanethidine	28-39	phenothiazines	88-101	

Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.
propranolol	30-40	phenothiazines	47-60	

The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.)
DIPRIVAN	35-42	narcotics	158-166	
DIPRIVAN	35-42	morphine	173-180	
DIPRIVAN	35-42	meperidine	183-192	
DIPRIVAN	35-42	fentanyl	199-206	
narcotics	158-166	morphine	173-180	
narcotics	158-166	meperidine	183-192	
narcotics	158-166	fentanyl	199-206	
morphine	173-180	meperidine	183-192	
morphine	173-180	fentanyl	199-206	
meperidine	183-192	fentanyl	199-206	

and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).
opioids	20-26	sedatives	32-40	
opioids	20-26	benzodiazepines	47-61	
opioids	20-26	barbiturates	64-75	
opioids	20-26	chloral hydrate	78-92	
opioids	20-26	droperidol	95-104	
sedatives	32-40	benzodiazepines	47-61	
sedatives	32-40	barbiturates	64-75	
sedatives	32-40	chloral hydrate	78-92	
sedatives	32-40	droperidol	95-104	
benzodiazepines	47-61	barbiturates	64-75	
benzodiazepines	47-61	chloral hydrate	78-92	
benzodiazepines	47-61	droperidol	95-104	
barbiturates	64-75	chloral hydrate	78-92	
barbiturates	64-75	droperidol	95-104	
chloral hydrate	78-92	droperidol	95-104	

During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids).
DIPRIVAN	58-65	analgesic agents	229-244	
DIPRIVAN	58-65	nitrous oxide	251-263	
DIPRIVAN	58-65	opioids	268-274	
analgesic agents	229-244	nitrous oxide	251-263	
analgesic agents	229-244	opioids	268-274	
nitrous oxide	251-263	opioids	268-274	

The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated.
isoflurane	65-74	enflurane	77-85	
isoflurane	65-74	halothane	92-100	
isoflurane	65-74	DIPRIVAN	127-134	
enflurane	77-85	halothane	92-100	
enflurane	77-85	DIPRIVAN	127-134	
halothane	92-100	DIPRIVAN	127-134	

DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants).
DIPRIVAN	0-7	neuromuscular blocking agents	140-168	
DIPRIVAN	0-7	succinylcholine	175-189	
DIPRIVAN	0-7	nondepolarizing muscle relaxants	195-226	
neuromuscular blocking agents	140-168	succinylcholine	175-189	
neuromuscular blocking agents	140-168	nondepolarizing muscle relaxants	195-226	
succinylcholine	175-189	nondepolarizing muscle relaxants	195-226	

No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed.
muscle relaxants	136-151	analgesic agents	175-190	
muscle relaxants	136-151	anesthetic agents	203-219	
analgesic agents	175-190	anesthetic agents	203-219	

The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol.
propoxyphene	29-40	CNS depressants	73-87	
propoxyphene	29-40	alcohol	100-106	
CNS depressants	73-87	alcohol	100-106	

Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs.
propoxyphene	41-52	antidepressants	86-100	
propoxyphene	41-52	anticonvulsants	103-117	
propoxyphene	41-52	warfarin	123-130	
antidepressants	86-100	anticonvulsants	103-117	
antidepressants	86-100	warfarin	123-130	
anticonvulsants	103-117	warfarin	123-130	

MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine.
MAO inhibitors	0-13	beta adrenergic blockers	19-42	
MAO inhibitors	0-13	pseudoephedrine	68-82	
beta adrenergic blockers	19-42	pseudoephedrine	68-82	

Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.
Sympathomimetics	0-15	methyldopa	60-69	
Sympathomimetics	0-15	mecamylamine	72-83	
Sympathomimetics	0-15	reserpine	86-94	
Sympathomimetics	0-15	veratrum alkaloids	100-117	
methyldopa	60-69	mecamylamine	72-83	
methyldopa	60-69	reserpine	86-94	
methyldopa	60-69	veratrum alkaloids	100-117	
mecamylamine	72-83	reserpine	86-94	
mecamylamine	72-83	veratrum alkaloids	100-117	
reserpine	86-94	veratrum alkaloids	100-117	

Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics.
Pyrimethamine	0-12	sulfonamides	31-42	
Pyrimethamine	0-12	quinine	45-51	
Pyrimethamine	0-12	antimalarials	63-75	
Pyrimethamine	0-12	antibiotics	93-103	
sulfonamides	31-42	quinine	45-51	
sulfonamides	31-42	antimalarials	63-75	
sulfonamides	31-42	antibiotics	93-103	
quinine	45-51	antimalarials	63-75	
quinine	45-51	antibiotics	93-103	
antimalarials	63-75	antibiotics	93-103	

Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored.
Folinic acid	0-11	leucovorin	14-23	

Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.
lorazepam	60-68	pyrimethamine	74-86	

Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA.
Cholestyramine	0-13	Cholestyramine	16-29	
Cholestyramine	0-13	raloxifene	101-110	
Cholestyramine	0-13	EVISTA	150-155	
Cholestyramine	16-29	raloxifene	101-110	
Cholestyramine	16-29	EVISTA	150-155	
raloxifene	101-110	EVISTA	150-155	

Warfarin: The coadministration of EVISTA and warfarin has not been assessed under chronic conditions.
Warfarin	0-7	EVISTA	34-39	
Warfarin	0-7	warfarin	45-52	
EVISTA	34-39	warfarin	45-52	

If EVISTA is given concurrently with warfarin, prothrombin time should be monitored.
EVISTA	3-8	warfarin	37-44	

In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen.
raloxifene	10-19	warfarin	51-58	
raloxifene	10-19	phenytoin	61-69	
raloxifene	10-19	tamoxifen	75-83	
warfarin	51-58	phenytoin	61-69	
warfarin	51-58	tamoxifen	75-83	
phenytoin	61-69	tamoxifen	75-83	

Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.
EVISTA	28-33	clofibrate	100-109	
EVISTA	28-33	indomethacin	112-123	
EVISTA	28-33	naproxen	126-133	
EVISTA	28-33	ibuprofen	136-144	
EVISTA	28-33	diazepam	147-154	
EVISTA	28-33	diazoxide	161-169	
clofibrate	100-109	indomethacin	112-123	
clofibrate	100-109	naproxen	126-133	
clofibrate	100-109	ibuprofen	136-144	
clofibrate	100-109	diazepam	147-154	
clofibrate	100-109	diazoxide	161-169	
indomethacin	112-123	naproxen	126-133	
indomethacin	112-123	ibuprofen	136-144	
indomethacin	112-123	diazepam	147-154	
indomethacin	112-123	diazoxide	161-169	
naproxen	126-133	ibuprofen	136-144	
naproxen	126-133	diazepam	147-154	
naproxen	126-133	diazoxide	161-169	
ibuprofen	136-144	diazepam	147-154	
ibuprofen	136-144	diazoxide	161-169	
diazepam	147-154	diazoxide	161-169	

Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).
TRITEC	20-25	clarithromycin	32-45	
TRITEC	20-25	ranitidine	76-85	
TRITEC	20-25	14- hydroxy- clarithromycin	177-203	
clarithromycin	32-45	ranitidine	76-85	
clarithromycin	32-45	14- hydroxy- clarithromycin	177-203	
ranitidine	76-85	14- hydroxy- clarithromycin	177-203	

Coadministration with aspirin results in a slight decrease in the rate of salicylate absorption that is clinically unimportant.
aspirin	22-28	salicylate	74-83	

Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC.
antacid	37-43	ranitidine	109-118	
antacid	37-43	TRITEC	175-180	
ranitidine	109-118	TRITEC	175-180	

For information on drug interactions associated with ranitidine, refer to the ZANTAC     package insert.
ranitidine	53-62	ZANTAC	78-83	

Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males.
ketoconazole	26-37	retapamulin	68-78	
ketoconazole	26-37	retapamulin	150-160	
retapamulin	68-78	retapamulin	150-160	

Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as ketoconazole.
retapamulin	32-42	retapamulin	110-120	
retapamulin	32-42	ketoconazole	191-202	
retapamulin	110-120	ketoconazole	191-202	

Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of ALTABAX, retapamulin is unlikely to affect the metabolism of other P450 substrates.
ALTABAX	114-120	retapamulin	123-133	

In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
heparin	40-46	vitamin K antagonists	52-72	
heparin	40-46	aspirin	119-125	
heparin	40-46	dipyridamole	128-139	
heparin	40-46	abciximab	146-154	
heparin	40-46	Retavase	225-232	
vitamin K antagonists	52-72	aspirin	119-125	
vitamin K antagonists	52-72	dipyridamole	128-139	
vitamin K antagonists	52-72	abciximab	146-154	
vitamin K antagonists	52-72	Retavase	225-232	
aspirin	119-125	dipyridamole	128-139	
aspirin	119-125	abciximab	146-154	
aspirin	119-125	Retavase	225-232	
dipyridamole	128-139	abciximab	146-154	
dipyridamole	128-139	Retavase	225-232	
abciximab	146-154	Retavase	225-232	

Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin
Vitamin B2	17-26	Riboflavin	29-38	
Vitamin B2	17-26	Alcohol	43-49	
Vitamin B2	17-26	riboflavin	90-99	
Riboflavin	29-38	Alcohol	43-49	
Riboflavin	29-38	riboflavin	90-99	
Alcohol	43-49	riboflavin	90-99	

Probenecid - concurrent use decreases gastrointestinal absorption of riboflavin;
Probenecid	0-9	riboflavin	69-78	

requirements for riboflavin may be increased in patients receiving probenecid.
riboflavin	17-26	probenecid	67-76	

Cimetidine: The effects of chronic cimetidine use on the metabolism of rimantadine are not known.
Cimetidine	0-9	cimetidine	35-44	
Cimetidine	0-9	rimantadine	71-81	
cimetidine	35-44	rimantadine	71-81	

When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).
rimantadine HCl	29-43	Cimetidine	95-104	
rimantadine HCl	29-43	rimantadine	152-162	
rimantadine HCl	29-43	rimantadine	270-280	
rimantadine HCl	29-43	cimetidine	331-340	
Cimetidine	95-104	rimantadine	152-162	
Cimetidine	95-104	rimantadine	270-280	
Cimetidine	95-104	cimetidine	331-340	
rimantadine	152-162	rimantadine	270-280	
rimantadine	152-162	cimetidine	331-340	
rimantadine	270-280	cimetidine	331-340	

Acetaminophen: Rimantadine HCl, 100 mg, was given twice daily for 13 days to 12 healthy volunteers.
Acetaminophen	0-12	Rimantadine HCl	15-29	

Coadministration with acetaminophen reduced the peak concentration and AUC values for rimantadine by approximately 11%.
acetaminophen	22-34	rimantadine	86-96	

Aspirin: Rimantadine HCl, 100 mg, was given twice daily fro 13 days to 12 healthy volunteers.
Aspirin	0-6	Rimantadine HCl	9-23	

Peak plasma concentrations and AUC of rimantadine were reduced approximately 10% in the presence of aspirin.
rimantadine	38-48	aspirin	100-106	

Drug-Drug Interactions Effect of Exelon    (rivastigmine tartrate) on the Metabolism of Other Drugs: Rivastigmine is primarily metabolized through hydrolysis by esterases.
Exelon	33-38	rivastigmine tartrate	44-64	
Exelon	33-38	Rivastigmine	101-112	
rivastigmine tartrate	44-64	Rivastigmine	101-112	

No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers.
rivastigmine	52-63	digoxin	69-75	
rivastigmine	52-63	warfarin	78-85	
rivastigmine	52-63	diazepam	88-95	
rivastigmine	52-63	fluoxetine	101-110	
digoxin	69-75	warfarin	78-85	
digoxin	69-75	diazepam	88-95	
digoxin	69-75	fluoxetine	101-110	
warfarin	78-85	diazepam	88-95	
warfarin	78-85	fluoxetine	101-110	
diazepam	88-95	fluoxetine	101-110	

The elevation of prothrombin time induced by warfarin is not affected by administration of Exelon.
warfarin	45-52	Exelon	91-96	

Effect of Other Drugs on the Metabolism of Exelon: Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of rivastigmine.
Exelon	43-48	rivastigmine	142-153	

Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine.
rivastigmine	72-83	digoxin	147-153	
rivastigmine	72-83	warfarin	156-163	
rivastigmine	72-83	diazepam	166-173	
rivastigmine	72-83	fluoxetine	179-188	
digoxin	147-153	warfarin	156-163	
digoxin	147-153	diazepam	166-173	
digoxin	147-153	fluoxetine	179-188	
warfarin	156-163	diazepam	166-173	
warfarin	156-163	fluoxetine	179-188	
diazepam	166-173	fluoxetine	179-188	

Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
rivastigmine	91-102	antacids	167-174	
rivastigmine	91-102	antihypertensives	184-200	
rivastigmine	91-102	calcium channel blockers	210-233	
rivastigmine	91-102	antidiabetics	243-255	
rivastigmine	91-102	nonsteroidal anti-inflammatory drugs	265-300	
rivastigmine	91-102	estrogens	310-318	
rivastigmine	91-102	salicylate analgesics	328-348	
rivastigmine	91-102	antianginals	359-370	
rivastigmine	91-102	antihistamines	384-397	
antacids	167-174	antihypertensives	184-200	
antacids	167-174	calcium channel blockers	210-233	
antacids	167-174	antidiabetics	243-255	
antacids	167-174	nonsteroidal anti-inflammatory drugs	265-300	
antacids	167-174	estrogens	310-318	
antacids	167-174	salicylate analgesics	328-348	
antacids	167-174	antianginals	359-370	
antacids	167-174	antihistamines	384-397	
antihypertensives	184-200	calcium channel blockers	210-233	
antihypertensives	184-200	antidiabetics	243-255	
antihypertensives	184-200	nonsteroidal anti-inflammatory drugs	265-300	
antihypertensives	184-200	estrogens	310-318	
antihypertensives	184-200	salicylate analgesics	328-348	
antihypertensives	184-200	antianginals	359-370	
antihypertensives	184-200	antihistamines	384-397	
calcium channel blockers	210-233	antidiabetics	243-255	
calcium channel blockers	210-233	nonsteroidal anti-inflammatory drugs	265-300	
calcium channel blockers	210-233	estrogens	310-318	
calcium channel blockers	210-233	salicylate analgesics	328-348	
calcium channel blockers	210-233	antianginals	359-370	
calcium channel blockers	210-233	antihistamines	384-397	
antidiabetics	243-255	nonsteroidal anti-inflammatory drugs	265-300	
antidiabetics	243-255	estrogens	310-318	
antidiabetics	243-255	salicylate analgesics	328-348	
antidiabetics	243-255	antianginals	359-370	
antidiabetics	243-255	antihistamines	384-397	
nonsteroidal anti-inflammatory drugs	265-300	estrogens	310-318	
nonsteroidal anti-inflammatory drugs	265-300	salicylate analgesics	328-348	
nonsteroidal anti-inflammatory drugs	265-300	antianginals	359-370	
nonsteroidal anti-inflammatory drugs	265-300	antihistamines	384-397	
estrogens	310-318	salicylate analgesics	328-348	
estrogens	310-318	antianginals	359-370	
estrogens	310-318	antihistamines	384-397	
salicylate analgesics	328-348	antianginals	359-370	
salicylate analgesics	328-348	antihistamines	384-397	
antianginals	359-370	antihistamines	384-397	

Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications.
Anticholinergics	9-24	cholinesterase inhibitors	65-89	
Anticholinergics	9-24	anticholinergic medications	144-170	
cholinesterase inhibitors	65-89	anticholinergic medications	144-170	

Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
Cholinomimetics	9-23	Cholinesterase Inhibitors	35-59	
Cholinomimetics	9-23	cholinesterase inhibitors	104-128	
Cholinomimetics	9-23	succinylcholine	158-172	
Cholinomimetics	9-23	neuromuscular blocking agents	183-211	
Cholinomimetics	9-23	cholinergic agonists	216-235	
Cholinomimetics	9-23	bethanechol	245-255	
Cholinesterase Inhibitors	35-59	cholinesterase inhibitors	104-128	
Cholinesterase Inhibitors	35-59	succinylcholine	158-172	
Cholinesterase Inhibitors	35-59	neuromuscular blocking agents	183-211	
Cholinesterase Inhibitors	35-59	cholinergic agonists	216-235	
Cholinesterase Inhibitors	35-59	bethanechol	245-255	
cholinesterase inhibitors	104-128	succinylcholine	158-172	
cholinesterase inhibitors	104-128	neuromuscular blocking agents	183-211	
cholinesterase inhibitors	104-128	cholinergic agonists	216-235	
cholinesterase inhibitors	104-128	bethanechol	245-255	
succinylcholine	158-172	neuromuscular blocking agents	183-211	
succinylcholine	158-172	cholinergic agonists	216-235	
succinylcholine	158-172	bethanechol	245-255	
neuromuscular blocking agents	183-211	cholinergic agonists	216-235	
neuromuscular blocking agents	183-211	bethanechol	245-255	
cholinergic agonists	216-235	bethanechol	245-255	

Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied.
ZEMURON	30-36	rocuronium bromide	42-59	
ZEMURON	30-36	succinylcholine	79-93	
ZEMURON	30-36	succinylcholine	155-169	
rocuronium bromide	42-59	succinylcholine	79-93	
rocuronium bromide	42-59	succinylcholine	155-169	
succinylcholine	79-93	succinylcholine	155-169	

If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed.
ZEMURON	3-9	succinylcholine	58-72	
ZEMURON	3-9	succinylcholine	118-132	
succinylcholine	58-72	succinylcholine	118-132	

The median duration of action of ZEMURON    0.6 mg/kg administered after a 1 mg/kg dose of succinylcholine when T 1 returned to 75% of control was 36 minutes (range 14-57, n=12) vs.
ZEMURON	33-39	succinylcholine	91-105	

There are no controlled studies documenting the use of ZEMURON    before or after other nondepolarizing muscle relaxants.
ZEMURON	55-61	nondepolarizing muscle relaxants	88-119	

Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive.
Ropivacaine	0-10	anesthetics	74-84	
Ropivacaine	0-10	amide-type local anesthetics	120-147	
anesthetics	74-84	amide-type local anesthetics	120-147	

In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor.
ropivacaine	33-43	fluvoxamine	91-101	

Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels.
fluvoxamine	54-64	Ropivacaine	112-122	
fluvoxamine	54-64	Ropivacaine	143-153	
fluvoxamine	54-64	ropivacaine	176-186	
Ropivacaine	112-122	Ropivacaine	143-153	
Ropivacaine	112-122	ropivacaine	176-186	
Ropivacaine	143-153	ropivacaine	176-186	

Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as theophylline and imipramine may also occur.
theophylline	102-113	imipramine	119-128	

Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.
ketoconazole	64-75	ropivacaine	105-115	
ketoconazole	64-75	ketoconazole	152-163	
ketoconazole	64-75	ropivacaine	220-230	
ropivacaine	105-115	ketoconazole	152-163	
ropivacaine	105-115	ropivacaine	220-230	
ketoconazole	152-163	ropivacaine	220-230	

An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone.
gemfibrozil	32-42	rosiglitazone	69-81	
gemfibrozil	32-42	rifampin	117-124	
gemfibrozil	32-42	rosiglitazone	151-163	
rosiglitazone	69-81	rifampin	117-124	
rosiglitazone	69-81	rosiglitazone	151-163	
rifampin	117-124	rosiglitazone	151-163	

Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.
Terfenadine	48-58	astemizole	64-73	
Terfenadine	48-58	macrolides	84-93	
Terfenadine	48-58	terfenadine	109-119	
Terfenadine	48-58	astemizole	125-134	
astemizole	64-73	macrolides	84-93	
astemizole	64-73	terfenadine	109-119	
astemizole	64-73	astemizole	125-134	
macrolides	84-93	terfenadine	109-119	
macrolides	84-93	astemizole	125-134	
terfenadine	109-119	astemizole	125-134	

Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended.
roxithromycin	56-68	roxithromycin	101-113	
roxithromycin	56-68	terfenadine	120-130	
roxithromycin	56-68	astemizole	135-144	
roxithromycin	101-113	terfenadine	120-130	
roxithromycin	101-113	astemizole	135-144	
terfenadine	120-130	astemizole	135-144	

- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.
Cisapride	2-10	pimozide	13-20	
Cisapride	2-10	cisapride	43-51	
Cisapride	2-10	pimozide	56-63	
Cisapride	2-10	macrolide antibacterials	352-375	
pimozide	13-20	cisapride	43-51	
pimozide	13-20	pimozide	56-63	
pimozide	13-20	macrolide antibacterials	352-375	
cisapride	43-51	pimozide	56-63	
cisapride	43-51	macrolide antibacterials	352-375	
pimozide	56-63	macrolide antibacterials	352-375	

Although such a risk is not verified for roxithromycin, combination of roxithromycin with such drugs is not recommended.
roxithromycin	41-53	roxithromycin	71-83	

however, in patients with Paget's Disease prior diphosphonate use appears to reduce the anti-resorptive response to Calcitonin (salmon) nasal spray.
diphosphonate	48-60	Calcitonin (salmon)	116-134	

ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS.
ASPIRIN	0-6	SALICYLATE DRUGS	18-33	
ASPIRIN	0-6	DISALCID	55-62	
ASPIRIN	0-6	SALICYLIC ACID	106-119	
SALICYLATE DRUGS	18-33	DISALCID	55-62	
SALICYLATE DRUGS	18-33	SALICYLIC ACID	106-119	
DISALCID	55-62	SALICYLIC ACID	106-119	

Salicylates given concomitantly with anticoagulant drugs may predispose to systemic bleeding.
Salicylates	0-10	anticoagulant drugs	37-55	

Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class.
Salicylates	0-10	antidiabetic drugs	56-73	

Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
Salicylate	0-9	penicillin	78-87	
Salicylate	0-9	thiopental	90-99	
Salicylate	0-9	thyroxine	102-110	
Salicylate	0-9	triiodothyronine	113-128	
Salicylate	0-9	phenytoin	131-139	
Salicylate	0-9	sulfinpyrazone	142-155	
Salicylate	0-9	naproxen	158-165	
Salicylate	0-9	warfarin	168-175	
Salicylate	0-9	methotrexate	178-189	
Salicylate	0-9	corticosteroids	205-219	
penicillin	78-87	thiopental	90-99	
penicillin	78-87	thyroxine	102-110	
penicillin	78-87	triiodothyronine	113-128	
penicillin	78-87	phenytoin	131-139	
penicillin	78-87	sulfinpyrazone	142-155	
penicillin	78-87	naproxen	158-165	
penicillin	78-87	warfarin	168-175	
penicillin	78-87	methotrexate	178-189	
penicillin	78-87	corticosteroids	205-219	
thiopental	90-99	thyroxine	102-110	
thiopental	90-99	triiodothyronine	113-128	
thiopental	90-99	phenytoin	131-139	
thiopental	90-99	sulfinpyrazone	142-155	
thiopental	90-99	naproxen	158-165	
thiopental	90-99	warfarin	168-175	
thiopental	90-99	methotrexate	178-189	
thiopental	90-99	corticosteroids	205-219	
thyroxine	102-110	triiodothyronine	113-128	
thyroxine	102-110	phenytoin	131-139	
thyroxine	102-110	sulfinpyrazone	142-155	
thyroxine	102-110	naproxen	158-165	
thyroxine	102-110	warfarin	168-175	
thyroxine	102-110	methotrexate	178-189	
thyroxine	102-110	corticosteroids	205-219	
triiodothyronine	113-128	phenytoin	131-139	
triiodothyronine	113-128	sulfinpyrazone	142-155	
triiodothyronine	113-128	naproxen	158-165	
triiodothyronine	113-128	warfarin	168-175	
triiodothyronine	113-128	methotrexate	178-189	
triiodothyronine	113-128	corticosteroids	205-219	
phenytoin	131-139	sulfinpyrazone	142-155	
phenytoin	131-139	naproxen	158-165	
phenytoin	131-139	warfarin	168-175	
phenytoin	131-139	methotrexate	178-189	
phenytoin	131-139	corticosteroids	205-219	
sulfinpyrazone	142-155	naproxen	158-165	
sulfinpyrazone	142-155	warfarin	168-175	
sulfinpyrazone	142-155	methotrexate	178-189	
sulfinpyrazone	142-155	corticosteroids	205-219	
naproxen	158-165	warfarin	168-175	
naproxen	158-165	methotrexate	178-189	
naproxen	158-165	corticosteroids	205-219	
warfarin	168-175	methotrexate	178-189	
warfarin	168-175	corticosteroids	205-219	
methotrexate	178-189	corticosteroids	205-219	

Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.
Leukine	61-67	lithium	78-84	
Leukine	61-67	corticosteroids	90-104	
lithium	78-84	corticosteroids	90-104	

Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol.
Scopolamine	0-10	sedatives	116-124	
Scopolamine	0-10	tranquilizers	127-139	
Scopolamine	0-10	alcohol	145-151	
sedatives	116-124	tranquilizers	127-139	
sedatives	116-124	alcohol	145-151	
tranquilizers	127-139	alcohol	145-151	

e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants.
belladonna alkaloids	12-31	antihistamines	34-47	
belladonna alkaloids	12-31	meclizine	60-68	
belladonna alkaloids	12-31	tricyclic antidepressants	72-96	
belladonna alkaloids	12-31	muscle relaxants	103-118	
antihistamines	34-47	meclizine	60-68	
antihistamines	34-47	tricyclic antidepressants	72-96	
antihistamines	34-47	muscle relaxants	103-118	
meclizine	60-68	tricyclic antidepressants	72-96	
meclizine	60-68	muscle relaxants	103-118	
tricyclic antidepressants	72-96	muscle relaxants	103-118	

Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
Barbiturates	0-11	contraceptives	52-65	
Barbiturates	0-11	antibiotics	76-86	
Barbiturates	0-11	quinidine	89-97	
Barbiturates	0-11	theophylline	100-111	
Barbiturates	0-11	corticosteroids	114-128	
Barbiturates	0-11	anticoagulants	131-144	
Barbiturates	0-11	beta blockers	151-163	
contraceptives	52-65	antibiotics	76-86	
contraceptives	52-65	quinidine	89-97	
contraceptives	52-65	theophylline	100-111	
contraceptives	52-65	corticosteroids	114-128	
contraceptives	52-65	anticoagulants	131-144	
contraceptives	52-65	beta blockers	151-163	
antibiotics	76-86	quinidine	89-97	
antibiotics	76-86	theophylline	100-111	
antibiotics	76-86	corticosteroids	114-128	
antibiotics	76-86	anticoagulants	131-144	
antibiotics	76-86	beta blockers	151-163	
quinidine	89-97	theophylline	100-111	
quinidine	89-97	corticosteroids	114-128	
quinidine	89-97	anticoagulants	131-144	
quinidine	89-97	beta blockers	151-163	
theophylline	100-111	corticosteroids	114-128	
theophylline	100-111	anticoagulants	131-144	
theophylline	100-111	beta blockers	151-163	
corticosteroids	114-128	anticoagulants	131-144	
corticosteroids	114-128	beta blockers	151-163	
anticoagulants	131-144	beta blockers	151-163	

The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine.
selegiline	152-161	meperidine	167-176	

This is typical of the interaction of meperidine and MAOIs.
meperidine	38-47	MAOIs	53-57	

Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL.
tricyclic antidepressants	80-104	ELDEPRYL	110-117	
tricyclic antidepressants	80-104	selective serotonin reuptake inhibitors	123-161	
tricyclic antidepressants	80-104	ELDEPRYL	167-174	
ELDEPRYL	110-117	selective serotonin reuptake inhibitors	123-161	
ELDEPRYL	110-117	ELDEPRYL	167-174	
selective serotonin reuptake inhibitors	123-161	ELDEPRYL	167-174	

One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).
selegiline	95-104	sympathomimetic medication	112-137	
selegiline	95-104	ephedrine	140-148	
sympathomimetic medication	112-137	ephedrine	140-148	

Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.
Digoxin	0-6	digoxin	124-130	
Digoxin	0-6	sitagliptin	169-179	
digoxin	124-130	sitagliptin	169-179	

No dosage adjustment of digoxin or JANUVIA is recommended.
digoxin	24-30	JANUVIA	35-41	

norepinephrine and dobutamine are incompatible with sodium bicarbonate solution.
norepinephrine	0-13	dobutamine	19-28	
norepinephrine	0-13	sodium bicarbonate	52-69	
dobutamine	19-28	sodium bicarbonate	52-69	

The addition of sodium bicarbonate to parenteral solutions containing calcium should be avoided, except where compatibility has been previously established.
sodium bicarbonate	16-33	calcium	70-76	

Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors.
VESIcare	35-42	ketoconazole	88-99	

Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose.
solifenacin	81-91	solifenacin	177-187	
solifenacin	81-91	solifenacin	273-283	
solifenacin	81-91	moxifloxacin	347-358	
solifenacin	177-187	solifenacin	273-283	
solifenacin	177-187	moxifloxacin	347-358	
solifenacin	273-283	moxifloxacin	347-358	

If glucocorticoid replacement is required, the glucocorticoid dose should be carefully adjusted.
glucocorticoid	3-16	glucocorticoid	47-60	

Limited published data indicate that GH treatment increases cytochrome P450 (CP450) mediated antipyrine clearance in man.
GH	37-38	antipyrine	93-102	

These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin).
GH	24-25	corticosteroids	133-147	
GH	24-25	sex steroids	150-161	
GH	24-25	anticonvulsants	164-178	
GH	24-25	cyclosporin	181-191	
corticosteroids	133-147	sex steroids	150-161	
corticosteroids	133-147	anticonvulsants	164-178	
corticosteroids	133-147	cyclosporin	181-191	
sex steroids	150-161	anticonvulsants	164-178	
sex steroids	150-161	cyclosporin	181-191	
anticonvulsants	164-178	cyclosporin	181-191	

Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan).
NEXAVAR	42-48	irinotecan	139-148	

Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of doxorubicin.
NEXAVAR	27-33	doxorubicin	76-86	

Caution is recommended when administering doxorubicin with NEXAVAR.
doxorubicin	42-52	NEXAVAR	59-65	

Zidovudine competitively inhibits the intracellular phosphorylation of stavudine.
Zidovudine	0-9	stavudine	71-79	

Therefore, use of zidovudine in combination with ZERIT should be avoided.
zidovudine	18-27	ZERIT	49-53	

In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin.
stavudine	51-59	doxorubicin	109-119	
stavudine	51-59	ribavirin	125-133	
doxorubicin	109-119	ribavirin	125-133	

The interaction of Streptase, Streptokinase, with other drugs has not been well studied.
Streptase	19-27	Streptokinase	30-42	

Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.
Anticoagulants	7-20	Antiplatelet Agents	26-44	
Anticoagulants	7-20	Streptase	49-57	
Anticoagulants	7-20	Streptokinase	60-72	
Anticoagulants	7-20	antiplatelet agents	104-122	
Anticoagulants	7-20	anticoagulants	128-141	
Antiplatelet Agents	26-44	Streptase	49-57	
Antiplatelet Agents	26-44	Streptokinase	60-72	
Antiplatelet Agents	26-44	antiplatelet agents	104-122	
Antiplatelet Agents	26-44	anticoagulants	128-141	
Streptase	49-57	Streptokinase	60-72	
Streptase	49-57	antiplatelet agents	104-122	
Streptase	49-57	anticoagulants	128-141	
Streptokinase	60-72	antiplatelet agents	104-122	
Streptokinase	60-72	anticoagulants	128-141	
antiplatelet agents	104-122	anticoagulants	128-141	

In the treatment of acute MI, aspirin, when not otherwise contraindicated, should be administered with Streptokinase ( see below ).
aspirin	30-36	Streptokinase	103-115	

Anticoagulation and Antiplatelets After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of aspirin has been shown to reduce the incidence of reinfarction and stroke.
Antiplatelets	20-32	aspirin	139-145	

The addition of aspirin to Streptokinase causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see
aspirin	16-22	Streptokinase	27-39	

Streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression;
Streptozocin	0-11	doxorubicin	71-81	

a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently.
doxorubicin	19-29	ZANOSAR	81-87	

The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.
streptozocin	22-33	phenytoin	39-47	
streptozocin	22-33	streptozocin	100-111	
phenytoin	39-47	streptozocin	100-111	

CHEMET is not known to interact with other drugs including iron supplements;
CHEMET	0-5	iron	59-62	

Concomitant administration of CHEMET with other chelation therapy, such as CaNa 2 EDTA is not recommended.
CHEMET	30-35	CaNa 2 EDTA	75-85	

Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics.
Sulfamethizole	0-13	barbiturates	43-54	
Sulfamethizole	0-13	tolbutamide	57-67	
Sulfamethizole	0-13	uricosurics	74-84	
barbiturates	43-54	tolbutamide	57-67	
barbiturates	43-54	uricosurics	74-84	
tolbutamide	57-67	uricosurics	74-84	

It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
thiazides	26-34	cyclosporine	66-77	
thiazides	26-34	sulfonylurea agents	107-125	
thiazides	26-34	warfarin	162-169	
thiazides	26-34	methotrexate	205-216	
thiazides	26-34	methotrexate	248-259	
thiazides	26-34	phenytoin	263-271	
thiazides	26-34	phenytoin	305-313	
cyclosporine	66-77	sulfonylurea agents	107-125	
cyclosporine	66-77	warfarin	162-169	
cyclosporine	66-77	methotrexate	205-216	
cyclosporine	66-77	methotrexate	248-259	
cyclosporine	66-77	phenytoin	263-271	
cyclosporine	66-77	phenytoin	305-313	
sulfonylurea agents	107-125	warfarin	162-169	
sulfonylurea agents	107-125	methotrexate	205-216	
sulfonylurea agents	107-125	methotrexate	248-259	
sulfonylurea agents	107-125	phenytoin	263-271	
sulfonylurea agents	107-125	phenytoin	305-313	
warfarin	162-169	methotrexate	205-216	
warfarin	162-169	methotrexate	248-259	
warfarin	162-169	phenytoin	263-271	
warfarin	162-169	phenytoin	305-313	
methotrexate	205-216	methotrexate	248-259	
methotrexate	205-216	phenytoin	263-271	
methotrexate	205-216	phenytoin	305-313	
methotrexate	248-259	phenytoin	263-271	
methotrexate	248-259	phenytoin	305-313	
phenytoin	263-271	phenytoin	305-313	

In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombopenia with purpura has been reported.
diuretics	51-59	thiazides	72-80	

It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin.
sulfamethoxazole	26-41	anticoagulant	110-122	
sulfamethoxazole	26-41	warfarin	124-131	
anticoagulant	110-122	warfarin	124-131	

Sulfamethoxazole may inhibit the hepatic metabolism of phenytoin.
Sulfamethoxazole	0-15	phenytoin	55-63	

At a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate.
sulfamethoxazole	17-32	phenytoin	97-105	

Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations.
Sulfonamides	0-11	methotrexate	31-42	
Sulfonamides	0-11	methotrexate	100-111	
methotrexate	31-42	methotrexate	100-111	

Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine.
folic acid	22-31	digoxin	37-43	
folic acid	22-31	sulfasalazine	119-131	
digoxin	37-43	sulfasalazine	119-131	

When daily doses of sulfasalazine 2 g and weekly doses of methotrexate 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered.
sulfasalazine	20-32	methotrexate	58-69	

Daily doses of sulfasalazine 2 g (maximum 3 g) and weekly doses of methotrexate 7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies.
sulfasalazine	15-27	methotrexate	67-78	

Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics.
Sulfoxone	0-8	barbiturates	38-49	
Sulfoxone	0-8	tolbutamide	52-62	
Sulfoxone	0-8	uricosurics	69-79	
barbiturates	38-49	tolbutamide	52-62	
barbiturates	38-49	uricosurics	69-79	
tolbutamide	52-62	uricosurics	69-79	

It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
thiazides	26-34	cyclosporine	66-77	
thiazides	26-34	sulfonylurea agents	107-125	
thiazides	26-34	warfarin	162-169	
thiazides	26-34	methotrexate	205-216	
thiazides	26-34	methotrexate	248-259	
thiazides	26-34	phenytoin	263-271	
thiazides	26-34	phenytoin	305-313	
cyclosporine	66-77	sulfonylurea agents	107-125	
cyclosporine	66-77	warfarin	162-169	
cyclosporine	66-77	methotrexate	205-216	
cyclosporine	66-77	methotrexate	248-259	
cyclosporine	66-77	phenytoin	263-271	
cyclosporine	66-77	phenytoin	305-313	
sulfonylurea agents	107-125	warfarin	162-169	
sulfonylurea agents	107-125	methotrexate	205-216	
sulfonylurea agents	107-125	methotrexate	248-259	
sulfonylurea agents	107-125	phenytoin	263-271	
sulfonylurea agents	107-125	phenytoin	305-313	
warfarin	162-169	methotrexate	205-216	
warfarin	162-169	methotrexate	248-259	
warfarin	162-169	phenytoin	263-271	
warfarin	162-169	phenytoin	305-313	
methotrexate	205-216	methotrexate	248-259	
methotrexate	205-216	phenytoin	263-271	
methotrexate	205-216	phenytoin	305-313	
methotrexate	248-259	phenytoin	263-271	
methotrexate	248-259	phenytoin	305-313	
phenytoin	263-271	phenytoin	305-313	

Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.
ergotamine	80-89	ergot-type medications	105-126	
ergotamine	80-89	dihydroergotamine	134-150	
ergotamine	80-89	methysergide	155-166	
ergotamine	80-89	sumatriptan	173-183	
ergot-type medications	105-126	dihydroergotamine	134-150	
ergot-type medications	105-126	methysergide	155-166	
ergot-type medications	105-126	sumatriptan	173-183	
dihydroergotamine	134-150	methysergide	155-166	
dihydroergotamine	134-150	sumatriptan	173-183	
methysergide	155-166	sumatriptan	173-183	

MAO-A inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure.
MAO-A inhibitors	0-15	sumatriptan	24-34	

Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
sumatriptan succinate	22-42	MAO-A inhibitors	74-89	
sumatriptan succinate	22-42	Selective serotonin reuptake inhibitors	112-150	
sumatriptan succinate	22-42	SSRIs	153-157	
sumatriptan succinate	22-42	fluoxetine	167-176	
sumatriptan succinate	22-42	fluvoxamine	179-189	
sumatriptan succinate	22-42	paroxetine	192-201	
sumatriptan succinate	22-42	sertraline	204-213	
sumatriptan succinate	22-42	sumatriptan	322-332	
MAO-A inhibitors	74-89	Selective serotonin reuptake inhibitors	112-150	
MAO-A inhibitors	74-89	SSRIs	153-157	
MAO-A inhibitors	74-89	fluoxetine	167-176	
MAO-A inhibitors	74-89	fluvoxamine	179-189	
MAO-A inhibitors	74-89	paroxetine	192-201	
MAO-A inhibitors	74-89	sertraline	204-213	
MAO-A inhibitors	74-89	sumatriptan	322-332	
Selective serotonin reuptake inhibitors	112-150	SSRIs	153-157	
Selective serotonin reuptake inhibitors	112-150	fluoxetine	167-176	
Selective serotonin reuptake inhibitors	112-150	fluvoxamine	179-189	
Selective serotonin reuptake inhibitors	112-150	paroxetine	192-201	
Selective serotonin reuptake inhibitors	112-150	sertraline	204-213	
Selective serotonin reuptake inhibitors	112-150	sumatriptan	322-332	
SSRIs	153-157	fluoxetine	167-176	
SSRIs	153-157	fluvoxamine	179-189	
SSRIs	153-157	paroxetine	192-201	
SSRIs	153-157	sertraline	204-213	
SSRIs	153-157	sumatriptan	322-332	
fluoxetine	167-176	fluvoxamine	179-189	
fluoxetine	167-176	paroxetine	192-201	
fluoxetine	167-176	sertraline	204-213	
fluoxetine	167-176	sumatriptan	322-332	
fluvoxamine	179-189	paroxetine	192-201	
fluvoxamine	179-189	sertraline	204-213	
fluvoxamine	179-189	sumatriptan	322-332	
paroxetine	192-201	sertraline	204-213	
paroxetine	192-201	sumatriptan	322-332	
sertraline	204-213	sumatriptan	322-332	

If concomitant treatment with sumatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.
sumatriptan	30-40	SSRI	49-52	

Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
SUTENT	21-26	ketoconazole	79-90	
SUTENT	21-26	itraconazole	93-104	
SUTENT	21-26	clarithromycin	107-120	
SUTENT	21-26	atazanavir	123-132	
SUTENT	21-26	indinavir	135-143	
SUTENT	21-26	nefazodone	146-155	
SUTENT	21-26	nelfinavir	158-167	
SUTENT	21-26	ritonavir	170-178	
SUTENT	21-26	saquinavir	181-190	
SUTENT	21-26	telithromycin	193-205	
SUTENT	21-26	voriconizole	208-219	
SUTENT	21-26	sunitinib	236-244	
ketoconazole	79-90	itraconazole	93-104	
ketoconazole	79-90	clarithromycin	107-120	
ketoconazole	79-90	atazanavir	123-132	
ketoconazole	79-90	indinavir	135-143	
ketoconazole	79-90	nefazodone	146-155	
ketoconazole	79-90	nelfinavir	158-167	
ketoconazole	79-90	ritonavir	170-178	
ketoconazole	79-90	saquinavir	181-190	
ketoconazole	79-90	telithromycin	193-205	
ketoconazole	79-90	voriconizole	208-219	
ketoconazole	79-90	sunitinib	236-244	
itraconazole	93-104	clarithromycin	107-120	
itraconazole	93-104	atazanavir	123-132	
itraconazole	93-104	indinavir	135-143	
itraconazole	93-104	nefazodone	146-155	
itraconazole	93-104	nelfinavir	158-167	
itraconazole	93-104	ritonavir	170-178	
itraconazole	93-104	saquinavir	181-190	
itraconazole	93-104	telithromycin	193-205	
itraconazole	93-104	voriconizole	208-219	
itraconazole	93-104	sunitinib	236-244	
clarithromycin	107-120	atazanavir	123-132	
clarithromycin	107-120	indinavir	135-143	
clarithromycin	107-120	nefazodone	146-155	
clarithromycin	107-120	nelfinavir	158-167	
clarithromycin	107-120	ritonavir	170-178	
clarithromycin	107-120	saquinavir	181-190	
clarithromycin	107-120	telithromycin	193-205	
clarithromycin	107-120	voriconizole	208-219	
clarithromycin	107-120	sunitinib	236-244	
atazanavir	123-132	indinavir	135-143	
atazanavir	123-132	nefazodone	146-155	
atazanavir	123-132	nelfinavir	158-167	
atazanavir	123-132	ritonavir	170-178	
atazanavir	123-132	saquinavir	181-190	
atazanavir	123-132	telithromycin	193-205	
atazanavir	123-132	voriconizole	208-219	
atazanavir	123-132	sunitinib	236-244	
indinavir	135-143	nefazodone	146-155	
indinavir	135-143	nelfinavir	158-167	
indinavir	135-143	ritonavir	170-178	
indinavir	135-143	saquinavir	181-190	
indinavir	135-143	telithromycin	193-205	
indinavir	135-143	voriconizole	208-219	
indinavir	135-143	sunitinib	236-244	
nefazodone	146-155	nelfinavir	158-167	
nefazodone	146-155	ritonavir	170-178	
nefazodone	146-155	saquinavir	181-190	
nefazodone	146-155	telithromycin	193-205	
nefazodone	146-155	voriconizole	208-219	
nefazodone	146-155	sunitinib	236-244	
nelfinavir	158-167	ritonavir	170-178	
nelfinavir	158-167	saquinavir	181-190	
nelfinavir	158-167	telithromycin	193-205	
nelfinavir	158-167	voriconizole	208-219	
nelfinavir	158-167	sunitinib	236-244	
ritonavir	170-178	saquinavir	181-190	
ritonavir	170-178	telithromycin	193-205	
ritonavir	170-178	voriconizole	208-219	
ritonavir	170-178	sunitinib	236-244	
saquinavir	181-190	telithromycin	193-205	
saquinavir	181-190	voriconizole	208-219	
saquinavir	181-190	sunitinib	236-244	
telithromycin	193-205	voriconizole	208-219	
telithromycin	193-205	sunitinib	236-244	
voriconizole	208-219	sunitinib	236-244	

Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
SUTENT	21-26	dexamethasone	70-82	
SUTENT	21-26	phenytoin	85-93	
SUTENT	21-26	carbamazepine	96-108	
SUTENT	21-26	rifampin	111-118	
SUTENT	21-26	rifabutin	121-129	
SUTENT	21-26	rifapentin	132-141	
SUTENT	21-26	phenobarbital	144-156	
SUTENT	21-26	sunitinib	188-196	
dexamethasone	70-82	phenytoin	85-93	
dexamethasone	70-82	carbamazepine	96-108	
dexamethasone	70-82	rifampin	111-118	
dexamethasone	70-82	rifabutin	121-129	
dexamethasone	70-82	rifapentin	132-141	
dexamethasone	70-82	phenobarbital	144-156	
dexamethasone	70-82	sunitinib	188-196	
phenytoin	85-93	carbamazepine	96-108	
phenytoin	85-93	rifampin	111-118	
phenytoin	85-93	rifabutin	121-129	
phenytoin	85-93	rifapentin	132-141	
phenytoin	85-93	phenobarbital	144-156	
phenytoin	85-93	sunitinib	188-196	
carbamazepine	96-108	rifampin	111-118	
carbamazepine	96-108	rifabutin	121-129	
carbamazepine	96-108	rifapentin	132-141	
carbamazepine	96-108	phenobarbital	144-156	
carbamazepine	96-108	sunitinib	188-196	
rifampin	111-118	rifabutin	121-129	
rifampin	111-118	rifapentin	132-141	
rifampin	111-118	phenobarbital	144-156	
rifampin	111-118	sunitinib	188-196	
rifabutin	121-129	rifapentin	132-141	
rifabutin	121-129	phenobarbital	144-156	
rifabutin	121-129	sunitinib	188-196	
rifapentin	132-141	phenobarbital	144-156	
rifapentin	132-141	sunitinib	188-196	
phenobarbital	144-156	sunitinib	188-196	

Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.
acetylcholine chloride	39-60	Miochol	63-69	
acetylcholine chloride	39-60	carbachol	76-84	
acetylcholine chloride	39-60	Carboptic	87-95	
acetylcholine chloride	39-60	Isopto Carbachol	98-113	
acetylcholine chloride	39-60	suprofen	144-151	
Miochol	63-69	carbachol	76-84	
Miochol	63-69	Carboptic	87-95	
Miochol	63-69	Isopto Carbachol	98-113	
Miochol	63-69	suprofen	144-151	
carbachol	76-84	Carboptic	87-95	
carbachol	76-84	Isopto Carbachol	98-113	
carbachol	76-84	suprofen	144-151	
Carboptic	87-95	Isopto Carbachol	98-113	
Carboptic	87-95	suprofen	144-151	
Isopto Carbachol	98-113	suprofen	144-151	

Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between FLOMAX capsules and other alpha-adrenergic blocking agents have not been determined.
FLOMAX	85-90	alpha-adrenergic blocking agents	111-142	

However, interactions may be expected and FLOMAX capsules should NOT be used in combination with other alpha-adrenergic blocking agents.
FLOMAX	42-47	alpha-adrenergic blocking agents	103-134	

The pharmacokinetic interaction between cimetidine and FLOMAX capsules was investigated.
cimetidine	40-49	FLOMAX	55-60	

Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg.
FLOMAX	11-16	cimetidine	75-84	

Results from limited in vitro and in vivo drug-drug interaction studies between tamsulosin HCI and warfarin are inconclusive.
tamsulosin HCI	80-93	warfarin	99-106	

Therefore, caution should be exercised with concomitant administration of warfarin and FLOMAX capsules.
warfarin	74-81	FLOMAX	87-92	

Administration of valproic acid decreases oral clearance of temozolomide by about 5%.
valproic acid	18-30	temozolomide	60-71	

Patients studied in clinical trials of TNKase were routinely treated with heparin and aspirin.
TNKase	39-44	heparin	74-80	
TNKase	39-44	aspirin	86-92	
heparin	74-80	aspirin	86-92	

Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
Anticoagulants	0-13	heparin	24-30	
Anticoagulants	0-13	vitamin K antagonists	36-56	
Anticoagulants	0-13	acetylsalicylic acid	107-126	
Anticoagulants	0-13	dipyridamole	129-140	
Anticoagulants	0-13	TNKase	248-253	
heparin	24-30	vitamin K antagonists	36-56	
heparin	24-30	acetylsalicylic acid	107-126	
heparin	24-30	dipyridamole	129-140	
heparin	24-30	TNKase	248-253	
vitamin K antagonists	36-56	acetylsalicylic acid	107-126	
vitamin K antagonists	36-56	dipyridamole	129-140	
vitamin K antagonists	36-56	TNKase	248-253	
acetylsalicylic acid	107-126	dipyridamole	129-140	
acetylsalicylic acid	107-126	TNKase	248-253	
dipyridamole	129-140	TNKase	248-253	

In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent.
tolbutamide	95-105	sodium salicylate	108-124	
tolbutamide	95-105	sulfamethizole	130-143	
tolbutamide	95-105	teniposide	169-178	
sodium salicylate	108-124	sulfamethizole	130-143	
sodium salicylate	108-124	teniposide	169-178	
sulfamethizole	130-143	teniposide	169-178	

Therefore, caution should be used in administering VUMON (teniposide injection) to patients receiving these other agents.
VUMON	51-55	teniposide	58-67	

There was no change in the plasma kinetics of teniposide when coadministered with methotrexate.
teniposide	46-55	methotrexate	82-93	

An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide.
methotrexate	39-50	teniposide	93-102	

In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine.
terbinafine	57-67	tolbutamide	104-114	
terbinafine	57-67	ethinylestradiol	117-132	
terbinafine	57-67	ethoxycoumarin	135-148	
terbinafine	57-67	cyclosporine	155-166	
tolbutamide	104-114	ethinylestradiol	117-132	
tolbutamide	104-114	ethoxycoumarin	135-148	
tolbutamide	104-114	cyclosporine	155-166	
ethinylestradiol	117-132	ethoxycoumarin	135-148	
ethinylestradiol	117-132	cyclosporine	155-166	
ethoxycoumarin	135-148	cyclosporine	155-166	

This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window.
tricyclic antidepressants	98-122	selective serotonin reuptake inhibitors	139-177	
tricyclic antidepressants	98-122	SSRIs	180-184	
tricyclic antidepressants	98-122	monoamine oxidase inhibitors (MAO-Is) Type B	192-235	
selective serotonin reuptake inhibitors	139-177	SSRIs	180-184	
selective serotonin reuptake inhibitors	139-177	monoamine oxidase inhibitors (MAO-Is) Type B	192-235	
SSRIs	180-184	monoamine oxidase inhibitors (MAO-Is) Type B	192-235	

In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin.
terbinafine	89-99	antipyrine	134-143	
terbinafine	89-99	digoxin	148-154	
antipyrine	134-143	digoxin	148-154	

Terbinafine decreases the clearance of caffeine by 19%.
Terbinafine	0-10	caffeine	39-46	

Terbinafine increases the clearance of cyclosporine by 15%.
Terbinafine	0-10	cyclosporine	39-50	

There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established.
terbinafine	119-129	warfarin	135-142	
terbinafine	119-129	LAMISIL	184-190	
warfarin	135-142	LAMISIL	184-190	

Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor.
Terbinafine	0-10	rifampin	43-50	
Terbinafine	0-10	cimetidine	99-108	
rifampin	43-50	cimetidine	99-108	

Terbinafine clearance is unaffected by cyclosporine.
Terbinafine	0-10	cyclosporine	39-50	

There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.
contraceptives	120-133	hypoglycemics	167-179	
contraceptives	120-133	theophyllines	182-194	
contraceptives	120-133	phenytoins	197-206	
contraceptives	120-133	thiazide diuretics	209-226	
contraceptives	120-133	beta blockers	229-241	
contraceptives	120-133	calcium channel blockers	248-271	
hypoglycemics	167-179	theophyllines	182-194	
hypoglycemics	167-179	phenytoins	197-206	
hypoglycemics	167-179	thiazide diuretics	209-226	
hypoglycemics	167-179	beta blockers	229-241	
hypoglycemics	167-179	calcium channel blockers	248-271	
theophyllines	182-194	phenytoins	197-206	
theophyllines	182-194	thiazide diuretics	209-226	
theophyllines	182-194	beta blockers	229-241	
theophyllines	182-194	calcium channel blockers	248-271	
phenytoins	197-206	thiazide diuretics	209-226	
phenytoins	197-206	beta blockers	229-241	
phenytoins	197-206	calcium channel blockers	248-271	
thiazide diuretics	209-226	beta blockers	229-241	
thiazide diuretics	209-226	calcium channel blockers	248-271	
beta blockers	229-241	calcium channel blockers	248-271	

Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g.
Ketoconazole	0-11	ketoconazole	82-93	
Ketoconazole	0-11	terfenadine	121-131	
ketoconazole	82-93	terfenadine	121-131	

Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels.
ketoconazole	35-46	terfenadine	84-94	
ketoconazole	35-46	terfenadine	126-136	
terfenadine	84-94	terfenadine	126-136	

Concomitant administration of ketoconazole and terfenadine is contraindicated.
ketoconazole	30-41	terfenadine	47-57	

Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.
Itraconazole	0-11	terfenadine	54-64	
Itraconazole	0-11	terfenadine	118-128	
Itraconazole	0-11	itraconazole	134-145	
Itraconazole	0-11	itraconazole	169-180	
terfenadine	54-64	terfenadine	118-128	
terfenadine	54-64	itraconazole	134-145	
terfenadine	54-64	itraconazole	169-180	
terfenadine	118-128	itraconazole	134-145	
terfenadine	118-128	itraconazole	169-180	
itraconazole	134-145	itraconazole	169-180	

Concomitant administration of itraconazole and terfenadine is contraindicated.
itraconazole	30-41	terfenadine	47-57	

Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
azole-type antifungal agents	40-67	fluconazole	80-90	
azole-type antifungal agents	40-67	metronidazole	93-105	
azole-type antifungal agents	40-67	miconazole	112-121	
azole-type antifungal agents	40-67	ketoconazole	127-138	
azole-type antifungal agents	40-67	itraconazole	145-156	
azole-type antifungal agents	40-67	terfenadine	198-208	
fluconazole	80-90	metronidazole	93-105	
fluconazole	80-90	miconazole	112-121	
fluconazole	80-90	ketoconazole	127-138	
fluconazole	80-90	itraconazole	145-156	
fluconazole	80-90	terfenadine	198-208	
metronidazole	93-105	miconazole	112-121	
metronidazole	93-105	ketoconazole	127-138	
metronidazole	93-105	itraconazole	145-156	
metronidazole	93-105	terfenadine	198-208	
miconazole	112-121	ketoconazole	127-138	
miconazole	112-121	itraconazole	145-156	
miconazole	112-121	terfenadine	198-208	
ketoconazole	127-138	itraconazole	145-156	
ketoconazole	127-138	terfenadine	198-208	
itraconazole	145-156	terfenadine	198-208	

Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.
Macrolides	0-9	erythromycin	60-71	
Macrolides	0-9	clarithromycin	77-90	
Macrolides	0-9	terfenadine	115-125	
Macrolides	0-9	ketoconazole	185-196	
erythromycin	60-71	clarithromycin	77-90	
erythromycin	60-71	terfenadine	115-125	
erythromycin	60-71	ketoconazole	185-196	
clarithromycin	77-90	terfenadine	115-125	
clarithromycin	77-90	ketoconazole	185-196	
terfenadine	115-125	ketoconazole	185-196	

A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving erythromycin or troleandomycin.
erythromycin	155-166	troleandomycin	171-184	

Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.
terfenadine	30-40	clarithromycin	47-60	
terfenadine	30-40	erythromycin	63-74	
terfenadine	30-40	troleandomycin	80-93	
terfenadine	30-40	terfenadine	202-212	
terfenadine	30-40	macrolide antibiotics	225-245	
terfenadine	30-40	azithromycin	258-269	
clarithromycin	47-60	erythromycin	63-74	
clarithromycin	47-60	troleandomycin	80-93	
clarithromycin	47-60	terfenadine	202-212	
clarithromycin	47-60	macrolide antibiotics	225-245	
clarithromycin	47-60	azithromycin	258-269	
erythromycin	63-74	troleandomycin	80-93	
erythromycin	63-74	terfenadine	202-212	
erythromycin	63-74	macrolide antibiotics	225-245	
erythromycin	63-74	azithromycin	258-269	
troleandomycin	80-93	terfenadine	202-212	
troleandomycin	80-93	macrolide antibiotics	225-245	
troleandomycin	80-93	azithromycin	258-269	
terfenadine	202-212	macrolide antibiotics	225-245	
terfenadine	202-212	azithromycin	258-269	
macrolide antibiotics	225-245	azithromycin	258-269	

Studies to evaluate potential interactions of terfenadine with azithromycin are in progress.
terfenadine	46-56	azithromycin	63-74	

When administered concurrently, testolactone may increase the effects of oral anticoagulants;
testolactone	32-43	anticoagulants	78-91	

Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine.
Thalidomide	0-10	barbiturates	66-77	
Thalidomide	0-10	alcohol	80-86	
Thalidomide	0-10	chlorpromazine	89-102	
Thalidomide	0-10	reserpine	109-117	
barbiturates	66-77	alcohol	80-86	
barbiturates	66-77	chlorpromazine	89-102	
barbiturates	66-77	reserpine	109-117	
alcohol	80-86	chlorpromazine	89-102	
alcohol	80-86	reserpine	109-117	
chlorpromazine	89-102	reserpine	109-117	

Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied.
Contraceptives	5-18	norethindrone	74-86	
Contraceptives	5-18	ethinyl estradiol	92-108	
Contraceptives	5-18	norethindrone acetate	173-193	
Contraceptives	5-18	ethinyl estradiol	210-226	
norethindrone	74-86	ethinyl estradiol	92-108	
norethindrone	74-86	norethindrone acetate	173-193	
norethindrone	74-86	ethinyl estradiol	210-226	
ethinyl estradiol	92-108	norethindrone acetate	173-193	
ethinyl estradiol	92-108	ethinyl estradiol	210-226	
norethindrone acetate	173-193	ethinyl estradiol	210-226	

Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
Thalidomide	14-24	Hormonal Contraceptives	70-92	
Thalidomide	14-24	HIV-protease inhibitors	114-136	
Thalidomide	14-24	griseofulvin	139-150	
Thalidomide	14-24	modafinil	153-161	
Thalidomide	14-24	penicillins	164-174	
Thalidomide	14-24	rifampin	177-184	
Thalidomide	14-24	rifabutin	187-195	
Thalidomide	14-24	phenytoin	198-206	
Thalidomide	14-24	carbamazepine	209-221	
Hormonal Contraceptives	70-92	HIV-protease inhibitors	114-136	
Hormonal Contraceptives	70-92	griseofulvin	139-150	
Hormonal Contraceptives	70-92	modafinil	153-161	
Hormonal Contraceptives	70-92	penicillins	164-174	
Hormonal Contraceptives	70-92	rifampin	177-184	
Hormonal Contraceptives	70-92	rifabutin	187-195	
Hormonal Contraceptives	70-92	phenytoin	198-206	
Hormonal Contraceptives	70-92	carbamazepine	209-221	
HIV-protease inhibitors	114-136	griseofulvin	139-150	
HIV-protease inhibitors	114-136	modafinil	153-161	
HIV-protease inhibitors	114-136	penicillins	164-174	
HIV-protease inhibitors	114-136	rifampin	177-184	
HIV-protease inhibitors	114-136	rifabutin	187-195	
HIV-protease inhibitors	114-136	phenytoin	198-206	
HIV-protease inhibitors	114-136	carbamazepine	209-221	
griseofulvin	139-150	modafinil	153-161	
griseofulvin	139-150	penicillins	164-174	
griseofulvin	139-150	rifampin	177-184	
griseofulvin	139-150	rifabutin	187-195	
griseofulvin	139-150	phenytoin	198-206	
griseofulvin	139-150	carbamazepine	209-221	
modafinil	153-161	penicillins	164-174	
modafinil	153-161	rifampin	177-184	
modafinil	153-161	rifabutin	187-195	
modafinil	153-161	phenytoin	198-206	
modafinil	153-161	carbamazepine	209-221	
penicillins	164-174	rifampin	177-184	
penicillins	164-174	rifabutin	187-195	
penicillins	164-174	phenytoin	198-206	
penicillins	164-174	carbamazepine	209-221	
rifampin	177-184	rifabutin	187-195	
rifampin	177-184	phenytoin	198-206	
rifampin	177-184	carbamazepine	209-221	
rifabutin	187-195	phenytoin	198-206	
rifabutin	187-195	carbamazepine	209-221	
phenytoin	198-206	carbamazepine	209-221	

John's Wort with hormonal contraceptive agents may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies.
John's Wort	0-10	hormonal contraceptive agents	17-45	

Thiabendazole may compete with other drugs, such as theophylline, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels.
Thiabendazole	0-12	theophylline	52-63	

Therefore, when concomitant use of thiabendazole and xanthine derivatives is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds.
thiabendazole	35-47	xanthine derivatives	53-72	

Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants
Vitamin B1	17-26	Thiamine	29-36	
Vitamin B1	17-26	Loop Diuretics	41-54	
Vitamin B1	17-26	Contraceptives	62-75	
Vitamin B1	17-26	Stavudine	78-86	
Vitamin B1	17-26	Tricyclic Antidepressants	89-113	
Thiamine	29-36	Loop Diuretics	41-54	
Thiamine	29-36	Contraceptives	62-75	
Thiamine	29-36	Stavudine	78-86	
Thiamine	29-36	Tricyclic Antidepressants	89-113	
Loop Diuretics	41-54	Contraceptives	62-75	
Loop Diuretics	41-54	Stavudine	78-86	
Loop Diuretics	41-54	Tricyclic Antidepressants	89-113	
Contraceptives	62-75	Stavudine	78-86	
Contraceptives	62-75	Tricyclic Antidepressants	89-113	
Stavudine	78-86	Tricyclic Antidepressants	89-113	

Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)
Phenothiazines	0-13	CNS depressants	43-57	
Phenothiazines	0-13	barbiturates	66-77	
Phenothiazines	0-13	anesthetics	80-90	
Phenothiazines	0-13	opiates	93-99	
Phenothiazines	0-13	alcohol	102-108	
CNS depressants	43-57	barbiturates	66-77	
CNS depressants	43-57	anesthetics	80-90	
CNS depressants	43-57	opiates	93-99	
CNS depressants	43-57	alcohol	102-108	
barbiturates	66-77	anesthetics	80-90	
barbiturates	66-77	opiates	93-99	
barbiturates	66-77	alcohol	102-108	
anesthetics	80-90	opiates	93-99	
anesthetics	80-90	alcohol	102-108	
opiates	93-99	alcohol	102-108	

as well as atropine and phosphorous insecticides.
atropine	11-18	phosphorous insecticides	24-47	

There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine.
PURINETHOL	51-60	mercaptopurine	63-76	
PURINETHOL	51-60	TABLOID	83-89	
PURINETHOL	51-60	Thioguanine	97-107	
mercaptopurine	63-76	TABLOID	83-89	
mercaptopurine	63-76	Thioguanine	97-107	
TABLOID	83-89	Thioguanine	97-107	

As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.
aminosalicylate derivatives	35-61	olsalazine	70-79	
aminosalicylate derivatives	35-61	mesalazine	82-91	
aminosalicylate derivatives	35-61	sulphasalazine	97-110	
aminosalicylate derivatives	35-61	thioguanine	212-222	
olsalazine	70-79	mesalazine	82-91	
olsalazine	70-79	sulphasalazine	97-110	
olsalazine	70-79	thioguanine	212-222	
mesalazine	82-91	sulphasalazine	97-110	
mesalazine	82-91	thioguanine	212-222	
sulphasalazine	97-110	thioguanine	212-222	

Caution should be exercised when administering ZADAXIN therapy in combination with other immunomodulating drugs.
ZADAXIN	47-53	immunomodulating drugs	89-110	

Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin.
tigecycline	79-89	warfarin	112-119	

Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.
antibacterial drugs	18-36	contraceptives	48-61	
antibacterial drugs	18-36	contraceptives	79-92	
contraceptives	48-61	contraceptives	79-92	

The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.
SKELID	23-28	calcium	50-56	
SKELID	23-28	calcium	64-70	
SKELID	23-28	SKELID	76-81	
SKELID	23-28	aluminum	134-141	
SKELID	23-28	magnesium	147-155	
SKELID	23-28	antacids	168-175	
SKELID	23-28	SKELID	210-215	
calcium	50-56	calcium	64-70	
calcium	50-56	SKELID	76-81	
calcium	50-56	aluminum	134-141	
calcium	50-56	magnesium	147-155	
calcium	50-56	antacids	168-175	
calcium	50-56	SKELID	210-215	
calcium	64-70	SKELID	76-81	
calcium	64-70	aluminum	134-141	
calcium	64-70	magnesium	147-155	
calcium	64-70	antacids	168-175	
calcium	64-70	SKELID	210-215	
SKELID	76-81	aluminum	134-141	
SKELID	76-81	magnesium	147-155	
SKELID	76-81	antacids	168-175	
SKELID	76-81	SKELID	210-215	
aluminum	134-141	magnesium	147-155	
aluminum	134-141	antacids	168-175	
aluminum	134-141	SKELID	210-215	
magnesium	147-155	antacids	168-175	
magnesium	147-155	SKELID	210-215	
antacids	168-175	SKELID	210-215	

Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID.
Aspirin	0-6	SKELID	40-45	
Aspirin	0-6	SKELID	85-90	
SKELID	40-45	SKELID	85-90	

The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac.
SKELID	23-28	indomethacin	55-66	
SKELID	23-28	diclofenac	124-133	
indomethacin	55-66	diclofenac	124-133	

The pharmacokinetic parameters of digoxin are not significantly modified by SKELID coadministration.
digoxin	34-40	SKELID	76-81	

In vitro studies show that tiludronate does not displace warfarin from its binding site on protein.
tiludronate	27-37	warfarin	57-64	

These include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids.
sympathomimetic bronchodilators	14-44	methylxanthines	47-61	
sympathomimetic bronchodilators	14-44	steroids	85-92	
methylxanthines	47-61	steroids	85-92	

However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.
SPIRIVA	36-42	anticholinergic	55-69	
SPIRIVA	36-42	ipratropium	97-107	
anticholinergic	55-69	ipratropium	97-107	

AGGRASTAT has been studied on a background of aspirin and heparin.
AGGRASTAT	0-8	aspirin	46-52	
AGGRASTAT	0-8	heparin	58-64	
aspirin	46-52	heparin	58-64	

The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see
AGGRASTAT	11-19	heparin	42-48	
AGGRASTAT	11-19	aspirin	54-60	
AGGRASTAT	11-19	heparin	124-130	
AGGRASTAT	11-19	aspirin	136-142	
heparin	42-48	aspirin	54-60	
heparin	42-48	heparin	124-130	
heparin	42-48	aspirin	136-142	
aspirin	54-60	heparin	124-130	
aspirin	54-60	aspirin	136-142	
heparin	124-130	aspirin	136-142	

In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
TOBI	23-26	TOBI	45-48	
TOBI	23-26	dornase alfa	69-80	
TOBI	23-26	PULMOZYME	83-91	
TOBI	23-26	(beta)-agonists	109-123	
TOBI	23-26	corticosteroids	134-148	
TOBI	23-26	anti-pseudomonal antibiotics	157-184	
TOBI	23-26	aminoglycosides	201-215	
TOBI	45-48	dornase alfa	69-80	
TOBI	45-48	PULMOZYME	83-91	
TOBI	45-48	(beta)-agonists	109-123	
TOBI	45-48	corticosteroids	134-148	
TOBI	45-48	anti-pseudomonal antibiotics	157-184	
TOBI	45-48	aminoglycosides	201-215	
dornase alfa	69-80	PULMOZYME	83-91	
dornase alfa	69-80	(beta)-agonists	109-123	
dornase alfa	69-80	corticosteroids	134-148	
dornase alfa	69-80	anti-pseudomonal antibiotics	157-184	
dornase alfa	69-80	aminoglycosides	201-215	
PULMOZYME	83-91	(beta)-agonists	109-123	
PULMOZYME	83-91	corticosteroids	134-148	
PULMOZYME	83-91	anti-pseudomonal antibiotics	157-184	
PULMOZYME	83-91	aminoglycosides	201-215	
(beta)-agonists	109-123	corticosteroids	134-148	
(beta)-agonists	109-123	anti-pseudomonal antibiotics	157-184	
(beta)-agonists	109-123	aminoglycosides	201-215	
corticosteroids	134-148	anti-pseudomonal antibiotics	157-184	
corticosteroids	134-148	aminoglycosides	201-215	
anti-pseudomonal antibiotics	157-184	aminoglycosides	201-215	

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.
diuretics	5-13	aminoglycoside	27-40	
diuretics	5-13	antibiotic	63-72	
aminoglycoside	27-40	antibiotic	63-72	

TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.
TOBI	0-3	ethacrynic acid	51-65	
TOBI	0-3	furosemide	68-77	
TOBI	0-3	urea	80-83	
TOBI	0-3	mannitol	89-96	
ethacrynic acid	51-65	furosemide	68-77	
ethacrynic acid	51-65	urea	80-83	
ethacrynic acid	51-65	mannitol	89-96	
furosemide	68-77	urea	80-83	
furosemide	68-77	mannitol	89-96	
urea	80-83	mannitol	89-96	

The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers.
warfarin	24-31	tolmetin	75-82	
warfarin	24-31	tolmetin	89-96	
tolmetin	75-82	tolmetin	89-96	

However, increased prothrombin time and bleeding have been reported in patients on concomitant TOLECTIN and warfarin therapy.
TOLECTIN	95-102	warfarin	108-115	

Therefore, caution should be exercised when administering TOLECTIN to patients on anticoagulants.
TOLECTIN	58-65	anticoagulants	82-95	

In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents.
sulfonylureas	55-67	insulin	72-78	
sulfonylureas	55-67	TOLECTIN	133-140	
sulfonylureas	55-67	hypoglycemic agents	149-167	
insulin	72-78	TOLECTIN	133-140	
insulin	72-78	hypoglycemic agents	149-167	
TOLECTIN	133-140	hypoglycemic agents	149-167	

Caution should be used if TOLECTIN is administered concomitantly with methotrexate.
TOLECTIN	26-33	methotrexate	70-81	

TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate.
TOLECTIN	0-7	nonsteroidal anti-inflammatory drugs	19-54	
TOLECTIN	0-7	methotrexate	110-121	
TOLECTIN	0-7	methotrexate	178-189	
nonsteroidal anti-inflammatory drugs	19-54	methotrexate	110-121	
nonsteroidal anti-inflammatory drugs	19-54	methotrexate	178-189	
methotrexate	110-121	methotrexate	178-189	

CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions).
Ketoconazole	19-30	tolterodine	135-145	

For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
ketoconazole	23-34	azole antifungals	84-100	
ketoconazole	23-34	itraconazole	107-118	
ketoconazole	23-34	miconazole	121-130	
ketoconazole	23-34	macrolide antibiotics	136-156	
ketoconazole	23-34	erythromycin	163-174	
ketoconazole	23-34	clarithromycin	177-190	
ketoconazole	23-34	cyclosporine	196-207	
ketoconazole	23-34	vinblastine	212-222	
ketoconazole	23-34	DETROL LA	249-257	
azole antifungals	84-100	itraconazole	107-118	
azole antifungals	84-100	miconazole	121-130	
azole antifungals	84-100	macrolide antibiotics	136-156	
azole antifungals	84-100	erythromycin	163-174	
azole antifungals	84-100	clarithromycin	177-190	
azole antifungals	84-100	cyclosporine	196-207	
azole antifungals	84-100	vinblastine	212-222	
azole antifungals	84-100	DETROL LA	249-257	
itraconazole	107-118	miconazole	121-130	
itraconazole	107-118	macrolide antibiotics	136-156	
itraconazole	107-118	erythromycin	163-174	
itraconazole	107-118	clarithromycin	177-190	
itraconazole	107-118	cyclosporine	196-207	
itraconazole	107-118	vinblastine	212-222	
itraconazole	107-118	DETROL LA	249-257	
miconazole	121-130	macrolide antibiotics	136-156	
miconazole	121-130	erythromycin	163-174	
miconazole	121-130	clarithromycin	177-190	
miconazole	121-130	cyclosporine	196-207	
miconazole	121-130	vinblastine	212-222	
miconazole	121-130	DETROL LA	249-257	
macrolide antibiotics	136-156	erythromycin	163-174	
macrolide antibiotics	136-156	clarithromycin	177-190	
macrolide antibiotics	136-156	cyclosporine	196-207	
macrolide antibiotics	136-156	vinblastine	212-222	
macrolide antibiotics	136-156	DETROL LA	249-257	
erythromycin	163-174	clarithromycin	177-190	
erythromycin	163-174	cyclosporine	196-207	
erythromycin	163-174	vinblastine	212-222	
erythromycin	163-174	DETROL LA	249-257	
clarithromycin	177-190	cyclosporine	196-207	
clarithromycin	177-190	vinblastine	212-222	
clarithromycin	177-190	DETROL LA	249-257	
cyclosporine	196-207	vinblastine	212-222	
cyclosporine	196-207	DETROL LA	249-257	
vinblastine	212-222	DETROL LA	249-257	

Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.
paclitaxel	18-27	HERCEPTIN	49-57	
paclitaxel	18-27	HERCEPTIN	94-102	
paclitaxel	18-27	HERCEPTIN	173-181	
HERCEPTIN	49-57	HERCEPTIN	94-102	
HERCEPTIN	49-57	HERCEPTIN	173-181	
HERCEPTIN	94-102	HERCEPTIN	173-181	

Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).
Trilostane	0-9	aminoglutethimide	29-45	
Trilostane	0-9	mitotane	50-57	
aminoglutethimide	29-45	mitotane	50-57	

Trimethoprim may inhibit the hepatic metabolism of phenytoin.
Trimethoprim	0-11	phenytoin	51-59	

Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%.
Trimethoprim	0-11	phenytoin	63-71	
Trimethoprim	0-11	phenytoin	108-116	
phenytoin	63-71	phenytoin	108-116	

Since trimetrexate is metabolized by a P450 enzyme system, drugs that induce or inhibit this drug metabolizing enzyme system may elicit important drug-drug interactions that may alter trimetrexate plasma concentrations.
trimetrexate	6-17	trimetrexate	184-195	

Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.
trimetrexate	41-52	erythromycin	133-144	
trimetrexate	41-52	rifampin	147-154	
trimetrexate	41-52	rifabutin	157-165	
trimetrexate	41-52	ketoconazole	168-179	
trimetrexate	41-52	fluconazole	186-196	
erythromycin	133-144	rifampin	147-154	
erythromycin	133-144	rifabutin	157-165	
erythromycin	133-144	ketoconazole	168-179	
erythromycin	133-144	fluconazole	186-196	
rifampin	147-154	rifabutin	157-165	
rifampin	147-154	ketoconazole	168-179	
rifampin	147-154	fluconazole	186-196	
rifabutin	157-165	ketoconazole	168-179	
rifabutin	157-165	fluconazole	186-196	
ketoconazole	168-179	fluconazole	186-196	

In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.
cimetidine	56-65	trimetrexate	101-112	
cimetidine	56-65	acetaminophen	134-146	
trimetrexate	101-112	acetaminophen	134-146	

Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.
imidazole drugs	59-73	clotrimazole	76-87	
imidazole drugs	59-73	ketoconazole	90-101	
imidazole drugs	59-73	miconazole	104-113	
imidazole drugs	59-73	trimetrexate	159-170	
clotrimazole	76-87	ketoconazole	90-101	
clotrimazole	76-87	miconazole	104-113	
clotrimazole	76-87	trimetrexate	159-170	
ketoconazole	90-101	miconazole	104-113	
ketoconazole	90-101	trimetrexate	159-170	
miconazole	104-113	trimetrexate	159-170	

Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.
Triprolidine	0-11	central nervous system depressants	49-82	
Triprolidine	0-11	alcohol	94-100	
Triprolidine	0-11	barbiturates	103-114	
Triprolidine	0-11	hypnotics	117-125	
Triprolidine	0-11	narcotic analgesics	128-146	
Triprolidine	0-11	sedatives	149-157	
Triprolidine	0-11	tranquillisers	164-177	
central nervous system depressants	49-82	alcohol	94-100	
central nervous system depressants	49-82	barbiturates	103-114	
central nervous system depressants	49-82	hypnotics	117-125	
central nervous system depressants	49-82	narcotic analgesics	128-146	
central nervous system depressants	49-82	sedatives	149-157	
central nervous system depressants	49-82	tranquillisers	164-177	
alcohol	94-100	barbiturates	103-114	
alcohol	94-100	hypnotics	117-125	
alcohol	94-100	narcotic analgesics	128-146	
alcohol	94-100	sedatives	149-157	
alcohol	94-100	tranquillisers	164-177	
barbiturates	103-114	hypnotics	117-125	
barbiturates	103-114	narcotic analgesics	128-146	
barbiturates	103-114	sedatives	149-157	
barbiturates	103-114	tranquillisers	164-177	
hypnotics	117-125	narcotic analgesics	128-146	
hypnotics	117-125	sedatives	149-157	
hypnotics	117-125	tranquillisers	164-177	
narcotic analgesics	128-146	sedatives	149-157	
narcotic analgesics	128-146	tranquillisers	164-177	
sedatives	149-157	tranquillisers	164-177	

The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine.
anticholinergic drugs	15-35	atropine	46-53	
anticholinergic drugs	15-35	tricyclic antidepressants	59-83	
anticholinergic drugs	15-35	triprolidine	138-149	
atropine	46-53	tricyclic antidepressants	59-83	
atropine	46-53	triprolidine	138-149	
tricyclic antidepressants	59-83	triprolidine	138-149	

The concomitant use of Sanctura with other anticholinergic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects.
Sanctura	23-30	anticholinergic agents	43-64	

Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).
Sanctura	101-108	Sanctura	135-142	
Sanctura	101-108	digoxin	266-272	
Sanctura	101-108	procainamide	275-286	
Sanctura	101-108	pancuronium	289-299	
Sanctura	101-108	morphine	302-309	
Sanctura	101-108	vancomycin	312-321	
Sanctura	101-108	metformin	324-332	
Sanctura	101-108	tenofovir	338-346	
Sanctura	135-142	digoxin	266-272	
Sanctura	135-142	procainamide	275-286	
Sanctura	135-142	pancuronium	289-299	
Sanctura	135-142	morphine	302-309	
Sanctura	135-142	vancomycin	312-321	
Sanctura	135-142	metformin	324-332	
Sanctura	135-142	tenofovir	338-346	
digoxin	266-272	procainamide	275-286	
digoxin	266-272	pancuronium	289-299	
digoxin	266-272	morphine	302-309	
digoxin	266-272	vancomycin	312-321	
digoxin	266-272	metformin	324-332	
digoxin	266-272	tenofovir	338-346	
procainamide	275-286	pancuronium	289-299	
procainamide	275-286	morphine	302-309	
procainamide	275-286	vancomycin	312-321	
procainamide	275-286	metformin	324-332	
procainamide	275-286	tenofovir	338-346	
pancuronium	289-299	morphine	302-309	
pancuronium	289-299	vancomycin	312-321	
pancuronium	289-299	metformin	324-332	
pancuronium	289-299	tenofovir	338-346	
morphine	302-309	vancomycin	312-321	
morphine	302-309	metformin	324-332	
morphine	302-309	tenofovir	338-346	
vancomycin	312-321	metformin	324-332	
vancomycin	312-321	tenofovir	338-346	
metformin	324-332	tenofovir	338-346	

Coadministration of Sanctura with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of Sanctura and/or the coadministered drug due to competition for this elimination pathway.
Sanctura	20-27	Sanctura	134-141	

Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing and anaphylactoid reactions.
vancomycin	30-39	anesthetic agents	45-61	

Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.
amphotericin B	119-132	aminoglycosides	135-149	
amphotericin B	119-132	bacitracin	152-161	
amphotericin B	119-132	polymyxin B	164-174	
amphotericin B	119-132	colistin	177-184	
amphotericin B	119-132	viomycin	187-194	
amphotericin B	119-132	cisplatin	200-208	
aminoglycosides	135-149	bacitracin	152-161	
aminoglycosides	135-149	polymyxin B	164-174	
aminoglycosides	135-149	colistin	177-184	
aminoglycosides	135-149	viomycin	187-194	
aminoglycosides	135-149	cisplatin	200-208	
bacitracin	152-161	polymyxin B	164-174	
bacitracin	152-161	colistin	177-184	
bacitracin	152-161	viomycin	187-194	
bacitracin	152-161	cisplatin	200-208	
polymyxin B	164-174	colistin	177-184	
polymyxin B	164-174	viomycin	187-194	
polymyxin B	164-174	cisplatin	200-208	
colistin	177-184	viomycin	187-194	
colistin	177-184	cisplatin	200-208	
viomycin	187-194	cisplatin	200-208	

A study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine.
vigabatrin	37-46	carbamazepine	115-127	

In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy.
vigabatrin	87-96	phenytoin	103-111	
vigabatrin	87-96	phenytoin	131-139	
phenytoin	103-111	phenytoin	131-139	

Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
Vindesine	0-8	Phenytoin	310-318	
Vindesine	0-8	Live virus vaccines	353-371	
Vindesine	0-8	vaccine	412-418	
Vindesine	0-8	Mitomycin-C	526-536	
Vindesine	0-8	Killed virus vaccines	588-608	
Vindesine	0-8	vaccine	650-656	
Phenytoin	310-318	Live virus vaccines	353-371	
Phenytoin	310-318	vaccine	412-418	
Phenytoin	310-318	Mitomycin-C	526-536	
Phenytoin	310-318	Killed virus vaccines	588-608	
Phenytoin	310-318	vaccine	650-656	
Live virus vaccines	353-371	vaccine	412-418	
Live virus vaccines	353-371	Mitomycin-C	526-536	
Live virus vaccines	353-371	Killed virus vaccines	588-608	
Live virus vaccines	353-371	vaccine	650-656	
vaccine	412-418	Mitomycin-C	526-536	
vaccine	412-418	Killed virus vaccines	588-608	
vaccine	412-418	vaccine	650-656	
Mitomycin-C	526-536	Killed virus vaccines	588-608	
Mitomycin-C	526-536	vaccine	650-656	
Killed virus vaccines	588-608	vaccine	650-656	

Drug Interactions: Women on oral contraceptives have shown a significant increase in plasma vitamin A levels.
contraceptives	33-46	vitamin A	92-100	

Limited evidence suggests that ascorbic acid may influence the intensity and duration of action of bishydroxycoumarin.
ascorbic acid	31-43	bishydroxycoumarin	99-116	

Coumarin-Derivative Anticoagulants: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with coumarin-derivative anticoagulants.
Coumarin-Derivative Anticoagulants	0-33	ZOLINZA	151-157	
Coumarin-Derivative Anticoagulants	0-33	coumarin-derivative anticoagulants	178-211	
ZOLINZA	151-157	coumarin-derivative anticoagulants	178-211	

Physicians should carefully monitor PT and INR in patients concurrently administered ZOLINZA and coumarin derivatives.
ZOLINZA	85-91	coumarin derivatives	97-116	

Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid).
HDAC Inhibitors	6-20	ZOLINZA	119-125	
HDAC Inhibitors	6-20	HDAC inhibitors	137-151	
HDAC Inhibitors	6-20	valproic acid	160-172	
ZOLINZA	119-125	HDAC inhibitors	137-151	
ZOLINZA	119-125	valproic acid	160-172	
HDAC inhibitors	137-151	valproic acid	160-172	

